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ABSTRACT 
Costimulation blockade based on a donor-specific transfusion and anti-CD154 mAb 
is effective for establishing mixed allogeneic hematopoietic chimerism and inducing 
transplantation tolerance. Despite its potential, recent evidence suggests that the efficacy 
of costimulation blockade can be reduced by environmental perturbations such as 
infection or inflammation that activate toll-like receptors (TLR). TLR agonists prevent 
costimulation blockade-induced prolongation of solid organ allografts, but their effect on 
the establishment of hematopoietic chimerism has not been reported.  
In this dissertation, we hypothesized that TLR activation during costimulation 
blockade would prevent the establishment of mixed hematopoietic chimerism and shorten 
skin allograft survival. To test this hypothesis, costimulation blockade-treated mice were 
co-injected with TLR2 (Pam3Cys), TLR3 (poly I:C), or TLR4 (LPS) agonists and 
transplanted with allogeneic bone marrow and skin grafts. Supporting our hypothesis, we 
observed that TLR agonists administered at the time of costimulation blockade prevented 
the establishment of mixed hematopoietic chimerism and shortened skin allograft 
survival.  
To investigate underlying cellular and molecular mechanisms, we first determined 
that LPS administration during costimulation blockade did not increase production of 
alloantibodies or activate natural killer cells. Similarly, costimulation blockade-treated 
mice depleted of CD4+ or CD8+ cells did not become chimeric when co-injected with 
LPS. In contrast, mice depleted of both CD4+ and CD8+ cell subsets were resistant to the 
effects of LPS.  
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We next observed that alloreactive T cells were activated by TLR agonists in mice 
treated with costimulation blockade, and this activation correlated with LPS-induced 
maturation of donor and host alloantigen-presenting cells. In contrast, TLR4-deficient 
mice treated with costimulation blockade and LPS did not upregulate costimulatory 
molecules on their APCs, and mixed chimerism and permanent skin allograft survival 
were readily achieved. We further observed that injection of recombinant IFN-β 
recapitulated the detrimental effects of LPS, and that LPS-injected mice deficient in the 
type I IFN receptor were partially protected. Importantly, alloantigen-presenting cells did 
not upregulate costimulatory molecules in response to LPS, and mixed chimerism and 
permanent skin allograft survival were readily established in type I IFN receptor and 
MyD88 double deficient mice treated with costimulation blockade. We conclude that the 
TLR4 agonist LPS prevents the establishment of mixed hematopoietic chimerism and 
shortens skin allograft survival in mice treated with costimulation blockade by inducing 
the production of type 1 IFN and MyD88-dependent factors that upregulate costimulatory 
molecules on APCs, leading to the generation of activated alloreactive T cells. 
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ABBREVIATIONS 
APC  antigen presenting cell 
APDC alloantigen-presenting dendritic 
cell 
BM  bone marrow 
BMT  bone marrow transplantation 
CARD caspase recruitment domain 
CARDIF CARD adaptor inducing IFN-β 
CB  costimulation blockade 
cDC  conventional dendritic cell 
cTEC  cortical epithelial cell 
CTL  cytotoxic T lymphocytes 
DC  dendritic cell 
DAI DNA-dependent activator of 
IFN-regulatory factors 
dsRNA double stranded RNA 
DST  donor-specific transfusion 
FoxP3 forkhead box P3 
GVHD graft-versus-host disease 
HLA  human leukocyte antigen 
HSC  hematopoietic stem cell 
IFN  interferon 
IFNAR1 interferon-α/β receptor 
IKK  IκB kinase 
IKK-I inducible IκB kinase 
IL  interleukin 
I.P.  intraperitoneally 
I.V  intravenous 
IPS-1 interferon-β promoter 
stimulator 
IRAK IL-1 receptor associated kinase 
IRF  interferon regulatory factory 
ISRE interferon-stimulated response 
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LCMV lymphocytic choriomeningitis 
virus 
LPS  lipopolysaccharide 
mAb  monoclonal antibody 
MAL  MyD88-adaptor-like 
MAPK mitogen-activated protein 
kinase 
MAVS mitochondrial antiviral 
signaling protein 
MCMV murine cytomegalovirus 
MDA5 melanoma differentiation-
associated factor-5 
MFI  median fluorescence intensity 
MHC major histocompatibility 
complex 
MST  median survival time 
mTEC medullary epithelial cell 
MyD88 myeloid differentiation primary 
response gene-88 
NF-κB nuclear factor κ B 
NLR  NOD-like receptor 
NOD nucleotide binding and 
oligomerization domain  
Pam3Cys Pam3-Cys-Ser-(Lys)4 
PAMP pathogen-associated molecular 
pattern 
PMBC peripheral blood mononuclear 
cell 
pDC  plasmacytoid dendritic cell 
PFU  plaque forming units 
Poly I:C polyinosinic: polycytidylic acid 
PRR  pattern recognition receptor 
PV  Pichinde virus 
RIG-I retinoic acid inducible gene I 
RIP  receptor-interacting protein 
RLR  RIG-I-like receptor 
S.D. standard deviation 
SNP single nucleotide 
polymorphism 
ssRNA single-stranded RNA 
TANK TNFR-associated factor family 
member-associated NF-κB 
activator 
TBK-1 TANK-binding kinase 1 
TCR  T cell receptor 
TGF  transforming growth factor 
TIR   Toll/interleukin-1 receptor 
TLR  Toll-like receptor 
TNF tumor necrosis factor 
TRAF tumor necrosis factor receptor-
associated factor 
Treg  regulatory T cell 
TRIF TIR-domain-containing 
adaptor protein inducing IFN-β 
VISA  virus-induced signaling adaptor 
VV   Vaccinia virus 
VSV  vesicular stomatitis virus 
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CHAPTER I: INTRODUCTION 
History of Transplantation 
Early Pioneers 
Remarkably, reports of transplantation surgery date as far back as two millennia ago. 
In the ancient Sanskrit text, the Sushruta Samhita, the Indian surgeon Sushruta described 
methods for reconstructing noses amputed during battle or as a form of punishment   
using tissue grafts from the patient’s own forehead [1,2]. Additional early accounts of 
rhinoplasty can be found in the works of the Italian surgeon Gaspare Tagliacozzi. In the 
late 16th century, he succeeded at replacing the lost nose of a patient using the pedicle 
flap of the person’s own arm [3]. Interestingly, Tagliacozzi is reported to have observed 
that transplanting tissue from allogeneic donors was not tenable. He eloquently wrote that 
“the singular character of the individual entirely dissuades us from attempting this work 
on another person” [3]. Given the inchoate understanding of medicine at the time, one 
can imagine that his impressive observation was only made after unsuccessful attempts 
that were no doubt painstaking for Tagliacozzi and punishingly painful for the patient.    
Despite these extraordinary early attempts, the field of transplantation did not 
significantly advance until the 20th century. Advancements in anesthesia and surgical 
technique, including the work done by Alexis Carrel at the turn of the 20th century in 
improving vascular anastomosis [4], permitted more rigorous investigation by enabling 
animal, and some human, experiments to be performed. Interestingly, many of the 
important discoveries in the first decade of the 20th century were made by tumor 
biologists, studying the outcome of transplanted tumors. In 1912, George Schone 
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synthesized many of these thoughtful insights into what are now commonly referred to as 
the “laws of transplantation” [3]. He stated that: 1) Transplantation of tissue from foreign 
species (xenogeneic) never succeeds. 2) Transplantation of tissue from unrelated 
members of the same species (allogeneic) typically fails. 3) Transplantation of autologous 
tissue typically survives. 4) Recipients of allogeneic grafts tolerate the graft for a brief 
period, before ultimately rejecting the tissue. 5) Recipients of a second allogeneic graft 
from the same donor reject the second graft more rapidly than they reject the first. 6) 
Allograft survival is more likely if the donor and recipient have a close “blood 
relationship”.  
Pioneering research in the 1940s and 1950s provided both a genetic, as well as 
immunological, understanding of Schone’s laws of transplantation.  Work done at the 
Jackson Laboratory in Maine by George Snell and colleagues, provided the genetic 
understanding, while research done in England by Peter Medawar’s lab helped elucidate 
the role of the immune system. The seminal discoveries of both of these groups provided 
the basis for many of the important breakthroughs that were to follow in the second half 
of the 20th century. 
The Advent of Immunogenetics 
Working under the aegis of Clarence Little, George Snell discovered an interval of 
DNA, or ‘genetic locus”, that was critically related to the survival of transplanted 
allografts. Utilizing mice that were genetically identical except for a short, defined locus 
(a.k.a. congenic mice), Snell discovered that mice rejected tissue from their “genetic 
cousins” if they differed at a specific locus, which he then called H, for histocompatibility 
3 
 
 
[3]. Following a year-long stay at the Jackson Laboratory by Peter Gorer, Snell and Gorer 
realized that the H locus, and the blood group locus that Gorer had discovered earlier  - 
known as “antigen II” [5] - were the same  [6,7].  Consequently, this genetic locus was 
renamed “H-2”. The genes contained within the murine H-2 locus have proven to be 
critical determinants of transplantation success, tumor surveillance, and cell-mediated 
immunity. This genetic region has also come to be known as the major histocompatibility 
complex (MHC). The “singular character of the individual” that Tagliacozzi so 
presciently spoke of is largely a manifestation of the uniqueness of each person’s MHC. 
The relationship between polymorphisms in the MHC and allograft success will be 
discussed later.   
Working independently of the immunogeneticists in Maine, the zoologist Peter 
Medawar and his colleague Thomas Gibson began their work in transplantation biology 
following World War II. They were commissioned by the War Wounds Committee of the 
British Medical Research Council to study skin allograft rejection in the hope of 
improving techniques of skin grafting for soldiers burned during the war [3]. At the time, 
attempts to replace damaged skin on burn victims with allografts were invariably 
unsuccessful.  
In 1943, Gibson and Medawar published a report detailing the fate of a skin allograft 
placed on a 22-year-old female burn victim, which provided insight into the mechanism 
of allograft rejection. Due to the extensive nature of the patient’s thermal burns, she 
required multiple skin grafts from both her own thigh, as well as the thigh of her brother.  
Over the several months of treatment, the patient had repeat surgeries, including serial 
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transplants from her brother. This enabled Gibson and Medawar to examine the tenets of 
Schone’s laws. They observed that: 1) tissue transplanted from the patient’s own thigh 
survived; 2) tissue transplanted from the brother’s thigh was initially tolerated, but began 
to degenerate after two weeks (a process known as first-set rejection); and 3) subsequent 
skin grafts from her brother displayed accelerated rejection (a process known as second-
set rejection). These observations led them to conclude that the rejection of foreign tissue 
was “brought about by a mechanism of active immunization” [8].  
These key insights, as well as others acquired from experiments in animal models 
[9], demonstrated that allograft rejection was mediated by the immune system. This led to 
the rigorous investigation into how the immune system recognizes foreign tissues, and 
how it distinguishes “self-tissues” from “non-self tissues”. It also prompted the discovery 
of chemotherapeutic agents that could thwart the immune system’s ability to abrogate 
allograft survival, and made allograft transplantation a therapeutic reality. The 
development of modern day immunosuppressive agents and their caveats will be 
discussed later.  
Distinguishing Self from Non-self: The Immune Response To Foreign Tissues 
Innate Immunity 
The human immune system employs an intricate array of mechanisms to distinguish 
native structures from foreign ones. Structures from evolutionarily distant species (e.g. 
microbes) are recognized by members of the innate immune system. Often considered as 
the first line of defense, the innate immune system consists of epithelial barriers, 
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circulating proteins and effector cells. Innate immunity has been highly conserved 
throughout evolution, and elements of it exist in all multicelluar organisms [10]. The 
effector cells of the innate immune system consist principally of monocytes, 
macrophages, dendritic cells, natural killer (NK) cells, mast cells and neutrophils. These 
cells possess specific germ-line encoded pattern recognition receptors (PRR) that can 
discern distinct molecules that are common to groups of related pathogens. These 
structures, which are also known as pathogen-associated molecular patterns or PAMPs, 
are typically microbial products that are required for the survival of the microorganism. 
Thus, PAMPs cannot be easily altered by the microbe as a way of evading the host’s 
defenses.  Specific PRRs recognize distinct PAMPs, and have distinguishing expression 
patterns and signaling pathways, which will be discussed in detail in a later section.  
Adaptive Immunity 
Most members of the innate immune system, however, are not effective at 
recognizing structures from closely related species, or from members of the same species. 
For this purpose, the immune system has evolved a sophisticated system that is often 
referred to as adaptive or acquired immunity. The adaptive immune system is comprised 
of T and B-lymphocytes, which possess antigen-specific cell-surface receptors that are 
generated via rearrangement of their T cell receptor and immunoglobulin genes, 
respectively. A large repertoire of peptide-specific receptors is produced by this process, 
allowing the acquired immune system to respond to a wide range of potential pathogens. 
Due to the enormous diversity produced by gene rearrangement, T and B cells undergo 
extensive selection processes to ensure to a great degree that the cells that are found 
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circulating in the body possess receptors that only react to antigens from non-native 
sources. One practical consequence of this for transplantation is that a recipient’s B and T 
cells can mount immune responses to the genetic differences found on donor tissues. The 
antigenic differences between recipients and donors are the result of polymorphic genes 
that are found throughout the population, and are often referred to as alloantigens. There 
are three immune reactions generated in response to alloantigens, and these typically lead 
to the rejection of the transplanted graft. These responses are often categorized as 
hyperacute, acute, and chronic rejection.  
Mechanisms of Allograft Rejection 
Hyperacute rejection is mediated by circulating antibodies that bind to antigens on 
the allografts’ endothelium, and it can begin minutes to hours after organ transplantation. 
These antibodies are believed to arise either from prior exposure of the host to tissues 
from the same donor, or in response to carbohydrate moieties expressed by colonized 
bacteria that mimic antigens found on the donor [11]. For example, antigens found on 
common bacteria of the gut closely resemble those of the A, B, O antigens found on 
erythrocytes and endothelial cells. If donor tissues are not properly matched to the 
recipient for these antigens they will quickly be rejected. Transplanted tissues subjected 
to hyperacute rejection rapidly become necrotic, as antibody-mediated thrombotic 
occlusions develop in the endothelium of the tissues.  
 In the absence of immunosuppression, all allografts that do not elicit a hyperacute 
response will be subjected to acute rejection. Acute rejection typically develops after the 
first week of transplantation, and is characterized by a T cell response directed against 
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alloantigens. Due to their highly  polymorphic nature, the genes located within the locus 
of the MHC produce the most important alloantigens for acute rejection [12]. 
There are two distinct mechanisms by which T cells recognize and respond to 
alloantigens, a process also known as allorecognition. The first mechanism, also called 
the direct allorecognition pathway, involves host T cells recognizing donor MHC 
molecules found on the surface of cells of the graft, such as dendritic cells [13,14]. The 
frequency of T cells with TCRs specific for foreign MHC molecules is believed to be 
100-1000 fold higher than the precursor frequency of T cells specific for any self-MHC-
foreign-peptide complex [15]. As a consequence, the direct allopresentation pathway 
produces a robust immune response, and has traditionally been considered the 
predominate mechanism in acute rejection [16]. In contrast, donor MHC and other minor 
antigens can be phagocytosed and processed by recipient APCs, and presented to host T 
cells. This process, also known as indirect allorecognition, is analogous to the 
presentation of conventional pathogen-derived protein antigens in which self-MHC-
foreign peptide complexes on host APCs engage the TCR of host T cells. 
The mechanisms of allorecognition can be contravened by modern 
immunosuppressive chemotherapies, and thus acute rejection can be avoided in a great 
number of recipients. However, eventually the majority of allografts fail to survive, as 
they fall victim to chronic rejection. The mechanisms of chronic rejection have not been 
clearly elucidated; however, it likely results from fibrosis of the graft’s vasculature, 
secondary to chronic immune stimulation.  
Despite the inexorable loss of allografts, the ability to preclude acute rejection has 
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greatly improved the outcome and quality of life of many patients. There are 
approximately 28,000 organ transplants per year in the U.S [17]. These are only feasible 
because of the work done in the fields of tissue matching and immunosuppression, which 
are the focus of the next section.    
Clinical Advancements in Transplantation 
Tissue Matching 
Snell’s discovery of the major histocompatibility complex in mice became clinically 
relevant to humans with the discovery in the late 1950s of the human counterpart, the 
human leukocyte antigen (HLA), by Jean Dausset [18]. His report of circulating 
antibodies in the blood of transfusion patients that were directed against leukocyte 
antigens provided the groundwork for the development of tools that could identify 
individual HLA antigens. This knowledge, coupled with the discovery of the ABO blood 
system a half a century earlier by Karl Landsteiner [3], provided physicians with 
powerful tools to minimize the differences in the donor and recipient’s “blood 
relationship”. 
In the decades to follow, it would be learned that the HLA complex on chromosome 
6 is comprised of two major clusters of genes that are critically related to the outcome of 
transplanted tissues. These distinct regions of the complex, named class I and class II, 
possess genes with a vast number of genetic variants, or alleles, within the human 
population. For transplantation, the three most important genes are HLA-A, HLA-B, and 
HLA-DR, as minimizing allelic differences at these loci correlate with better clinical 
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outcomes. Each person possesses a maternal and a paternal copy of these genes. Given 
the large number of polymorphisms at each of these genes, most individuals inherit 
different alleles from their parents. Therefore, attempting to match donor and recipients 
for these six genetic possibilities has become the standard. Even perfect “6/6” matches, 
however, do not ensure prolonged allograft survival, as variations at other genes, known 
as minor histocompatibility antigens, can elicit an immune response. Therefore, even 
with perfect matches, the utilization of immunosuppressive agents is critical to ensure 
extended allograft survival.      
Immunosuppression  
Pharmacotherapy and Radiation 
Gibson and Medawar’s realization that allograft rejection was mediated by the 
immune system ignited a community of scientists to investigate methods of prolonging 
allograft survival by suppressing the recipient’s immune system. Early attempts at 
prolonging the survival of allografts were also performed by Medawar and colleagues. At 
the time, Medawar knew that tissues of mesenchymal origin were the cells that mediated 
immunological responses. Having observed that the glucocorticoid cortisone had 
“profound influence on the activity of all mesenchymal tissues”, he hypothesized that 
treatment with cortisone would prolong skin allograft survival in rabbits [19].  His 
hypothesis did prove correct, as skin graft survival was prolonged. However, the survival 
was only extended a few days, and the quest for additional modalities continued. 
A significant advance came in the late 1950s and early 1960s with the observation 
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that allograft survival could be significantly extended if the recipient was treated with 
total body irradiation (TBI). Surgeons in Boston and Paris reported renal allograft 
function up to a year in patient’s treated with sublethal doses of TBI [20]. In fact, using 
this modality the Boston group of Merril, Murray and Harrison was able to perform the 
first successful kidney allograft transplantation [21].  However, these cases did little to 
incite optimism, as the majority of the patients fell subject to infection, and died within 
weeks of irradiation [21]. Therefore, the pursuit for chemotherapeutics, which could 
mimic the cytoablative qualities of TBI without the high degree of morbidity and 
mortality, continued. 
 In 1959 and 1960, work done by Schwartz and Dameshek [22,23], Meeker [24] and 
Calne [25] demonstrated that allograft survival could be prolonged by administering the 
anti-metabolite 6-mercaptopurine (6-MP). After being taken up by cells, 6-MP is 
converted to thioinosinic acid, which disrupts the de novo synthesis of purine nucleotides. 
This has a profound effect on proliferating cells, such as those participating in an immune 
reaction. Unfortunately, other proliferating cells such as those of the intestinal epithelium, 
hair follicle and bone marrow are also significantly damaged. Therefore, less toxic anti-
metabolites including azathioprine and mycophenolate mofetil were developed. 
The discovery in 1976 that an extract of the fungi Trichoderma polysporum (later re-
identified as Tolypocladium inflatum) had potent and largely selective effects against T 
lymphocytes, marked another significant advance in the field of transplantation [21,26]. 
The compound, named cyclosporine, and its successor tacrolimus, disrupt the antigen 
activation of T cells by inhibiting the molecule calcineurin. The serine/threonine 
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phosphatase calcineurin plays a critical role in the T cell signaling cascade by activating 
the transcription factor NFAT. Without NFAT activation, the downstream targets of T 
cell signaling, such as interleukin (IL)-2, are not produced. Due to their relative 
specificity to T cells, cyclosporine and tracrolimus are less toxic than myeloablative 
agents such as 6-MP and azathioprine. Consequently, both are used routinely for kidney, 
liver, and heart transplantation. However, despite their efficacy and decreased side-effect 
profile, adverse effects such as increased incidence of neoplasia, nephrotoxicity, 
hypertension, tremor, hirsutism, and islet-toxicity are not uncommon [27]. 
Additional attempts to target T cell signaling as a way of extending allograft survival 
led to the discovery of inhibitors of the protein kinase, mammalian target of rapamycin 
(mTOR). Sirolimus (rapamcyin), and the related compound everolimus, prevent antigen 
activation of T cells by first forming a complex with the immunophilin FKBP-12. The 
sirolimus/everolims-FKBP-12 complex then binds and inhibits mTOR, a key regulator of 
cell-cycle progression downstream of the IL-2 receptor [27,28]. By preventing T cell 
proliferation, these agents effectively reduce the host’s immune response against the 
transplanted organ. Unfortunately, adverse effects such as hypercholesterolemia, 
hypertriglyceridemia, anemia, leukopenia and lymphoid malignancy have been reported 
[27].   
 Immunosuppressive Antibodies 
Antibodies directed against lymphocyte-specific antigens can also be used as an 
adjunct to the aforementioned agents. In the 1960s and 1970s, the polyclonal preparation 
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antilymphocyte globulin (ALG) was used clinically with varying degrees of success. 
ALG is a mixture of antibodies directed against a variety of lymphocyte cell-surface 
proteins. The heterologous nature of ALG, coupled with variations in batch-to-batch 
potency, prompted the development of monoclonal antibodies directed against specific T 
cell antigens [21]. Antibodies specific for CD3 (OKT3) [29], CD52 (Alemtuzumab) [30], 
CD11a (Efalizumab) [31], CD25 (Daclizumab and Basiliximab) [32,33] have proven 
efficacious at suppressing the immune response to alloantigens, and have demonstrated 
the ability to extend the lifespan of various allografts. Scientists have also utilized 
monoclonal antibodies to target costimulatory molecules involved in T cell activation in 
the hope of inducing a state transplantation tolerance, which will be discussed in more 
detail later.   
Immunosuppressive Regimens 
The ever-increasing immunosuppressive armament has provided the transplant 
caregiver with a multitude of potential drug combinations. However, there are three main 
uses of immunosuppressants. The first is to establish initial acceptance of the allograft 
and to prevent acute rejection. This is often accomplished with an initial heavy dose of 
immunosuppression [34]. During the initial induction, a biological agent such as 
daclizumab, basiliximab, or anti-thymocyte globulin (ATG) may be used. This is then 
followed typically by a three-drug cocktail that includes a calcineurin inhibitor, such as 
tacrolimus or cyclosporine, an anti-metabolite such as mycophenolate mofetil, and the 
glucocorticoid prednisone. The second use of immunosuppressants is maintenance. 
During the maintenance phase, the level of immunosuppression is reduced to preserve 
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host defenses, but maintained at a level to prevent rejection. The dosage of prednisone is 
frequently tapered during this phase. The final use of immunosuppressants is to reverse a 
rejection episode. High-dose corticosteroids or lymphocyte-depleting antibodies can be 
employed to quell an acute rejection episode. 
Transplantation Tolerance 
Although prolonged graft survival can be achieved with modern immunosuppressive 
regimens, it is clear that all immunosuppressive drugs, even the newer generations of 
immunosuppressive regimens, are toxic [35,36]. Immunosuppressive drugs are also 
known to increase the risk of infection and neoplasia [37,38], and their associated side-
effects can lead to patient non-compliance [39]. Since most patients eventually reject 
transplanted allografts either acutely or through a process of chronic rejection [40-42], 
these deleterious side-effects make organ transplantation a therapy in which the 
risk/benefit ratio must be carefully weighed.  
To overcome issues associated with chronic immunosuppression, investigators have 
focused on approaches that lead to the induction of tolerance to transplanted organ 
allografts [43]. Operationally, transplantation tolerance is defined as the survival of a 
donor allogeneic graft in the absence of immunosuppression. Most transplantation 
tolerance induction protocols take advantage of information resulting from studies on the 
natural mechanisms by which the immune system prevents self-reactivity and 
autoimmune disease. Two major forms of natural tolerance have been identified: central 
tolerance and peripheral tolerance.  
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Central Transplantation Tolerance  
In 1953, Billingham, Brent and Medawar demonstrated for the first time that the 
establishment of allogeneic hematopoietic chimerism leads to the induction of central 
tolerance and permits permanent acceptance of skin allografts [44]. Inspired by the work 
done in freemartin cattle by Owen in 1945 [45], and the clonal selection theory 
subsequently proposed by Burnet [46], Medawar demonstrated in mice that the transfer 
of allogeneic hematopoietic cells in utero could induce tolerance to skin transplanted 
from the original donor later in life [44].  
Medawar’s demonstration of acquired neonatal tolerance inspired Main and Prehn 
two years later to recapitulate that phenomenon in adult mice.  Their strategy entailed 
ablating the recipient’s immune system with lethal irradiation, reconstituting it with 
allogeneic bone marrow, followed by transplantation with donor-strain-matched skin 
allografts [47]. This protocol successfully induced tolerance to skin allografts, 
conclusively linking the establishment of hematopoietic chimerism with subsequent 
allograft survival.  
Mechanisms of Central Transplantation Tolerance 
The mechanisms by which hematopoietic chimerism induces a state of central 
tolerance are believed to mirror those the body normally uses to prevent autoreactivity 
and establish a state of self-tolerance. The wide array of pathogen-specific T cells the 
human body possesses is ultimately the result of random gene rearrangements of the T 
cell receptor (TCR). The aleatory nature of TCR rearrangement, however, presents a 
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potential problem, as a number of developing T cells could express receptors that not 
only react to pathogenic antigens presented on self-MHC, but also self-proteins. The 
hazard of autoimmunity is mitigated by a selection process in the thymus that ensures the 
survival of only those T cells that recognize self-MHC (a process known as positive 
selection) that present foreign peptides (negative selection). 
During positive selection, developing T cells that have migrated from the bone 
marrow interact with cortical thymic epithelial cells (cTECs). MHC class I and class II-
expressing cTECs present self-peptides that bind to the TCR of developing T cells 
(thymocytes), imparting crucial survival signals [48]. TCR gene rearrangement produces 
a repertoire of immature T cells with a wide range of specificities. Therefore, only a 
small proportion of the developing T cells possess TCRs that recognize self-
peptide/MHC complexes [49]. Cells that survive positive selection display a vast 
heterogeneity in their specificities. Some express TCRs with low-affinity for self-
peptide/MHC, while many have receptors with a high-affinity for self-peptide MHC 
complexes, and are thus possibly autoreactive. Potentially autoreactive cells are 
eliminated by a process carried out in the medulla of the thymus, designated negative 
selection. 
The principal mediators of negative selection are bone marrow-derived APCs and 
resident medullary thymic epithelial cells (mTECs). These cells present maturing 
thymocytes with an assortment of self antigens. Bone marrow-derived APCs sample and 
present antigens from the environment, while mTECs have the ability to promiscuously 
express otherwise tissue-specific antigens [50,51]. Following positive selection, 
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developing thymocytes migrate to the medulla of the thymus and engage these self-
antigen-presenting cells. Those thymocytes with high-affinity TCRs receive a death 
signal, rapidly undergo cell death, and are effectively purged from the T cell repertoire 
[52-55].  
The mechanisms that govern the clonal deletion of self-reactive T lymphocytes also 
mediate the elimination of lymphocytes with TCR specificities to alloantigens in 
hematopoietic chimeras (Figure 1). After transplantation into conditioned 
(immunosuppressed) recipients, allogeneic hematopoietic stem cells (HSCs) home to the 
bone marrow. Following engraftment, donor HSCs differentiate into a population of 
antigen-presenting cells (both dendritic cells and macrophages), which can seed the 
thymus and participate in thymic selection of T lymphocytes. In the thymus, similar to 
host derived-APCs, those from the donor are able to mediate negative selection by 
presenting self-antigens. Consequently, host thymocytes with donor-specific TCRs 
(which can be as high in frequency as 1 in 103-104 of all circulating T cells [15]) are 
induced to die [56].     
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FIGURE 1: CENTRAL TOLERANCE INDUCED BY MIXED CHIMERISM 
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Figure 1. After transplantation, allogeneic hematopoietic stem cells (HSCs) (light brown 
round cells) home to the bone marrow. Host (light blue round cells) and donor HSCs can 
differentiate into antigen-presenting cells (stellate cells), which can seed the thymus and 
participate in thymic selection of T lymphocytes. In the thymus, host bone marrow-
derived APCs induce the deletion of donor-derived thymocytes with high-affinity TCRs 
towards the host (dark red cell). In contrast, donor-derived APCs mediate the negative 
selection of host thymocytes with donor-specific TCRs. Consequently, mature T cells 
that emigrate from the thymus and take residence in secondary lymphoid organs in the 
periphery are tolerant to both host and donor tissues.    
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Barriers Limiting the Translation of Mixed Chimerism To The Clinic 
Despite the robust form of tolerance hematopoietic chimerism induces, stem cell 
transplantation is not routinely used as an adjunct to solid-organ transplantation. Two 
primary barriers exist that have slowed its clinical application. The first is the 
requirement for significant immunosuppression in order for allogeneic stem cells to 
survive and engraft in the recipient. The second is the development of lethal graft-versus-
host disease (GVHD), a condition where lymphocytes in the donor bone marrow incite an 
immune reaction against the recipient. Therefore, modern conditioning protocols to 
induce central tolerance have been designed to address the common objectives of 1) 
establishing hematopoietic chimerism using a relatively benign preconditioning protocol 
that 2) prevents the development of GVHD.  
Hematopoietic Chimerism Induction Protocols 
Despite these common objectives, modern conditioning regimens can differ quite 
significantly in their methodology. In pre-clinical models of hematopoietic chimerism, 
conditioning regimens span the spectrum from myeloablative protocols, which often 
entail lethal irradiation and subsequent stem cell rescue, to non-cytoreductive treatments 
that do not require irradiation (e.g. costimulation blockade [57-59]). Myeloablative 
protocols typically produce a state of full chimerism, in which all of the hematopoietic 
cells in the recipient are derived from the donor [60]. In contrast, non-cytoreductive 
regimens produce a state where donor and host hematopoietic cells co-exist [60]. This 
state is known as mixed chimerism. A third type of conditioning regimen exists between 
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these two extremes. These protocols are often referred to as non-myeloablative, and are 
designed to significantly weaken, but not ablate, the recipient’s immune system through 
selective antibody-mediated elimination of specific immune populations (e.g. CD4+ and 
CD8+ T cells) coupled with targeted irradiation (e.g. thymic irradiation) [61]. In clinical 
trials, successful non-myeloablative approaches have recently been described [62,63]. 
Stable renal allograft function in recipients for as long as five years after complete 
withdrawal of immunosuppressive drugs was observed in recipients in which 
hematopoietic chimerism was established [62,63]. These observations show that in 
humans, as in rodents, establishment of hematopoietic chimerism is a robust approach for 
the development of central tolerance and the permanent survival of donor-specific 
allografts. 
Peripheral Transplantation Tolerance  
The second major form of tolerance is peripheral tolerance. Different from central 
tolerance in which hematopoietic chimerism leads to the clonal deletion of antigen-
specific cells during development, peripheral tolerance targets pre-existing cells that have 
already been generated. To induce tolerance in this population, fundamental insights into 
how naïve antigen-specific T cells become activated have led to protocols designed to 
prevent this process. Naïve T cell activation is initiated by the interaction of the antigen-
specific T cell receptor with a peptide presented by the MHC. This interaction conveys 
specificity, leading to the activation of only antigen-specific T cells. This signal is often 
termed “signal 1” (Figure 2). Following TCR-peptide/MHC ligation, a T cell then 
receives a number of costimulatory signals [64-66]. A key costimulatory signal in this 
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pathway that permits the activated naïve T cells to become functional effector/memory T 
cells is provided by CD28-CD80/86 interaction [67], which has often been referred to as 
“signal 2.” In early studies it was shown in vitro that T cells that receive signals through 
their TCR in the absence of engagement of the CD28-CD80/86 costimulation pathway 
became non-responsive, a state of T cell non-responsiveness often referred to as anergy 
[43,68]. Following induction of signal 2, cytokines are produced that impart the final 
signal for T cell activation, and this is termed “signal 3” [65,69,70]. Although these three 
critical signals are required for the full activation of T cells, additional signals such as 
those derived from CD40-CD154 interaction can have potent effects on the activation of 
naïve T cells [71-74] (Figure 2).  
Understanding of these mechanisms provided the conceptual basis for the induction 
of peripheral transplantation tolerance, where the in vivo disruption of the costimulatory 
process – referred to as costimulation blockade – leads to the induction of tolerance in an 
antigen-specific manner [43]. 
Costimulation blockade therapies can target several different steps in the process of 
T cell activation. However, the CD40-CD154 pathway linking signal 1 to signal 2 has 
been identified to be a critical step in the activation of naïve T cells. Anti-CD154 mAb 
blocks the interaction between CD154 on the T cell and CD40 on the APC [75,76], and 
prevents the differentiation of naïve T cells to effector/memory T cells [76,77] (Figure 
2).  
In peripheral tolerance induction protocols, anti-CD154 monotherapy significantly 
improves islet [78] and cardiac [79] allograft survival in mice and islet allograft survival 
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in non-human primates [80-83]. In combination with a donor-specific transfusion (DST), 
anti-CD154 monoclonal antibody (mAb) induces permanent islet [78] and prolonged skin 
[84] allograft survival in mice. DST provides selective activation of the alloantigen-
specific T cells, and our lab has shown that the subsequent blockade of costimulation by 
anti-CD154 mAb leads to selective depletion of only the specific alloantigen-reactive 
CD8+ T cells [85,86]. Another reagent, CTLA4-Ig, binds to the costimulatory molecules 
CD80/86 on the APC. This blocks its interaction with CD28 on the T cell, preventing 
signal 2. CTLA4-Ig monotherapy induces the survival of xenogeneic islets [87] and 
allogeneic cardiac grafts [88]. Not surprisingly, the combination of anti-CD154 mAb and 
CTLA4-Ig has shown great potential in prolonging skin and cardiac allograft survival in 
mice [89]. 
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FIGURE 2: COSTIMULATION BLOCKADE 
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Figure 2. Activation of a T cell involves a series of interactive steps with an APC. The 
first signal imparts antigen specificity and commences when the TCR engages the 
antigen/MHC complex presented by the APC and it is commonly referred to as “signal 
1.” In subsequent steps, the T cell upregulates CD154, which matures the APC by 
engaging CD40. The next step commonly referred to as “signal 2” involves the 
upregulation of costimulatory molecules by the mature APC. These activated APCs 
secrete cytokines, which provide the final activation signals to the T cell; this step is 
commonly referred to as “signal 3.” Protocols based on costimulation blockade can 
prevent T cell activation by targeting steps in the T cell activation cascade. Anti-CD154 
mAb prevents the T cell from licensing the APC by blocking the interaction between 
CD154 and CD40. This prevents the upregulation of costimulatory molecules and the 
secretion of stimulatory cytokines, thus depriving the T cell of signals 2 and 3. As a 
result, of costimulation blockade, the T cell does not develop an activated phenotype, and 
consequently becomes tolerant to allogeneic antigens.  
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Costimulation Blockade‐Based Strategies for the Induction of Hematopoietic Chimerism 
Effective as a peripheral tolerance induction protocol, costimulation blockade 
protocols based on blockade of the CD40-CD154 pathway have also been used to 
establish hematopoietic chimerism leading to the generation of central tolerance [57-59]. 
By establishing multi-lineage hematopoietic chimerism, these non-cytoreductive 
protocols have proven to promote robust transplantation tolerance to a variety of solid-
organ allografts across fully-allogeneic barriers when transplanted several weeks after 
bone marrow transplantation (BMT) [57,58] or concurrent with BMT [59,90]. 
Furthermore, because donor-reactivity against the host is dependent on the CD40-CD154 
pathway [91], costimulation blockade effectively establishes hematopoietic chimerism in 
the absence of GVHD [57,58].  
Our lab has developed a conditioning regimen for the induction of hematopoietic 
mixed chimerism that is based on costimulation blockade, and due to its minimal toxicity 
is amenable to clinical use. By coupling donor specific transfusion with anti-CD154 
mAb, Seung et al. were able to establish mixed chimerism across fully MHC-disparate 
barriers by transplanting 50x106 bone marrow cells in the absence of radiation [58]. On 
the first day of tolerance induction (referred to as “day -7”), recipients received 10x106 
splenocytes from the donor in the form of DST intravenously (i.v), and a 0.5mg dose of 
anti-CD154 mAb intraperitoneally (i.p). Three days later, another 0.5mg dose of anti-
CD154 mAb was given i.p. Four days later (referred to as “day 0”), the recipients 
received a third 0.5mg dose of anti-CD154 mAb, and were transplanted with donor-
strain-matched bone marrow i.v. Four days after transplantation, a final 0.5mg dose of 
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anti-CD154 mAb was administered. Depending on the genotype of the recipient and the 
donor, this protocol can produce levels of mixed chimerism that range between 1-10%. 
Interestingly, permanent tolerance to donor-specific skin allografts transplanted on the 
same day as the bone marrow, or eight weeks post bone marrow-transplant, can be 
established in animals that circulate as low as 1% donor-origin peripheral blood 
mononuclear cells (PBMCs).  
Innate Immunity and Transplantation Tolerance 
As costimulation blockade protocols move closer to clinical reality, investigations 
into the interplay between innate and adaptive immunity have intensified. Although 
alloantigen-specific responses dictated by the adaptive immune system are paramount in 
transplant rejection, the role of antigen-independent responses by the innate immune 
system is increasingly being appreciated [92-98]. Transplantation can result in the 
activation of innate immunity via several mechanisms including tissue damage, ischemia, 
reperfusion, and through the introduction of pathogens present on colonized organs. 
Activation of innate immunity leads to the modulation of adaptive immunity, and has 
been shown to impair transplantation tolerance induction and allograft survival [99-108]. 
The mechanisms that govern innate immune activation will be the focus of the next 
section. 
Signaling Pathways Involved in Innate Immune Cell Activation 
As mentioned earlier, cells of the innate immune, in contrast to B and T 
lymphocytes, use a limited repertoire of non-rearranged receptors to perform their 
sentinel functions. These receptors, referred to as pattern recognition receptors (PRRs), 
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have evolved to recognize conserved pathogen-associated moieties, such as microbial 
cell-wall components, hypomethylated DNA, and double-stranded RNA (dsRNA) [109]. 
The three best-characterized PRRs include Toll-like receptors (TLRs), retinoic acid 
inducible gene I (RIG-I)-like receptors (RLRs) and nucleotide binding and 
oligomerization domain (NOD)-like receptors (NLRs). 
TLRs 
Members of the TLR family all share a structural homology to the Drosophila 
receptor Toll, which in 1985, was found to govern control over body pattern formation 
[110,111]. The toll receptor was demonstrated to control the function of a morphogen 
protein known as dorsal [112]. Dorsal, a member of the NF-κB family, was found to be a 
critical determinant in the dorsoventral axis formation in drosophila [112]. In 1996, 
Lemaitre and colleagues discovered that the toll receptor, when engaged by its putative 
ligand spatzle, controlled a signaling cascade that regulated the antifungal molecule 
drosomycin in adult fruit flies [113]. They showed that flies deficient in Toll showed 
marked susceptibility to disseminated Aspergillus fumigates infection, a relatively weak 
pathogen in insects, highlighting the importance of the toll pathway in fungal immunity. 
Interestingly, wild-type and Toll mutants demonstrated similar survival to infection with 
the gram-negative bacterium Escherichia coli, indicating that other pathways than Toll 
regulated the expression of the Drosophila’s antibacterial peptides such as Diptericin 
[113]. A year later, Ruslan Medzhitov and Charles Janeway discovered the human 
homologue of Toll [114]. In the decade to follow, 12 additional mammalian TLRs would 
be discovered [115].  
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TLRs are found on a vast number of cells, including those of the innate and adaptive 
immune system. Expression has also been described on non-immune cells, such as those 
of the endothelium and organ parenchyma. Expression patterns of TLRs, however, vary 
from tissue to tissue. For example TLR7 and TLR9 - which recognize ssRNA [116,117] 
and unmethylated CpG-DNA [118], respectively - are thought to be largely restricted to 
hematopoietic cells such as B cells and conventional (cDC) and plasmacytoid (pDC) 
dendritic cells [119,120]. In contrast, TLR3, which recognizes dsRNA [121], has a 
broader distribution, and can also be found on non-hematopoietic cells such as astrocytes, 
epithelial cells of the cervix, airway, uterus, vagina, intestine, and cornea 
[119,120,122,123]. In addition, TLRs also differ in their subcellular localization. Certain 
TLRs, such as TLR1, 2, 4, 5, 6, 10, and 11 are mainly found on the extracellular surface 
of cells, while TLRs 3, 7, 8, and 9 are restricted to compartments within the cell such as 
endosomes [124].   
Structurally, TLRs are type I integral transmembrane receptors that have a leucine-
rich region (LRR) located in their ectodomain, and a Toll/Interleukin (IL)-1 receptor 
(TIR) domain found on their cytosolic face [115,123]. The LRR domain contains a region 
of 19-25 tandem leucine-rich repeats, and provides the receptor with its ligand specificity 
[123]. TLRs with similar primary amino acid sequences have been categorized into five 
subfamilies: TLR2, TLR3, TL4, TLR5, and TLR9 subfamilies [124]. Members of each 
subfamily recognize structurally related patterns. For example, those in the TLR9 family 
- TLR7, 8, and 9 - all recognize distinct nucleic acid moieties, while those in the TLR2 
family - TLR1, 2, 6, and 10 - recognize microbial lipids [123]. Interestingly, TLR4 has a 
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broad range of specificities that include bacterial lipopolysaccharide [125,126], viral 
glycoproteins [127], as well as host-derived molecules such as heat shock proteins 
(HSPs) [128], fibronectin [129], and hyaluronic acid [130]. The ligand specificities for 
the TLRs are summarized in Table 1.  
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TABLE 1: OVERVIEW OF PRRS: LIGANDS, ADAPTORS, CELL LOCALIZATION, AND ROLE IN 
TRANSPLANTATION 
 
PRR Adaptor Stimulatory Motif Motif Origin Tissue Distribution 
Subcellular 
Localization Role In Transplantation 
TLR1/2 MyD88 Triacyl Lipopeptides [131] Zymosan [132] 
Bacteria 
Fungi 
B cells, Tregs, Teffs, 
NK, Monos, pDCs  Cell Surface 
1) Activation by Pam3Cys abrogates 
tolerance induction to skin [133] and 
cardiac [108] allorafts 
TLR2/6 MyD88 Diacyl lipopeptides [134] Zymosan [135] 
Mycoplasma 
Fungi 
B cells, Tregs, Teffs, 
NK, Monos, pDCs Cell Surface ND 
TLR3 TRIF dsRNA [121] Viruses B cells, NK, various epithelial cells Endosome 
1) Activation by pI:C abrogates 
tolerance induction to skin allografts 
[133] 
TLR4 MyD88 TRIF 
LPS [126] 
Taxol [136] 
RSV Fusion Protein [127] 
HSPs [128,137] 
Fibronecitn [129] 
Hyalorinic Acid [130] 
Gram (-) Bacteria 
Plants 
Virus 
Host 
Host 
Host 
B cells, Monos, Tregs Cell Surface 
1) Activation by LPS abrogates 
tolerance induction to skin allografts 
[133] 
2) Hyporesponsive SNPs are 
associated with improved survival of 
lung [138,139] and renal [140-142] 
allografts 
TLR5 MyD88 Flagellin [143] Bacteria Tregs, Teffs, NK, Monos Cell Surface ND 
TLR7 MyD88 ssRNA [116,117] Viruses B cells, Tregs, pDCs Endosome ND 
TLR8 MyD88 ssRNA [116] Viruses B cells, Tregs, Monos Endosome ND 
TLR9 MyD88 CpG-containing DNA [118] Bacteria and Viruses B cells, pDCs Endosome 
1) Activation by CpG-DNA 
abrogates tolerance induction to skin 
[133] and cardiac [108] allorafts 
TLR10 ND ND ND B cells, pDCs Cell Surface ND 
TLR11 MyD88 Profilin [144] Uropathogenic Bacteria [145] ND Cell Surface ND 
TLR12 ND ND ND ND Cell Surface ND 
TLR13 ND ND ND ND Cell Surface ND 
RIG-I IPS1 dsRNA [146] Viruses Various Cytoplasm ND 
MDA-5 IPS1 dsRNA [147,148] Viruses Various Cytoplasm ND 
NALP3 ASC CARDINAL 
Peptidoglycan [149] 
Uric acid [150] 
ATP [151] 
Bacteria 
Host 
Host 
Various Cytoplasm ND 
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Upon recognition of its cognate ligand, TLRs activate specific signaling cascades 
that lead to a potent immunostimulatory response characterized by rapid induction of 
proinflammatory cytokines, antimicrobial peptides, and the enhanced expression of 
adhesion and costimulatory molecules [119]. The coupling of pathogen sensing and gene 
transcription is mediated by a family of TIR containing-adaptor molecules. TLRs, which 
function as dimers, undergo a conformational change after binding to their ligand. The 
intracellular TIR domains of each receptor rearrange, come together, and form a new 
stage for additional signaling molecules that contain the same TIR motif. Five adaptor 
molecules that bind to the TIR domain of TLRs have been characterized: myeloid 
differentiation primary response gene-88 (MyD88), TIR-domain-containing adaptor 
protein inducing IFN-β (TRIF), MyD88-adaptor-like (MAL), TRIF-related adaptor 
molecule (TRAM), and sterile-α-and armadillo-motif-containing protein (SARM) [152].  
 MyD88 was the first of the five to be described [153], and it was shown to be 
indispensable for cytokine induction to a variety of PAMPs [154,155]. It is now known 
that MyD88 is crucial for signaling of all TLRs with the exception of TLR3, which relies 
on TRIF [123,124] (Figure 3). As a result, TLR signaling pathways are typically referred 
to as the MyD88-dependent pathway or the MyD88-independent pathway (also called the 
TRIF pathway). MAL functions as a bridging adaptor for TLR2 and TLR4, aiding in the 
recruitment of MyD88 to these receptors [152]. TRAM is also thought to be important in 
TLR4 signaling, as TRAM is required for LPS-mediated expression of cytokines 
downstream of the MyD88-independent pathway [156]. SARM, in contrast, is believed to 
be a negative regulator of TLR signaling, largely by inhibiting the function of TRIF  
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[152].  
Both TLR signaling pathways have a common target, the transcription factor Nuclear 
Factor (NF)-κB. Following recruitment to the TLR, MyD88 recruits the kinases IL-1 
receptor-associated kinase (IRAK)-4 and IRAK-1, which subsequently activate tumor 
necrosis factor receptor-associated factor (TRAF)-6.  TRAF-6 stimulates the inhibitor of 
kappa B kinase (IκK) complex to phosphorylate and inactivate the inhibitor of kappa B 
(IkB). After phosphorylation, IkB releases NF-κB and permits its translocation into the 
nucleus, where it initiates the transcription of numerous inflammatory cytokines and 
chemokines [123]. For NF-κB activation, the TRIF pathway is thought to signal via two 
separate pathways. Through an N-terminal region consensus motif, TRIF is able to 
directly recruit TRAF-6 [157], while its C-terminus can recruit the molecule receptor-
interacting protein (RIP)1 [158]. Both TRAF-6 and RIP1 are believed to converge at the 
level of IκK [152].  
The MyD88 and TRIF pathways are also able to couple pathogen recognition to the 
induction of the type I interferons (IFNα/β). Interestingly, not all TLRs that recruit 
MyD88 to their TIR domain are able to access this pathway. In fact, only the endosomal 
TLRs 7, 8, and 9 are able to signal through the MyD88→IFNα/β axis [159]. Following 
recognition of either ssRNA or unmethylated CpG-DNA, a large complex consisting of 
MyD88, TRAF-3, TRAF-6, IRAK-4, IRAK-1, IκK-α is recruited to the TLR. This then 
results in the phosphorylation and activation of interferon regulatory factor (IRF)7 [160-
165]. Once activated, IRF7 translocates to the nucleus and binds to interferon-stimulated 
response elements (ISRE) to induce the expression of type I IFN, as well as other IFN-
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inducible genes [159,165,166].  Interestingly, TLR7 and TLR9 activation does not lead to 
type I IFN induction in all cell types. Stimulation of TLR7 and TLR9 in conventional 
DCs produces only cytokines that are downstream of the NF-κB pathway, while 
activation of these receptors in plasmacytoid DCs yields both NF-κB-dependent 
cytokines and IFN-α [122]. TRIF-mediated induction of type I IFN following TLR3 or 
TLR4 activation, involves recruitment of TRAF-3 to the N-terminal region of TRIF 
[160,161,167,168]. TRAF-3 then activates TANK-binding kinase (TBK) 1 [160], which 
phosphorylates IRF3 and IRF7 leading to the induction of type I IFN [157]. Thus, TLRs 
constitute a complex family of PRRs that can modulate the immune response to a variety 
of stimuli using a multitude of signaling pathways. 
RLRs and NLRs 
In addition to TLRs, members of the RLR and NLR families can link pathogenic 
perturbations to immune modulation, and thus profoundly affect transplantation 
outcomes.  In contrast to TLRs, RLRs are cytosolic receptors that detect nucleic acids 
upon viral infection, and are expressed ubiquitously by nucleated cells. Cytosolic RLRs, 
exemplified by the proteins RIG-I and melanoma differentiation-associated factor-5 
(MDA5), recognize double stranded RNA (dsRNA) located in the cytosol following 
replication by a ssRNA virus, or infection with a dsRNA-genome virus, through 
interaction with their helicase domains [165]. RLRs contain a caspase recruitment 
domain (CARD) [146] which link detection of viral dsRNA to the transcription of 
inflammatory cytokines and IFN-α/β by forming homotypic interactions with the CARD-
containing molecule interferon-β promoter stimulator (IPS-1, also known as CARD 
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adaptor inducing IFN-β (CARDIF), mitochondrial antiviral signaling protein (MAVS), 
and virus-induced signaling adaptor (VISA)) [169-172]. Activation of IPS-1 triggers 
TRAF-3, and subsequently members of the IκK family, specifically TBK-1 and IκKε 
(also known as inducible IκB kinase, IκK-i), to phosphorylate and activate IRF3 and/or 
IRF7 [160,161,173-176]. As described above, activation of IRF3 and IRF7 results in type 
I IFN production following their translocation to the nucleus and binding to interferon-
stimulated response elements [159,165,166]. RLRs can also activate NF-κB-dependent 
cytokines, likely through a pathway that involves IPS-1 triggering of FAS-associated 
death domain-containing protein (FADD) to induce caspase-8/-10 [165].  
It has recently been recognized that cytoplasmic sensing of DNA can also trigger 
IFN-α and IFN-β production [177-179]. This pathway is thought to intersect with the 
RIG-I and MDA5 pathways at the level of TBK-1 and IKK-I [177], and requires IRF3 for 
IFN-α/β induction [178]. A candidate cytosolic recognition receptor that senses and is 
activated by DNA has been described [180]. This receptor, known as DNA-dependent 
activator of IFN-regulatory factors (DAI), was reported to induce type I IFN upon 
recognition of bacterial, mammalian and viral DNA [180]. 
Similar to RLRs and DAI, NLRs consist of a large family of cytosolic immune 
regulatory receptors that couple the recognition of pathogen-associated patterns to a 
strong inflammatory response. NOD-like receptors belong to a diverse gene family for 
which the more unifying name nucleotide-binding domain and leucine-rich repeat 
containing gene family (NLR) has recently been proposed [181]. Similar to TLRs, NLRs 
possess leucine-rich repeat domains that serve to detect conserved microbial motifs. They 
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possess a domain that functions in nucleotide binding and self-oligomerization domain, 
which was given the appellation NOD. Protein-protein interactions are mediated by 
CARD, pyrin or baculovirus inhibitor repeat domains, contained in the N-terminus of the 
receptor [182]. There are currently 23 human and 34 murine NLRs that have been 
described [182].  
Three of the best-characterized NLRs include NOD1, NOD2, and NALP3. NOD1 
and NOD2 translate the presence of cytosolic bacterial peptidoglycan molecules into 
activation of the NF-κB and mitogen-activated protein kinase (MAPK) pathways. In 
contrast, NALP3, also known as cryopyrin, links cytosolic recognition of microbial 
components such as peptidoglycan, as well as the host molecules ATP and uric acid, to 
the induction of IL-1β and IL-18 via a molecular complex named the inflammasome 
[150,151,183]. The inflammasome – which consists of the NLRs NALP3, IPAF or 
NALP1, the adaptor molecules ASC and CARDINAL, and caspase-1 – has also been 
reported to produce IL-1β in response to both microbial and host DNA [184]. Hence, the 
innate immune system has evolved a multitude of mechanisms by which danger signals 
such as cellular stress and microbial invasion can be translated into a variety of stimuli 
that active innate immunity and modulate the adaptive immune system during  
transplantation. 
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FIGURE 3: PATHOGEN RECOGNITION SYSTEMS 
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Figure 3. The pathways for select TLRs, RLRs and NLRs are shown.  TLRs initiate a 
vigorous inflammatory response after sensing various PAMPs, such as microbial cell-
wall components, hypomethylated DNA, and double-stranded RNA (dsRNA). TLR 
signaling downstream of the adaptor molecules MyD88 and TRIF results in the 
transcription of cytokines regulated by NF-κB and the MAP kinase pathway. Select TLRs 
are also capable of inducing expression of type I IFN. The RNA helicase receptors 
MDA5 and RIG-I couple the recognition of viral RNA to the induction of pro-
inflammatory cytokines and IFNα/β via the adaptor molecule IPS-1. NLRs, such as 
NOD1 and NOD2 recognize components of the bacterial cell wall, and induce NF-κB 
activation by triggering the serine/threonine kinase RIP2/RICK. The NLR NALP3 
complexes with the adaptor molecules ASC and CARDINAL, and caspase-1 after 
sensing bacterial peptidoglycan. This complex, known as the inflammasome, catalyzes 
the processing of pro-IL-1β to the mature form.   
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PRRs: The Link Between Innate and Adaptive Immunity 
 In the last several years, the role of PRR signaling in adaptive immunity has been 
intensively studied. It is evident that activation of these germ-line encoded receptors can 
have profound effects on the adaptive immune response. Undoubtedly, we have only 
begun to understand the physiological effects of PRR activation; however, in the next 
section we will review some of the reported effects of PRR signaling on B cells, 
regulatory T cells (Treg), and effector T cells (Teff).   
Role of PPRs in B‐cell Immunity 
B cells play a significant role in transplantation by acting as both antigen-presenting 
cells and as effectors. As described above, B cells contribute to hyperacute rejection of 
solid organs, and they also pose a significant barrier to the engraftment of allogeneic 
bone marrow [185]. TLR signaling appears to affect B cell function in a number of ways. 
First, TLR signals are important in DC maturation and the subsequent activation of helper 
T cells (described in more detail later), which are crucial to provide stimulatory signals to 
B cells. Second, TLR signaling on B cells appear to be critical for activation and antibody 
production.  In 2005, Pasare and Medzhitov, showed signaling through TLRs governs 
several aspects of B cell physiology, including the production of IgM, IgG1, and IgG2 
antibodies, and the differentiation into germinal center cells [186]. Interestingly, certain 
aspects of the B cell phenotype, such as IgE and IgA responses, were shown not to be 
mediated by TLRs [186]. 
In addition to regulating differentiation and activation, TLR signaling on B cells may 
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also dampen immune responses in certain contexts. For example, in 2008, Lampropoulou 
and colleagues reported that LPS or CpG-DNA-activated B cells could suppress Th1 and 
Th17 immune responses, and stimulate the recovery of autoimmune experimental 
encephalomyelitis [187]. Therefore, it is clear that TLR signals can directly affect the 
phenotype of adaptive immune cells, and thus, the outcome of immune responses.   
Role of PRRs in T‐cell Immunity 
The role of TLRs in T cell function has also received extensive study in recent years. 
T cells are known to be pivotal players in allograft rejection, and their relationship with 
antigen presenting cells has been abundantly demonstrated. As described before, TLR 
activation can affect key steps in T cell activation, namely the upregulation of 
costimulatory molecules and secretion of stimulatory cytokines by APCs. Signaling 
downstream of MyD88 also appears to be important in the generation of CD4+ T cell 
memory responses [188]. In addition, TLRs can profoundly affect the intercourse 
between effector and regulatory T cells. This has significant ramification for 
transplantation, as the generation and maintenance of CD4+Foxp3+ Tregs has been shown 
to be  indispensable to the survival of allografts [189-191].  
 Both Tregs and Teffs have been shown to express various TLRs [192]. Therefore, 
TLR signaling can affect Treg-Teff interactions by directly activating receptors on either 
subset. Interestingly, Tregs have been shown to express a more diverse repertoire of 
TLRs, including TLR1, 2, 4, 5, 6, 7, and 8, while non-Treg cells express only TLR 1, 2, 
5, and 6 [192,193]. Consistent with the diverse signaling pathways exhibited by each 
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TLR, distinct PAMPs appear to induce distinct T cell responses.  
For example, Caramalho and colleagues demonstrated that TLR4 activation in 
conjunction with TCR ligation directly induces murine Treg survival and proliferation in 
vitro, as well as enhances their suppressive function in vitro and in vivo [192]. Consistent 
with the idea that TLR activation can produce anti-inflammatory responses as well as 
pro-inflammatory effects, Crellin et al. showed that activation of TLR5 with flagellin 
enhanced both the expression of the key regulatory transcription factor FOXP3, and the 
suppressive capacity of human Tregs [193]. Interestingly, Crellin found that TLR4 
activation in human Tregs did not reverse their anergic phenotype nor induce 
proliferation as Caramalho noted in murine Tregs [194]. Consequently, the influence of 
direct TLR4 stimulation on the Treg phenotype requires further inquiry.  
Interestingly, direct TLR signaling on Tregs can also suppress their regulatory 
abilities and result in enhanced immunity. Building on the observation that the numbers 
of circulating Tregs are significantly reduced in TLR2 knockout mice [195], Sutmuller 
and colleagues tested the hypothesis that triggering of TLR2 on Tregs would result in 
their proliferation [194]. In confirming their hypothesis, they also observed that during 
TLR2-mediated proliferation, Tregs experienced a moratorium of their suppressive 
capabilities. In vivo, TLR2-mediated cessation of suppression translated into enhanced 
anti-fungal immunity. Later that same year, Liu and colleagues also reported that TLR2 
activation in the absence of APCs induced Tregs to proliferate and temporarily lose their 
suppressive capacity [196]. In addition, TLR8 activation on Tregs is also capable of 
reversing their suppressive phenotype. In 2005, Peng et al. demonstrated that 
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pretreatment of Tregs with either ssRNA or guanosine-containing DNA oligonucleotides 
can abrogate their ability to suppress effector T cells in a TLR8-MyD88-IRAK-
dependent fashion [197].  
Collectively these studies suggest that regulatory cells have evolved a tailored 
response to distinct microbes, which allows them to enhance or attenuate immunity given 
the requirement of the organism. For example, as Sutmuller and colleagues have 
postulated [194], in the setting of acute infection, direct TLR ligation on Tregs permits 
the effector arms of the immune system to eradicate the pathogen by reversing 
suppressive mechanisms. Once the pathogen has been cleared, the lack of microbial 
components allows Tregs to regain their suppressive phenotype and provide a balance 
between immunity and tolerance.  
Increasing evidence suggests that regulatory mechanisms can also be affected by 
indirect pathways that do not require Tregs to directly sense PAMPs. In 2003, Pasare and 
Medzhitov demonstrated that microbial induction of the TLR pathway on DCs can enable 
effector T cells to overcome regulatory cell-mediated suppression [198]. The authors 
showed that LPS or CpG-DNA–activated DCs produced soluble mediators that act 
synergistically to render effector CD4+ T cells refractory to Treg-mediated regulation, 
permitting activation of antigen-specific T cells in the presence of Tregs. IL-6 was 
identified as one of the critical cytokines; however, it alone was not capable of blocking 
suppression of effector CD4+ T cells in vitro, suggesting that additional cytokines, such 
as IL-1 or IL-12, are also required. A year later, Yang et al. reported that persistent TLR 
signals were required for the reversal of Treg-mediated tolerance of CD8+ T cells in vivo 
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[199]. Administration of LPS or CpG-DNA was required for Treg-tolerized CD8+ T cells 
to proliferate in the presence of cognate antigen. Direct CpG-DNA activation of TLR9 on 
CD4+ effector cells was also shown to be sufficient to allow their escape from regulatory 
T cell suppression [200]. Together, these studies suggest that a variety of mechanisms 
exist by which TLR activation can affect the adaptive immune response and potentially 
alter transplantation outcomes.  
Evidence of TLR-Mediated Modulation of Transplantation 
Animal Models 
Mounting evidence suggests that transplantation outcomes can be greatly affected by 
environmental perturbations that activate various PRRs such as tissue damage, ischemia 
and microbial infection. In 2003, Goldstein and colleagues used a minor antigen 
mismatch model to investigate the role of TLR2, TLR4 and the adaptor molecule MyD88 
in allograft survival [201]. They reported that rejection of male skin grafts by female 
recipients was dependent on MyD88, as skin grafts from MyD88-deficient male donors 
survived indefinitely when transplanted on MyD88-deficient recipients. The authors also 
demonstrated the MyD88 was critical for optimal DC maturation and homing, and for 
CD8+ T cell priming. Interestingly, both host and donor MyD88 proved important, as 
graft rejection occurred if either the donor or the host expressed functional MyD88 
protein. The role of TLR2 and TLR4 proved less important, as rejection of skin allografts 
occurred in the absence of TLR2 and TLR4 signaling. A year later, the same group 
showed that despite the role of MyD88 in DC maturation, T cell priming, and TH1 
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immunity, fully MHC-mismatched skin and cardiac allografts were rejected with normal 
kinetics in the absence of MyD88 [202].  These data reveal several important insights. 
First, in the setting of minor-antigen mismatches, factors downstream of MyD88 
signaling are critical. Those factors can be contributed, however, by either host or donor, 
and seem to regulate DC function. Second, during strong immune responses, such as 
those seen in fully mismatched allograft rejection, MyD88-independent processes appear 
to be sufficient for alloimmunity. 
To address the role of MyD88-independent pathways in allograft rejection, McKay 
and colleagues examined the role of TRIF and MyD88 in major histocompatibility and 
minor antigen mismatch skin graft rejection [203]. Their work showed that the 
simultaneous absence of MyD88 and TRIF signaling on the donor (H-2b) resulted in 
modest but significantly prolonged skin graft survival when transplanted onto wild-type 
BALB/c (H-2d) mice. Absence of either signaling pathway by itself, however, did not 
prolong skin graft survival. This suggests that the MyD88 and TRIF pathways work 
synergistically to promote rejection of major antigen mismatched allografts. Furthermore, 
like Goldstein et al. [201], McKay attributed the prolonged skin graft survival in this 
model to the role these synergistic pathways play in the migration of donor cells to 
draining lymph nodes. Like cells in Goldstein’s MyD88-/- animals, donor cells in mice 
deficient in both MyD88 and TRIF exhibited impaired ability to traffic to draining nodes. 
Collectively, the data from the above experiments suggest that during allograft rejection, 
TLR-mediated maturation of DCs plays a critical role in alloreactive T cell priming and, 
thus, the survival of the graft.  
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     Given the role that TLR signals have in DC function and T cell priming, Thornley and 
colleagues from our lab hypothesized that direct TLR activation by microbial 
components would abrogate tolerance induction mediated by costimulation blockade. In 
2006, they reported that the activation of either TLR2, TLR3, TLR4 or TLR9 could 
prevent fully mismatched skin allograft survival established with donor-specific 
transfusion and anti-CD154 mAb treatment [133]. DST and anti-CD154 mAb 
conditioning has been shown to induce the deletion of alloreactive CD8+ T cells rapidly 
after tolerance induction, a process critical for graft acceptance [86].  Activation of TLRs 
on the day of tolerance induction was shown to rescue alloreactive CD8+ T cells from 
costimulation blockade-mediated apoptosis [133]. This mechanism proved essential, as 
removal of CD8+ T cells permitted the survival of allografts in the presence of TLR 
agonists.  
A year later, they also showed that rejection of skin grafts in the same model by LPS 
was dependent on TLR4 and MyD88, while polyI:C mediated-rejection was not 
dependent on TLR3 [204]. In addition, a critical role for type I interferon in TLR-
mediated abrogation of transplantation tolerance was demonstrated. Mice deficient in the 
IFN-α/β receptor exhibited prolonged skin allograft survival following DST and anti-
CD154 mAb treatment, even in the presence of LPS or poly I:C. Interestingly, similar to 
LPS and poly I:C, administration of recombinant IFN-β at the time of tolerance induction 
protected alloreactive T cells from costimulation blockade-induced cell death. These data 
indicate that production of type I IFN following TLR activation can contribute to the 
abrogation of transplantation tolerance by preventing the deletion of T cells specific for 
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the graft. It is also tempting to speculate that in the case of polyI:C, type I IFN induction 
via redundant mechanisms of nucleic acid sensing, such as the cytosolic helicase MDA-5, 
are sufficient to prevent peripheral tolerance. 
Additional evidence that TLR activation can compromise tolerance induction 
strategies was provided by Chen and colleagues. In 2006, they reported that treatment 
with the TLR2 agonist Pam3Cys or the TLR9 agonist CpG-DNA on the day of 
transplantation could abrogate anti-CD154 mAb-induced tolerance to fully mismatched 
cardiac allografts [108]. Interestingly, the effects of TLR activation in this model were 
not subscribed to alloantibody production or CD8+ T cells, but to CD4+ T cells. In fact, 
activation of TLR9 at the time of transplant was associated with a decrease in the intra-
graft accumulation of regulatory T cells. Whether or not TLR activation prevented the 
generation of regulatory T cells or affected their migration was not clearly elucidated; 
although, CpG-DNA was shown to prevent the anti-CD154 mAb-mediated upregulation 
of the putative Treg-homing ligands CCL17 and CCL22.  
In a separate set of studies that year, Walker et al. also demonstrated the importance 
of TLR signaling on peripheral tolerance induction. Using a fully-mismatched skin 
transplant model where modest allograft survival is established with anti-CD154 mAb 
and CTLA-4 Ig treatment, the authors demonstrated that MyD88 played a pivotal role 
[205]. They showed that in the absence of MyD88 signaling on both donor and host cells, 
costimulation blockade treatment could yield long-term skin allograft survival. The 
synergistic effect between costimulation blockade and the absence of MyD88 was 
attributed to a decrease in IL-6 production by DCs, and an increase in susceptibility of 
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effector T cells to the suppression of regulatory cells. Taken together, these studies show 
that TLR activation by PAMPs can affect peripheral tolerance induction by several 
mechanisms, which include: 1) modulating APC function, 2) preventing clonal deletion 
of donor-specific T cells, and 3) disrupting immune regulation. 
Clinical Studies 
The role of TLRs in human transplant outcomes has also begun to receive more 
attention. Polymorphisms in TLR4 have been reported to affect the development of graft-
versus-host-disease (GVHD) [206,207], as well as lung [138,139] and renal [140-142] 
allograft survival. The two most common polymorphisms that have been studied are the 
Asp299Gly and the Thr399Ile (TRL4 299/399) mutations. The resulting amino acid 
changes in the extracellular domain of the receptor produce a hyporesponsiveness to LPS, 
as evidenced by a blunted response to inhaled endotoxin [208].  
Endotoxin liberated from the gut during conditioning for BMT has been shown to be 
an important factor in precipitating GVHD [209]. Consequently, investigators have 
hypothesized that hyporesponsiveness mutations in either the donor or recipient would 
correlate with decreased incidence of GVHD. Two reports, however, have produced 
contrary and inconclusive results. In 2001, Lorenz and colleagues showed that TLR4 
mutations correlated with a decrease in risk for GVHD, although the results did not reach 
statistical significance [206]. In contrast, Elmaagacli et al. in a more recent paper claimed 
that the Thr399Ile mutation was associated with an increase in risk [207]. Therefore, the 
role of TLR4 signaling in the pathogenesis of GVHD has not been conclusively 
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established. 
  On the contrary, TLR4 signaling has been more definitively linked to outcomes in 
lung and renal allograft transplantation. In a series of studies by Palmer and colleagues, it 
was demonstrated that both Asp299Gly and Thr399Ile single nucleotide polymorphisms 
(SNP) in the recipient correlated with a decrease in incidence of acute rejection and the 
development of obliterative bronchiolitis, a major cause of morbidity in lung transplant 
patients [138,139]. In support of the hypothesis that induction of pulmonary innate 
immunity by LPS contributes to allograft pathology, Palmer and colleagues have recently 
reported that an increase-in-function polymorphism in the promoter of CD14 correlated 
with a poorer outcome [210]. Increased production of CD14 – a LPS binding protein that 
is indispensable for TLR4 signaling – in patients with the 159TT polymorphism was 
associated with higher rates of bronchiolitis obliterans syndrome, a putative manifestation 
of chronic rejection [211], increased TH1 immunity, and decreased graft survival. 
Together, these three reports indicate that allelic variation in pathways that govern 
pulmonary innate immunity can profoundly affect the development of both acute and 
chronic rejection in recipients of lung transplants. 
Pursuant of a similar hypothesis, Ducloux et al. investigated the role of TLR4 
polymorphisms in renal transplant patients. Concordant with the lung transplant studies, 
they found that renal transplant recipients with TLR4 299/399 polymorphisms benefitted 
from a lower risk of post-transplant atherosclerotic events and acute rejection; however, 
they suffered from a higher incidence of opportunistic infection [140]. Interestingly, 
Palmer and colleagues found that improved outcome was imparted only when the 
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hyporesponsive SNP was found on the donor [141]. No association between acute 
allograft rejection and recipient polymorphism was demonstrated. In support of a 
protective role of TLR4 Asp299Gly ((299)G) in recipients, Fekete et al. reported a year 
later that the (299)G SNP was more frequent in renal transplant recipients with long-term 
acceptance [142]. Furthermore, they documented that SNPs in the putative endogenous 
TLR4 ligand HSP70s also correlated with renal allograft outcome. The HSPA1B 
(1267)AA genotype was more common in renal transplant recipients with good renal 
graft function over 15 years compared to recipients that needed to be consecutively 
transplanted due to graft failure. Taken together, the above clinical and experimental 
studies suggest that by modulating both the innate and adaptive immune response, TLRs 
play an important role in allograft transplantation.  
Viral Infection: A Potent Barrier to Transplantation Tolerance 
The majority of the aforementioned studies have taken a reductionist approach to 
investigate how individual microbial components or specific molecules influence 
transplantation outcomes. However, actual infection stimulates multiple pattern 
recognition systems such as TLRs, RLRs and NLRs simultaneously. Therefore, it is no 
surprise that direct infection by virus has been shown to have deleterious effects on the 
induction of transplantation tolerance. For example, infections with lymphocytic 
choriomeningitis virus (LCMV) before [104], at the time of [101,106,212], or shortly 
after [107] costimulation blockade all impair allograft survival. Interestingly, this effect 
appeared to be virus-specific, as infection with vaccinia virus (VV) and murine 
cytomegalovirus (MCMV) the day after transplantation did not engender allograft 
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rejection [107].  
Barriers to the induction of hematopoietic chimerism and establishment of central 
tolerance in the setting of viral infection have also been reported. Anti-CD154 mAb, 
CTLA4-Ig and busulfan treatment fails to induce bone marrow chimerism and tolerance 
to skin allografts in the setting of multiple viral infections [103]. Moreover, using a non-
myeloablative protocol where anti-CD154 mAb treatment was coupled with sublethal 
irradiation, Forman et al. observed that infection with LCMV on the day of bone marrow 
transplantation resulted not only in allograft rejection, but also proved lethal to the 
recipient [105]. Interestingly, conditioned recipients that were infected and given 
syngeneic bone marrow grafts did not die. Recipients of allogeneic bone marrow died by 
a type I interferon-dependent mechanism, as mice deficient in the type I interferon 
receptor survived. The recent deaths of a cluster of human transplant recipients of 
LCMV-infected organs makes this finding particularly relevant to the safety and efficacy 
of tolerance induction protocols based on costimulation blockade [213].  
TLR activation may abrogate the establishment of hematopoietic mixed chimerism 
in recipients treated with costimulation blockade 
Despite the numerous clinical and experimental studies demonstrating an important 
role for toll-like receptors in solid-organ transplantation, very little is known about their 
function in establishing hematopoietic mixed chimerism. Understanding how TLRs affect 
hematopoietic chimerism induction is critical, however, as it is one of the most promising 
strategies to induce the acceptance of transplanted allografts in the absence of chronic 
immunosuppression. Conditioning regimens based on costimulation blockade are 
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effective at establishing mixed chimerism and inducing transplantation tolerance. 
However, activation of TLRs has been shown to shorten the survival of solid-organ grafts 
in recipients treated with costimulation blockade [133,204].  Therefore, we initially asked 
if perturbations that activate TLRs would also reduce the efficacy of costimulation 
blockade to establish mixed chimerism. In this dissertation, we show convincing data that 
TLR activation during tolerance induction prevents the establishment of hematopoietic 
mixed chimerism and the induction of transplantation tolerance to skin allografts in mice 
treated with costimulation blockade. In support of this hypothesis, we present data that 
TLR4 agonists prevent the establishment of mixed chimerism by inducing the production 
of type 1 IFN and MyD88-dependent factors that upregulate costimulatory molecules on 
APCs, leading to the generation of activated alloreactive T cells. 
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CHAPTER II: MATERIALS AND METHODS 
Animals 
BALB/c (H-2d) and C57BL/6 (H-2b) mice were obtained from Charles River 
Laboratories (Wilmington, MA), or The Jackson Laboratory (Bar Harbor, ME). 
C57BL/10ScSnJ (H-2b, abbreviated as C57BL/10), C57BL/10ScNJ-Tlr4lps-del (H-2b, 
abbreviated as C57BL/10.TLR4–/–), and C57BL/6.129S2-Cd8atm1Mak/J (H-2b, abbreviated 
as C57BL/6.CD8α–/–) mice were obtained from The Jackson Laboratory and bred at the 
University of Massachusetts Medical School. C57BL/6.IRF3-/- mice were the gift of Dr. 
Evelyn Kurt-Jones (University of Massachusetts Medical School). C57BL/6.MyD88–/– 
(N6, abbreviated as MyD88–/–) [214] and C57BL/6.129S2-Ifnar1tm1At (N12, abbreviated 
as IFNAR1–/–) [215] were the gift of Dr. Egil Lien (University of Massachusetts Medical 
School), who originally obtained the MyD88–/– mice from Dr. Douglas Golenbock 
(University of Massachusetts Medical School) and the IFNAR1–/– mice from Dr. 
Jonathan Sprent (Scripps Research Institute, La Jolla, CA). C57BL/6.MyD88-/-IFNAR1-/- 
mice were produced by crossing IFNAR1-/- and MyD88-/- mice, and then performing an 
F1 intercross. Confirmation of the targeted gene deletions were confirmed by PCR (see 
below). All animals were certified to be free of murine hepatitis virus, minute virus of 
mice, mouse adenovirus, Sendai virus, pneumonia virus of mice, ectromelia, LDH 
elevating virus, polyoma, mouse poliovirus, Reo-3 virus, LCMV, Mycoplasma pulmonis, 
and Encephalitozoon cuniculi. All mice were housed in microisolator cages, given ad 
libitum access to autoclaved food, and maintained in accordance with the guidelines of 
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Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School.  
Polymerase Chain Reaction 
Polymerase chain reaction (PCR) assays for the presence of targeted mutations in 
the MyD88 and IFNAR1 genes were performed on cells obtained from the ear. DNA was 
prepared by incubating cells in 21 μl of buffer containing 50mM Tris-HCl, 10mM 
EDTA, 2mM NaCl, 1% sodium dodecyl sulfate, and 1mg/ml proteinase K for 20 min at 
55oC. Samples were then vortexed and incubated for another 20 min at 55oC. 780μl of 
water was then added to the samples, which were then boiled for 5 min. One microliter of 
this sample was amplified for 35 cycles in 50ul of buffer containing 2mM MgCl2, 10mM 
Tris, 50 mM KCl, 2.5mM dNTPs, 1.5 U Taq polymerase (Boehringer Mannheim, 
Mannheim, Germany), 1.5 U anti-Taq antibody (Clontech, Palo Alto, CA) and 0.2μM 
primers.   
To detect the MyD88 gene mutation, two separate PCR reactions, using a 
combination of three primers, were performed. One reaction contained a primer sequence 
specific for the targeted MyD88 gene (5’- AGA CAG GCT GAG TGC AAA CTT GTG 
CTG-3’) and a primer directed to a sequence downstream of the targeted gene (5’-AGC 
CTC TAC ACC CTT CTC TTC TCC ACA-3’).  This reaction produces a 1000 base pair 
(bp) PCR product when the wild-type allele is present. The second reaction contained the 
primer for the neomycin resistance gene contained within the targeting construct (5’- 
ATC GCC TTC TAT CGC CTT CTT GAC GAG-3’) and the primer for the sequence 
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downstream of the target gene (see above). This reaction produces a 1000 bp PCR 
produce only when the mutated allele is present. The denaturation, annealing, and 
extension temperatures were 95oC, 65oC, and 72oC, respectively. The products from each 
reaction were run separately on a 1% agarose gel, and the genotype was assessed from 
the presence or absence of the mutated gene PCR product (i.e. the absence of a product 
from the first reaction, coupled with the presence of a product from the second reaction is 
indicative of a mouse homozygous for the gene mutation).  
To detect the IFNAR1 gene mutation, one reaction using three primer sequences 
was performed. A forward primer specific for the IFNAR1 gene (5’-AAG ATG TGC 
TGT TCC CTT CCT CTG CTC TGA-3’) and a reverse primer for the IFNAR1 gene (5’-
ATT ATT AAA AGA AAA GAC GAG GCG AAG TGG-3’) was used in combination 
with a primer for the neo resistance gene (5’-ATC GAC AAG ACC GGC TTC CAT 
CCG A-3’). DNA from wild-type mice amplified a PCR product that was 151bp, while 
DNA from IFNAR1-/- mice amplified a PCR product that was 826bp in length. The 
denaturation, annealing, and extension temperatures were 95oC, 60oC, and 72oC, 
respectively. 
Antibodies 
Purified hamster anti-mouse CD154 mAb (clone MR1) was produced at The 
National Cell Culture Center (Minneapolis, MN) [216]. FITC-conjugated anti-H-2Kd 
(clone SF1-1.1) anti-mouse H-2Kb-PE (clone AF6-88.5), anti-mouse CD8α-PerCP (clone 
53-6.7), anti-mouse CD8α-Pacific Blue (clone 53-6.7), anti-mouse CD8β-PE (clone H35-
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17.2), anti-mouse CD4-PerCP (clone RM4-5), anti-mouse CD4-PE (clone RM4-4), anti-
mouse CD3-biotin (clone 145-2C11), anti-mouse CD44-APC (clone IM7), anti-mouse 
IFN-γ-APC (clone XMG1.2), anti-mouse IFN-γ-PE (clone XMG1.2), anti-mouse CD11a-
FITC (clone 2D7), anti-mouse CD11a-PE-Cy7 (clone 2D7), anti-mouse CD49b-PE 
(clone DX5), allophycocyanin-conjugated Steptavidin, purified anti-Ly49D (clone 4E5), 
purified anti-mouse CD16/32 (clone 2.4G2) and corresponding isotype control antibodies 
were purchased from BD PharMingen (San Diego, CA).  
Flow Cytometry 
Single-cells suspensions were prepared from heparinized whole blood (acquired 
from the retro-orbital venous plexus) and spleens and washed two times with Ca2+Mg2+-
free Dulbecco’s phosphate-buffered saline (PBS; Invitrogen, Carlsbad, CA) containing 
1.0% fetal clone serum (HyClone, Logan, Utah) and 0.1% sodium azide (Sigma-Aldrich, 
St. Louis, MO). Cells were then incubated for 10 min with purified αCD16/32 
(100ng/1x106 cells) at 4oC before incubation for 20 min with fluorescent antibodies. 
Antibodies were used at a concentration of 0.2ug/1x106 cells unless specifically noted 
elsewhere. Samples were then treated with FACS Lysing Solution (BD Biosciences 
Immunocytometry Systems, San Jose, CA), and then washed two times with PBS before 
fixation in PBS containing 1% paraformaldehyde (Poly-Sciences, Warrington, PA).  
Labeled cells were analyzed with a FACSCalibur or LSRII instrument (BD Biosciences). 
For ex vivo cell analysis, at least 100,000 events were collected, unless specified 
elsewhere. FlowJo software (Tree Star, Ashland, OR) was used to analyze flow data after 
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acquisition.  
Donor-Specific Transfusion and Antibody Treatment 
Donor-specific transfusion (DST) was prepared as previously described [84]. Briefly, 
spleens were harvested from euthanized donors and single-cell suspensions were 
prepared by mechanical disruption. Cells were washed, diluted in PBS and counted with 
either a hemocytometer or a coulter counter (Beckman Coulter, Inc, Fullerton, CA). Cell 
viability was assessed using trypan blue exclusion, and viability was >90%. Recipient 
mice aged 5 to 10 weeks of age were treated with a DST consisting of 10x106 BALB/c 
spleen cells injected intravenously. DST was given on day −7, and 0.5 mg of anti-CD154 
mAb was injected intraperitoneally on days −7, −4, 0, and +4 relative to bone marrow 
transplantation on day 0. Anti-CD4 mAb (clone GK1.5, 0.5mg) or anti-CD8α (clone 
2.43, 0.5mg) was injected intraperitoneally on day −10, −9, and −8 relative to 
transplantation on day 0. We confirmed >90% CD4+ and CD8+ T-cell depletion by flow 
cytometry using antibodies against a noncompeting CD4 (clone RM4–4) epitope and the 
CD8β chain. Anti-NK1.1 antibody (clone PK136, 25μg) was injected i.p. on day −10 
relative to transplantation. We confirmed >90% NK cell depletion by flow cytometry 
using antibodies against CD49b and Ly-49D. 
Bone marrow transplantation 
Single cell suspensions of bone marrow were prepared from femurs and tibias, 
filtered through sterile 70-µm nylon mesh (Becton Dickinson, Franklin Lakes, NJ), 
washed in PBS and counted with either a hemocytometer or a coulter counter. Cell 
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viability was assessed using trypan blue exclusion, and viability was >90%. Recipient 
mice received a single intravenous injection of 50x106 bone marrow cells in a volume of 
0.5 ml D-PBS, as described previously [58]. 
Skin transplantation 
Full-thickness skin grafts 1-2 cm in diameter were obtained from the trunks of donor 
mice and transplanted onto the dorsal flanks of recipients as described [58,84]. Briefly, 
skin was removed from donors euthanized via cervical dislocation and pneumothorax, 
and the subcutaneous layer was scraped with a scalpel to remove muscle and adipose 
tissue. Skin was kept on sterile filter paper moistened with RPMI (Invitrogen) at room 
temperature until transplanted. The dorsal flank of the anesthetized recipient was shaved 
and washed with 70% ethanol. The graft bed was prepared by removing the epidermis 
and dermis down to the fascia of the muscle using scissors. A 1-2 cm2 skin graft was then 
placed on the graft bed and trimmed to fit the prepared area. Grafts were covered with 
Vaseline-impregnated gauze and secured with plastic bandage. One week following 
transplantation, bandages were removed and graft survival was evaluated three times a 
week by visual and tactile inspection. Graft rejection was defined as the first day on 
which the entire epidermal layer of the graft was necrotic. 
Determination of hematopoietic chimerism 
Heparinized whole blood samples were obtained from the retro-orbital venous plexus 
from anesthetized mice for determination of chimerism. The percentage of donor and 
host cells expressing MHC class I in chimeric mice was determined by dual-labeling with 
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antibodies to H-2Kb and H-2Kd as described previously [58]. We defined recipients as 
chimeric if the percentage of donor-origin peripheral blood mononuclear cells (PBMCs) 
was >0.10% at 8 weeks. 
IFN-α/β Bioassay 
IFN-α/β was measured using a standard virus-inhibition bioassay [217]. Briefly, 
whole blood was isolated from mice 8 and 24 hours after the indicated treatment, and was 
then centrifuged to obtain serum. The serum was then diluted two-fold across a 96-well 
plate. Wells were seeded with 3x104 mouse L-929 cells (NCTC clone 929; ATCC, 
Manassass, VA) and incubated overnight. The following day, each well was infected with 
2x105 PFUs of vesicular stomatitis virus (VSV) strain Indiana and incubated for 2 days. 
The cytopathic effects were evaluated using microscopy, and the IFN-α/β titer was 
determined as the reciprocal of the dilution that provided 50% protection from cytopathic 
effects [217]. 
Preparation and injection of TLR agonists and Recombinant IFN-β 
TLR agonists were prepared as previously described [133]. Briefly, LPS from 
Escherichia coli 0111:B4 (Sigma-Aldrich) was purified as previously described [218], 
except that phenol-PBS phase separation was conducted at 2000xg for 30 min to 
accommodate larger volumes. Repurified (pLPS) was suspended in PBS, and we 
assumed a 10% loss during purification [218]. pLPS was stored at 4oC until used. 
Polyinosinic:polycytidylic acid (poly I:C; Sigma-Aldrich) was dissolved in PBS at a 
concentration of 1 mg/ml. The stock was filtered through a 0.45-μm sterile nylon mesh 
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(BD Biosciences), and was stored at −20°C until used. Pam3-Cys-Ser-(Lys)4 (Pam3Cys) 
(EMC Microcollections) was reconstituted in PBS and was stored at -20oC until needed. 
TLR agonists were injected into the peritoneum (i.p.) of mice at the indicated ligand dose 
in a volume of 0.5 ml of PBS. Doses were determined to be active in previous 
publications [133,204]. Recombinant mouse IFN-β was obtained from PBL Interferon 
Source (Piscataway, NJ) and injected i.p. at the indicted dose on the day of DST and the 
first injection of anti-CD154 mAb. 
Alloantibody Assay 
The generation of donor-specific antibodies was determined by flow cytometry. 
Dilutions (undiluted, 1/10, 1/100) of mouse serum were incubated with BALB/c 
thymocytes for 20 minutes at 4○C. Cells were washed in PBS and incubated with FITC-
conjugated polyclonal anti-mouse immunoglobulin (BD Pharmingen) for 20 minutes. The 
median fluorescence intensity (MFI) of the samples was determined by flow cytometry. 
Intracellular IFN-γ Assay 
IFN-γ production was assayed in spleen cells and circulating leukocytes as described 
previously [133]. Briefly, red blood cells from heparinized whole blood or single-cell 
spleen suspensions were lysed using 0.84% ammonium chloride. Cells were then 
incubated for 5 h in Golgiplug (BD Pharmingen) with 10U/ml rIL-2 (R&D Systems) and 
1μg purified anti-CD28 mAb (BD Pharmingen) at 37ºC in the presence of single-cell 
suspensions of irradiated, LPS-treated syngeneic (C57BL/6, H-2b) or allogeneic 
(BALB/c, H-2d) splenocytes (1x106 cells per stimulation). Samples were stained with 
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anti-H-2Kb-PE, anti-CD8α-Pacific Blue, anti-CD4-PerCp, and anti-CD11a-FITC, 
followed by fixation with BD Cytofix/Cytoperm and staining with anti-IFN-γ-APC. 
In vivo Tracking of Donor Specific Transfusion 
BALB/c spleens were harvested and prepared into single-cell suspension by 
mechanical disruption, washed two times in PBS and counted. Splenocytes were 
incubated at 37oC in 5μM carboxyfluorescein diacetate succinimidyl ester (CFSE) 
(Molecular Probes, Eugene, OR). After 15 min, the cells were washed three times in PBS 
and counted. The cells were then suspended in PBS at a concentration of 2x107 cells/ml 
0.5 ml was injected into the tail veins of recipients. Sixteen hours later, recipients were 
euthanized and the splenocytes were recovered. Single-cell suspensions were prepared by 
mechanical disruption, and the cells washed with PBS two times at room temperature. 
Samples were stained with LIVE/DEAD blue (Molecular Probes) for 20 min to visualize 
and exclude dead cells. Cells were then washed with PBS, containing 1.0% fetal clone 
serum, 0.1% sodium azide, before incubating with αCD16/CD32 and fluorescent 
antibodies as described above. A LSR II was used to analyze at least 1x106 events.     
Statistical Methods 
Statistical analyses were made using Graphpad Prizm Software (Graphpad Software, 
Version 4.0, San Diego, CA). Comparisons of three or more means was performed via 
one-way analyses of variance (ANOVA), followed by Bonferroni’s adjusted unpaired t-
tests. Comparisons of two means used unpaired t-tests without assuming equal variance. 
Skin allograft survival curves were generated by the Kaplan and Meier method and 
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compared by the log-rank test. Duration of allograft survival is presented as the median. P 
values <0.05 were considered statistically significant.  
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CHAPTER III: TLR AGONISTS ACTIVATE ALLOREACTIVE T CELLS AND 
PREVENT THE ESTABLISHMENT OF HEMATOPOIETIC CHIMERISM AND 
SHORTEN ALLOGENEIC SKIN GRAFT SURVIVAL IN MICE TREATED WITH 
COSTIMULATION BLOCKADE  
Introduction: 
Mixed hematopoietic chimerism has the potential to be used in lieu of immune-
suppression for the induction of long-term survival of solid organ allografts. The current 
non-myeloablative conditioning regimens that are available for the establishment of 
mixed chimerism require significant depression of the host’s immune system, which can 
put the recipient at risk of infection and neoplasia. Costimulation blockade-based 
regimens are an attractive alternative as they are minimally toxic. However, perturbations 
that activate Toll-like receptors (TLRs) have been shown to reduce the efficacy of 
costimulation blockade-based regimens in inducing tolerance to solid-organs. Therefore, 
environmental stressors such as infection and tissue ischemia that activate TLRs could 
reduce the clinical applicability of costimulation blockade-based protocols. However, the 
effects of TLR activation on the establishment of mixed chimerism using costimulation 
blockade-based protocols is not known.  
We hypothesized that signaling through TLRs at the time of tolerance induction 
would prevent the establishment of mixed chimerism. We confirmed this hypothesis by 
treating animals with various TLR agonists at the start of costimulation blockade 
conditioning. Animals treated with agonists of TLR2, 3, and 4 at the start of the 
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costimulation blockade protocol failed to become chimeric and exhibited shortened skin 
allograft survival. Upon confirmation of this hypothesis, we investigated the cellular 
mechanisms governing this effect in the hope of establishing a conditioning regimen that 
is both safe and effective in a clinical setting. 
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Results: 
1.  TLR agonists administered at the time of DST and anti-CD154 mAb prevent the 
establishment of mixed hematopoietic chimerism and shorten skin allograft survival  
We first tested the hypothesis that TLR agonists given during tolerance induction 
with donor-specific transfusion (DST) and anti-CD154 mAb would prevent the 
establishment of hematopoietic mixed chimerism. To test this, we treated recipient mice 
with our standard costimulation blockade-based conditioning regimen, with or without 
the addition of a TLR agonist on the first day of treatment (Figure 4). Our tolerance 
induction protocol consists of a donor specific transfusion of splenocytes on day −7, and 
four injections of anti-CD154 mAb on days −7, −4, 0, and +4 relative to injection with 
50x106 donor-matched bone marrow cells and skin graft on day 0. We used two donor-
recipient strain combinations: C57BL/6 recipients transplanted with BALB/c DST, bone 
marrow and skin, and the reverse, BALB/c recipients transplanted with C57BL/6 DST, 
bone marrow and skin. We observed that the majority of C57BL/6 mice (29/45) treated 
with BALB/c DST, anti-CD154 mAb and transplanted with BALB/c bone marrow and 
skin established low levels of stable allogeneic hematopoietic chimerism (1.59 ± 1.81% 
of the circulating peripheral blood mononuclear cells (PBMCs) detected at 8 weeks post 
bone marrow transplant were of donor origin; Figure 5, group 1). These mice also 
exhibited prolonged skin graft survival (MST = 144 days). However, subanalysis of the 
groups revealed that the mice that developed hematopoietic chimerism displayed 
permanent skin graft survival (MST > 260 days), while those that failed to develop mixed 
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chimerism exhibited shorter survival (MST = 88 days; p<0.001 vs. treated mice that 
developed chimerism; Figure 5).  
Similarly, BALB/c mice treated with our standard conditioning regimen and 
transplanted with C57BL/6 bone marrow and skin established low levels of chimerism 
(4.3 ± 1.14% of the PBMCs detected at 8 weeks post BM transplant were of donor origin; 
Figure 5, group 5) and exhibited prolonged skin allograft survival (MST > 49 days; 
Figure 5, group 5). We also observed that chimeric mice developed B cells, T cells, and 
mononuclear phagocytes of donor origin in the blood, spleen, and bone marrow, 
indicating multi-lineage cell engraftment (Table 2). 
In contrast, mice treated with a TLR agonist on the day of tolerance induction (day -
7), universally failed to develop chimerism and exhibited shortened skin allograft 
survival. We observed that costimulation blockade-conditioned C57BL/6 mice 
transplanted with BALB/c bone marrow, skin, and treated with the TLR4 agonist LPS 
failed to become chimeric (0/23; p<0.001 vs. group 1), and rapidly rejected BALB/c skin 
grafts (MST = 11 days; p<0.001 vs. group 1; Figure 5, group 2). Demonstrating that this 
effect was not strain-specific, we observed that BALB/c recipients given LPS, C57BL/6 
DST, anti-CD154 mAb and transplanted with C57BL/6 bone marrow and skin also did 
not become chimeric (0/6, p<0.01 vs. group 5) and displayed short skin allograft survival 
(MST = 14 days; p<0.001 vs. group 5; Figure 5, group 6). 
We observed a similar phenotype with recipient mice conditioned with costimulation 
blockade in the presence of the TLR3 agonist poly I:C, or the TLR1/2 agonist Pam3Cys. 
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None of the C57BL/6 (0/23, p<0.001 vs. group 1) or BALB/c (0/3, p<0.01 vs. group 5) 
recipients treated with our standard conditioning regimen and poly I:C on day -7 became 
chimeric when transplanted with allogeneic bone marrow (Figure 5). In addition, 
polyI:C-treated recipients exhibited short survival of donor-specific skin allografts (MST 
= 9 days for C57BL/6 recipients; p<0.001 vs. group 1; MST = 14 days for BALB/c 
recipients; p<0.001 vs. group 5). Similarly, C57BL/6 mice conditioned with 
costimulation blockade and given Pam3Cys failed to become chimeric (0/3; p<0.05 vs. 
group 1), and skin graft survival was short (MST = 10 days; p<0.001 vs. group 1; Figure 
5, group 4).  
Importantly, transplantation of skin allografts was not required for TLR agonists to 
prevent bone marrow engraftment, as C57BL/6 mice conditioned with DST, anti-CD154 
mAb and given BALB/c bone marrow (and no skin graft) became chimeric at 8 weeks 
(6/7), while those given DST, anti-CD154 mAb, LPS, and BALB/c bone marrow did not 
(0/7; p<0.01). These data indicate that TLR agonists prevent induction of mixed 
hematopoietic chimerism and shorten allograft survival in mice treated with DST and 
anti-CD154 mAb. 
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FIGURE 4: TRANSPLANTATION PROTOCOL 
 
Figure 4. Recipient mice are treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 5x107 fully MHC-disparate allogeneic bone marrow cells 
and skin grafts. This protocol permits the establishment of mixed hematopoietic 
chimerism and induces permanent skin allograft survival in the majority of recipients. To 
investigate the effects of environmental perturbants, mice treated with the same 
conditioning protocol were also treated with an injection of 100ug LPS, 50ug poly I:C, or 
100ug of Pam3Cys on day -7, the day of injection of DST and anti-CD154 mAb.
67 
 
 
 
FIGURE 5: TLR AGONISTS PREVENT ALLOGENEIC BONE MARROW ENGRAFTMENT AND  
SHORTEN ALLOGENEIC SKIN GRAFT SURVIVAL 
 
A 
Group Recipient Donor TLR Agonist 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 C57BL/6 BALB/c None 29/45 (64%) 1.59 ± 1.81 144 88 >260 
2 C57BL/6 BALB/c LPS 0/23 (0%)* <0.10 11 11 N/A 
3 C57BL/6 BALB/c poly I:C 0/20 (0%)* <0.10 9 9 N/A 
4 C57BL/6 BALB/c Pam3Cys 0/3 (0%)** <0.10 10 10 N/A 
5 BALB/c C57BL/6 None 4/4 (100%) 4.3 ± 1.14 >49 N/A >49 
6 BALB/c C57BL/6 LPS 0/6 (0%)# <0.10 14 14 N/A 
7 BALB/c C57BL/6 poly I:C 0/3 (0%)# <0.10 14 14 N/A 
 
B        C        D 
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Figure 5. All mice were treated with a DST on day −7 and four injections of 0.5 mg of anti-
CD154 mAb on days −7, −4, 0, and +4 relative to transplantation on day 0 with 50x106 
donor-specific bone marrow cells and skin grafts. Mice treated with TLR agonists were given 
an i.p. injection of 50ug of poly I:C, 100ug LPS, or 100ug of Pam3Cys on day -7 relative to 
bone marrow and skin transplantation. Panel A. Hematopoietic chimerism was defined as 
>0.10% donor-origin peripheral blood mononuclear cells (PBMCs) 7-8 weeks after bone 
marrow injection as detected by flow cytometry. % donor-origin PBMCs is the mean ± S.D. 
of chimerism levels in chimeric mice. *p<0.0001 vs. group 1; **p<0.05 vs. group 1; #p<0.01 
vs. group 5 by chi-square analysis. N/A – not applicable. The median survival time (MST) of 
transplanted skin allografts for each group is displayed in three columns. The column third 
from the right displays the overall MST of the entire group. The second column from the 
right is a subset of that group. It shows the MST of skin grafts on treated mice in the group 
that did not develop mixed chimerism. The column furthest to the right displays the MST of 
skin grafts on treated mice within the group that developed mixed chimerism. Panel B: 
Kaplan-Meier plots for allogeneic skin graft survival in mice treated with DST and anti-
CD154 mAb and transplanted with donor bone marrow and skin (Group 1 from Panel A). 
The mice have been broken down into three groups to reflect the three columns in Panel A 
that show skin graft survival data: All of the mice treated (solid line); only treated mice that 
developed hematopoietic chimerism (dashed line); only treated mice that failed to become 
chimeric (dotted line). p<0.001 for treated mice that became chimeric vs. treated mice that 
failed to become chimeric. Panel C-D. Kaplan-Meier plots for allogeneic skin graft survival 
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in all mice transplanted with allogeneic bone marrow and skin (i.e. third column from the 
right in Panel A) is shown. P<0.001 for DST and anti-CD154 mAb vs. all other groups.  
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TABLE 2: MULTILINEAGE CHIMERISM IS ESTABLISHED IN MIXED CHIMERAS 
 
Tissue % Chimerism %CD3+ %CD4+ T cells %CD8+ T cells %CD19 %CD11b+ Gr-1+ 
% CD11b-
CD11c+ 
Blood 5.8 ± 2.6 62.2 ± 2.6 76.05 ± 3.49 20.95 ± 2.9 17.85 ± 7.7 0.067 ± 0.083 1.6 ± 1.8 
Spleen 8.14 ± 1.02 56.16 ± 3.5 62.22 ± 1.32 34.45 ± 2.14 31.3 ± 2.6 2.98 ± 0.42 0.89 ± 0.12 
Bone Marrow 7.02 ± 1.23 3.64 ± 0.59 0.3725 ± 0.46 0.8675 ± 1.39 23.27 ± 10.67 42.9 ± 8.0 3.2 ± 0.76 
 
 
Table 2: BALB/c mice were treated with a C57BL/6 DST on day −7 and four injections of 0.5 mg of anti-CD154 mAb on 
days −7, −4, 0, and +4 relative to transplantation on day 0 with 50x106 C57BL/6 bone marrow cells and C57BL/6 skin grafts. 
At 8 weeks, blood, spleen, and bone marrow were recovered from mice bearing intact skin grafts and analyzed by flow 
cytometry for percent donor hematopoietic chimerism and the presence of multilineage donor hematopoietic cells. The 
percentages of CD3+, CD19+, CD11b+/Gr-1+, CD11b-/CD11c+ cells represents their proportion of donor (H-2Kb) cells that 
express these phenotypes. The percentages of CD4+ and CD8+ cells represent the proportion of CD3+ cells that express those 
phenotypes. Data represent mean ± SD of four mice.  
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2.  Alloantibodies are not produced following the administration of LPS during 
costimulation blockade 
Given that B cells express TLRs [124], and anti-alloantibodies are known to induce 
allograft rejection [219], one mechanism by which TLR activation could prevent mixed 
chimerism induction is through the stimulation of B cells to produce alloantibodies. To 
investigate this hypothesis, we looked for anti-donor alloantibodies in the serum of 
C57BL/6 mice that were: 1) left untreated, 2) primed with BALB/c DST, or 3) given 
BALB/c DST, anti-CD154 mAb, and grafted with BALB/c bone marrow with or without 
LPS treatment. As shown in Figure 6, completely untreated (naïve) mice had background 
levels of serum alloantibodies (median fluorescence intensity (MFI) = 4.81 ± 0.87, n=4), 
whereas mice primed with BALB/c DST developed high levels of alloantibodies (MFI = 
45.63 ± 5.6; n=4; p <0.001 vs. untreated; Figure 6). In contrast, mice treated with anti-
CD154 mAb at the time of DST injection developed only background to very low levels 
of alloantibodies (MFI = 5.18 ± 0.68; n=6; p=NS vs. untreated, p <0.001 vs. DST 
primed), even in LPS-treated mice that had rejected BALB/c bone marrow (MFI = 8.59 ± 
6.59; n=5; p=NS vs. untreated or DST and anti-CD154 mAb treated, p <0.001 vs. DST 
primed; Figure 6). These data show that: 1) anti-CD154 mAb treatment prevents the 
generation of donor-specific alloantibodies, and 2) the ability of LPS to prevent the 
establishment of costimulation blockade-mediated hematopoietic mixed chimerism is not 
due to the production of alloantibodies. 
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FIGURE 6: LPS ADMINISTRATION DURING COSTIMULATION BLOCKADE 
DOES NOT INDUCE ALLOANTIBODY PRODUCTION 
 
 
 
Figure 6. C57BL/6 mice were treated with BALB/c DST and anti-CD154 mAb 
according to our standard protocol (DST and anti-CD154 mAb without or with co-
injection of 100ug LPS on day -7 relative to transplantation of BALB/c bone marrow on 
day 0. All mice were bled two weeks after transplantation. Serum was analyzed for 
alloantibody content by flow cytometry. Serum was also taken from untreated mice and 
mice primed with a single injection of BALB/c splenocytes (DST) to serve as negative 
and positive controls, respectively for the alloantibody assay. Data are presented as 
median fluorescence intensity (MFI) plus one standard deviation. Data are pooled from 
two independent experiment. *p<0.001 vs. splenocyte (DST) injected only group; p=NS 
vs. untreated group; p=NS for DST and anti-CD154 mAb vs. DST, anti-CD154 mAb and 
LPS. 
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 3.  Host NK cells are not required for TLR-dependent prevention of the establishment 
of mixed chimerism and shortened skin allograft survival in mice treated with 
costimulation blockade 
Based on the absence of alloantibodies in mice treated with DST, anti-CD154 mAb, 
and LPS, we next investigated the cell populations that are responsible for the TLR-
mediated effects. NK cells are known to be a potent barrier to the establishment of 
hematopoietic chimerism [220-222], and have been shown to express TLRs [223]. 
Therefore, we postulated that TLR activation at the initiation of costimulation blockade 
would stimulate host NK cells to become an even more potent barrier to allogeneic bone 
marrow engraftment. To test this, we depleted C57BL/6 mice of NK cells using anti-
NK1.1 mAb, and treated them with our standard costimulation blockade conditioning 
protocol with or without co-injection of LPS or poly I:C at the time of DST. To confirm 
depletion of host NK cells, treated mice were bled the day before transplantation, and 
circulating NK cells were assessed by flow cytometry using antibodies directed against 
the DX5 and Ly49D receptors. We observed that greater than 90% of host NK cells were 
depleted following antibody treatment.  
In the absence of TLR agonists, the majority of NK-cell depleted mice became 
chimeric (11/13), circulating low levels of donor-derived leukocytes (2.45 ± 1.16% at 8 
weeks post transplant; Figure 7, group 4). The mice that became chimeric exhibited 
permanent skin allograft survival (MST > 221 days; Figure 7). The two mice that did not 
become chimeric exhibited prolonged skin graft survival (MST = 72 days). In contrast, 
74 
 
 
 
mice depleted of NK cells and treated with LPS or poly I:C on day −7 failed to become 
chimeric (0/5 and 0/12, respectively; p<0.001 vs. group 4) and both groups exhibited 
shortened skin allograft survival (MST = 12 days for both groups; p=NS vs. group 2 and 
3, respectively; Figure 7). These data indicate that host NK cells are not required for LPS 
or polyI:C to prevent the establishment of mixed hematopoietic chimerism and shorten 
skin allograft survival in mice treated with costimulation blockade.  
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FIGURE 7: LPS AND POLY I:C EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT 
SURVIVAL IN MICE TREATED WITH COSTIMULATION BLOCKADE ARE NOT MEDIATED BY NATURAL 
KILLER CELLS 
 
A 
Group Recipient Donor TLR Agonist 
NK 
Depletion 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in non-
chimeric mice 
(days) 
MST of 
skin grafts 
in chimeric 
mice (days) 
1 C57BL/6 BALB/c None No 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
2 C57BL/6 BALB/c LPS No 0/23 (0.00%)* <0.10 11 11 N/A 
3 C57BL/6 BALB/c poly I:C No 0/20 (0.00%)* <0.10 9 9 N/A 
4 C57BL/6 BALB/c None Yes 11/13 (84.6%) 2.45 ± 1.16 >221 72 >221 
5 C57BL/6 BALB/c LPS Yes 0/5 (0.00%)** <0.10 12 12 N/A 
6 C57BL/6 BALB/c poly I:C Yes 0/12 (0.00%)** <0.10 12 12 N/A 
 
B                 C       
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Figure 7. All mice were treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice in groups 4-6 were given a 25μg injection of anti-NK1.1 mAb i.p on day −10 
relative to bone marrow and skin transplantation. Mice treated with TLR agonist were 
given either an i.p. injection of 50ug of poly I:C, or 100ug LPS on day -7 relative to bone 
marrow and skin transplantation. Panel A. Hematopoietic chimerism was defined as 
>0.10% donor-origin peripheral blood mononuclear cells (PBMCs) 7-8 weeks after bone 
marrow injection. % donor-origin PBMCs is the mean ± S.D. chimerism levels in 
chimeric mice. *p<0.0001 vs. group 1; **p<0.001 vs. group 4 by chi-square analysis. N/A 
– not applicable. Skin survival data have been separated into three groups to distinguish 
chimeric mice from non-chimeric mice. Data from groups 1-3 shown in Figure 5 are 
reproduced here for ease of comparison with other treatment groups. Panel B-C. Kaplan-
Meier plots for allogeneic skin graft survival in all mice transplanted with allogeneic 
bone marrow and skin is shown (third column from the right in Panel A). p<0.01 for DST 
and anti-CD154 mAb vs. DST, anti-CD154 and anti-NK1.1 mAbs; p=NS for DST, anti-
CD154 mAb and LPS vs. DST, anti-CD154, anti-NK1.1 mAbs and LPS; p=NS for DST, 
anti-CD154 mAb and poly I:C vs. DST, anti-CD154, anti-NK1.1 mAbs and poly I:C.  
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4.  Host CD8+ cells are not required for TLR-dependent prevention of the 
establishment of mixed chimerism and shortened skin allograft survival in mice treated 
with costimulation blockade  
Previously, our laboratory has shown that TLR-activation can impair the deletion of 
alloreactive CD8+ T cells in mice treated with DST and anti-CD154 mAb, and that host 
CD8+ T cells are required for LPS to shorten skin allograft survival in these mice [133]. 
To determine if CD8+ T cells are also required for the ability of the TLR agonists LPS 
and poly I:C to prevent the establishment of hematopoietic chimerism, C57BL/6.CD8α−/− 
mice were treated with our standard conditioning regimen with or without an injection of 
LPS or poly I:C at the time of DST. As expected, hematopoietic chimerism developed in 
the majority of C57BL/6.CD8α−/− mice treated with DST and anti-CD154 mAb (12/17; 
2.29 ± 1.76% donor PBMCs at 8 weeks post transplant; Figure 8, group 1). Skin graft 
survival was prolonged in all C57BL/6.CD8α−/− mice treated with costimulation blockade 
(MST = 96 days). However, skin allograft survival was longer in mice that developed 
mixed chimerism (MST = 136 days) compared to mice that failed to become chimeric 
(MST = 51 days). Surprisingly, LPS and poly I:C were able to prevent the establishment 
of chimerism in C57BL/6.CD8α−/− mice treated with DST and anti-CD154 mAb (0/17 
and 0/10, respectively; p<0.001 vs. group 1; Figure 8, groups 2 and 3). Similarly, skin 
graft survival was shortened in C57BL/6.CD8α−/− mice treated with LPS or poly I:C 
(MST = 21 days and 14 days, respectively; p<0.001 vs. group 1).  
Given this surprising result, we further tested the role of CD8+ cells using wild-type 
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C57BL/6 mice depleted of CD8+ cells using an anti-CD8α mAb. C57BL/6 mice were 
depleted of CD8+ cells and treated with our standard conditioning regimen with or 
without LPS or poly I:C at the time of DST injection. To confirm depletion of host CD8+ 
cells, treated mice were bled the day before transplantation, and circulating CD8+ cells 
were assessed by flow cytometry using an antibody directed against CD8β. We observed 
that greater than 95% of host CD8+ cells were depleted following antibody treatment. The 
majority of C57BL/6 mice depleted of CD8+ cells became chimeric (15/17) (0.90 ± 
1.13% donor PBMCs at 8 weeks post transplant) and exhibited prolonged skin allograft 
survival (MST = 144 days; Figure 8, group 7). Again, mice depleted of CD8+ cells and 
treated with LPS or poly I:C on day −7 failed to develop hematopoietic chimerism (0/16 
and 0/19, respectively; p<0.001 vs. group 7; Figure 8, groups 8 and 9). Skin allograft 
survival was also shortened in mice treated with LPS and poly I:C and depleted of CD8+ 
cells compared to CD8-depleted mice not given a TLR agonist (MST = 44 days and 56 
days, respectively; p<0.001; Figure 8, group 8-9). However, skin graft survival was 
significantly longer in TLR agonist-treated mice depleted of CD8+ cells compared to 
mice treated with LPS or poly I:C that had not been depleted of CD8+ cells (p<0.001 for 
group 8 vs. group 5 and for group 9 vs. group 6). These data indicate that host CD8+ cells 
are not required for LPS to prevent the establishment of hematopoietic chimerism in mice 
treated with costimulation blockade. However, CD8+ cells do appear to be important in 
the TLR-mediated rejection of skin allografts. 
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FIGURE 8: LPS AND POLY I:C EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT 
SURVIVAL IN MICE TREATED WITH COSTIMULATION BLOCKADE ARE NOT MEDIATED BY CD8+ CELLS 
 
A 
Group Recipient Donor TLR Agonist 
CD8 
Depletion 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 B6.CD8α-/- BALB/c None No 12/17 (70.5%) 2.29 ± 1.76 96 51 136 
2 B6.CD8α-/- BALB/c LPS No 0/17 (0.00%)* <0.10 21 21 N/A 
3 B6.CD8α-/- BALB/c poly I:C No 0/10 (0.00%)* <0.10 14 14 N/A 
4 C57BL/6 BALB/c None No 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
5 C57BL/6 BALB/c LPS No 0/23 (0.00%)** <0.10 11 11 N/A 
6 C57BL/6 BALB/c poly I:C No 0/20 (0.00%)** <0.10 9 9 N/A 
7 C57BL/6 BALB/c None Yes 15/17 (88.2%) 0.90 ± 1.13 144 72.5 148 
8 C57BL/6 BALB/c LPS Yes 0/16 (0.00%)# <0.10 44 44 N/A 
9 C57BL/6 BALB/c poly I:C Yes 0/19 (0.00%)# <0.10 56 56 N/A 
 
B                   C       
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Figure 8. All mice were treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice in groups 7-9 were given three doses of 0.5mg anti-CD8α mAb i.p. on days 
−10, −9, and −8 relative to bone marrow and skin transplantation. Mice treated with TLR 
agonist were given an i.p. injection of 50ug of poly I:C, or 100ug LPS on day -7 relative 
to bone marrow and skin transplantation. Panel A. Hematopoietic chimerism was defined 
as >0.10% donor-origin PBMCs 7-8 weeks after bone marrow injection. % donor-origin 
PBMCs is the mean ± S.D. chimerism levels in chimeric mice. *p<0.001 vs. group 1; 
**p<0.001 vs. group 4; #p<0.001 vs. group 7 by chi-square analysis. N/A – not applicable. 
Skin survival data have been separated into three groups to distinguish chimeric mice 
from non-chimeric mice in regards to skin MST. Data from groups 1-3 shown in Figure 5 
are reproduced here (as groups 4-6) for ease of comparison with other treatment groups. 
Panel B-E. Kaplan-Meier plots for allogeneic skin graft survival for the entire cohort of 
mice conditioned and transplanted with bone marrow and skin is shown (third column 
from the right in Panel A). Data for skin graft survival in wild-type mice shown in Figure 
5 is shown here for ease of comparison. Panel B: p=NS for DST and anti-CD154 mAb in 
C57BL/6 vs. DST and anti-CD154 mAb in C57BL/6.CD8α-/-; p<0.001 for DST, anti-
CD154 mAb, and LPS in C57BL/6 vs. DST, anti-CD154 mAb, and LPS in 
C57BL/6.CD8α-/-; Panel C: p=NS for DST, anti-CD154 mAb, and poly I:C in C57BL/6 
vs. DST, anti-CD154 mAb, and poly I:C in C57BL/6.CD8α-/-. Panel D: P=NS for DST 
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and anti-CD154 mAb vs. DST, anti-CD154 and anti-CD8 mAbs; p<0.001 for DST, anti-
CD154 mAb, and LPS vs. DST, anti-CD154 and anti-CD8 mAbs and LPS; Panel E: 
p<0.001 for DST, anti-CD154 mAb and poly I:C vs. DST, anti-CD154 and anti-CD8 
mAbs and poly I:C.  
83 
 
 
 
5.  Host CD8+ and NK cells are not required for TLR-dependent prevention of the 
establishment of mixed chimerism and shortened skin allograft survival in mice treated 
with costimulation blockade  
The fact that mixed chimerism was not established in mice treated with 
costimulation blockade and TLR agonists in the absence of either NK or CD8+ cells does 
not exclude the possibility that either population by itself could mediate these effects . To 
test this, mice were depleted of both NK and CD8+ cells and treated with DST and anti-
CD154 mAb with or without LPS and poly I:C at the time of DST injection. We 
confirmed depletion of both populations using flow cytometry as described before. In the 
absence of TLR agonist treatment, most mice developed hematopoietic chimerism (7/8) 
and exhibited higher levels of circulating donor-origin leukocytes (3.67 ± 1.23% donor 
PBMCs at 8 weeks post transplant) as compared to mice not depleted of NK and CD8+ 
cells; (1.59 ± 1.81%, p<0.01; Figure 9, group 4). These mice also displayed prolonged 
skin graft survival (MST = 81 days; Figure 9, group 4). In contrast, co-injection of LPS 
at the time of DST prevented the establishment of mixed chimerism (0/9; p<0.001 vs. 
group 4) and shortened skin allograft survival (MST = 28 days; p<0.001 vs. group 2; 
p<0.01 vs. group 4; Figure 9, group 5). Simultaneous injection of poly I:C at the time of 
DST similarly prevented mixed chimerism (0/14; p<0.001 vs. group 4) and shortened 
skin allograft survival (MST = 21 days; p<0.001 vs. group 3 and 4; Figure 9, group 6). 
Again, as seen with depletion of only CD8+ cells, skin allograft survival in the presence 
on TLR agonists was slightly prolonged in mice depleted of both NK and CD8+ cells as 
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compared to mice treated with LPS or poly I:C, but not depleted of NK and CD8+ cells. 
Taken together, these data indicate that host NK cells and CD8+ cells are not required for 
either LPS or poly I:C to prevent the establishment of hematopoietic chimerism, but 
CD8+ cells likely play a role in the rapid rejection of skin allografts in the setting of TLR 
activation. 
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FIGURE 9: LPS AND POLY I:C EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT 
SURVIVAL IN MICE TREATED WITH COSTIMULATION BLOCKADE ARE NOT MEDIATED BY CD8+  
CELLS OR NATURAL KILLER CELLS 
 
A 
Group TLR Agonist 
NK 
Depletion 
CD8 
Depletion 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of 
skin grafts 
in chimeric 
mice (days) 
1 None No No 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
2 LPS No No 0/23 (0.00%)* <0.10 11 11 N/A 
3 poly I:C No No 0/20 (0.00%)* <0.10 9 9 N/A 
4 None Yes Yes 7/8 (87.5%)  3.67 ± 1.23# 81 23 81 
5 LPS Yes Yes 0/9 (0.00%)** <0.10 28 28 N/A 
6 poly I:C Yes Yes 0/14 (0.00%)** <0.10 21 21 N/A 
 
B               C       
 
86 
 
 
 
Figure 9. C57BL/6 mice were treated with a BALB/c donor-specific transfusion on day 
−7 and four injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 BALB/c bone marrow cells and BALB/c skin 
grafts. Mice in groups 4-6 were given an injection of anti-NK1.1 mAb i.p on day -10, and 
three doses of 0.5mg anti-CD8 mAb i.p. on days -10, -9, and -8 relative to bone marrow 
and skin transplantation. Mice treated with TLR agonist were given either an i.p. 
injection of 50ug of poly I:C, or 100ug LPS on day -7 relative to bone marrow and skin 
transplantation. Panel A. Hematopoietic chimerism was defined as >0.10% donor-origin 
peripheral blood mononuclear cells (PBMCs) 7-8 weeks after bone marrow injection. % 
donor-origin PBMCs is the mean ± S.D. chimerism levels in chimeric mice. *p<0.0001 
vs. group 1; **p<0.001 vs. group 4 by chi-square analysis. #p<0.01 vs. group 1 by 
unpaired t-test. N/A – not applicable. Skin allograft survival data have been separated 
into three groups to distinguish chimeric mice from non-chimeric mice. Data from groups 
1-3 shown in Figure 5 are reproduced here for ease of comparison with other treatment 
groups. Panel B-C. Kaplan-Meier plots for allogeneic skin graft survival for all mice 
transplanted with bone marrow and skin is shown (third column from the right in Panel 
A). Data for skin graft survival in wild-type mice shown in Figure 5 is shown here for 
ease of comparison. Panel B: p=NS for DST and anti-CD154 mAb vs. DST, anti-CD154, 
anti-NK1.1 and anti-CD8 mAbs; p<0.001 for DST, anti-CD154 mAb, and LPS vs. DST, 
anti-CD154, anti-NK1.1, anti-CD8 mAbs, and LPS; p<0.001 for DST, anti-CD154 mAb, 
and LPS vs. DST, anti-CD154, anti-NK1.1, and anti-CD8 mAbs; Panel C: p< 0.001 for 
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DST, anti-CD154 mAb and poly I:C vs. DST, anti-CD154, anti-NK1.1, anti-CD8 mAbs 
and poly I:C; p<0.001 for DST, anti-CD154 mAb, anti-NK1.1, and anti-CD8 mAbs and 
poly I:C vs. DST, anti-CD154, anti-NK1.1, and anti-CD8 mAbs. 
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6.  TLR4 activation prevents the induction of tolerance in both the CD4+ and CD8+ T 
cell compartment in mice treated with costimulation blockade 
We next wanted to determine if LPS-mediated rejection of BALB/c allografts was 
dependent on host CD4+ T cells. However, we have previously shown using BALB/c 
mice as recipients of C57BL/6 bone marrow that CD4+ T cells are required for the 
establishment of mixed chimerism in mice treated with DST and anti-CD154 mAb, 
presumably because they are required for tolerizing the alloreactive CD8+ pool [90]. To 
determine if CD4+ cells were also required for the establishment of mixed chimerism in 
the reciprocal strain combination (C57BL/6 mice as recipients, and BALB/c mice as 
donors), mice were depleted of CD4+ cells using the GK1.5 mAb. Consistent with our 
previously published results, most mice depleted of CD4+ cells did not become chimeric 
(1/12; p<0.001 vs. group 1) and exhibited short skin graft survival (MST = 46 days; 
p<0.001 vs. group 1; Figure 10, group 3). Not surprisingly, all mice depleted of CD4+ 
cells and treated with DST, anti-CD154 mAb, and LPS also failed to become chimeric 
(0/12) and displayed short skin survival (MST = 18 days; p<0.01 vs. group 2; Figure 10, 
group 4). Interestingly, although the skin graft survival exhibited by these mice was short, 
it was longer than mice treated with DST, anti-CD154 mAb and LPS but not depleted of 
CD4+ cells (p<0.01 vs. group 3). These data indicate that CD4+ cells are important for 
both chimerism induction and skin graft survival. It is also likely, given the slight 
prolongation in skin survival time of mice depleted of CD4+ cells and treated with LPS 
compared to mice treated with LPS but not depleted of CD4+ cells, that CD4+ cells also 
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participate in the acute rejection of skin allografts after TLR activation.  
Therefore, because mixed chimerism could not be established in recipients treated 
with TLR agonists in the absence of either CD4+ or CD8+ cells, we hypothesized that 
TLR activation broke tolerance in both compartments and, consequently, both subsets 
would have to be depleted in order to establish mixed chimerism in mice treated with 
costimulation blockade and LPS. To test this hypothesis, we depleted C57BL/6 mice of 
both CD4+ and CD8+ cells and then treated the mice with our standard costimulation 
blockade protocol with or without co-injection of LPS. CD4 and CD8-depleted mice 
developed low levels of hematopoietic chimerism (4/4; 2.42 ± 0.55% donor-origin 
PBMCs at 8 weeks post transplant) and exhibited permanent skin graft survival (MST 
>228 days; Figure 10, group 5). In support of our hypothesis, low levels of 
hematopoietic chimerism (1.14 ± 0.35% donor-origin PBMCs at 8 weeks post transplant) 
was observed in all CD4 and CD8-depleted mice given LPS at the time of DST (4/4; 
Figure 10, group 6). Interestingly, the level of chimerism in CD4 and CD8-depleted mice 
given LPS was significantly lower than CD4 and CD8-depleted mice not given LPS 
(p<0.05). Nevertheless, mice depleted of CD4+ and CD8+ cells and given LPS at the time 
of DST exhibited prolonged skin allograft survival (MST = 228). These data suggest that 
TLR4 activation at the time of tolerance induction prevents mixed chimerism by 
modulating both alloreactive helper and cytotoxic T cells.  
Importantly, mice depleted of CD4+ and CD8+ cells but not conditioned with DST 
and anti-CD154 mAb did not become chimeric (0/4) and displayed short skin graft 
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survival (MST = 34 days) when transplanted with BALB/c bone marrow and skin 
(Figure 10, group 7). This indicates that costimulation blockade plays an important role 
in the mixed chimerism induction protocol even when CD4+ and CD8+ T cells are absent.  
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FIGURE 10: LPS EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT SURVIVAL IN  
MICE TREATED WITH COSTIMULATION BLOCKADE IS MEDIATED BY BOTH CD8+ AND CD4+ CELLS 
 
A 
Group TLR Agonist 
CD4 
Depletion 
CD8 
Depletion 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 None No No 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
2 LPS No No 0/23 (0.00%)* <0.10 11 11 N/A 
3 None Yes No 1/12 (8.33%)* 0.58 46 37 189 
4 LPS Yes No 0/12 (0.00%) <0.10 18 18 N/A 
5 None Yes Yes 4/4 (100%) 2.42 ± 0.55 >228 N/A >228 
6 LPS Yes Yes 4/4 (100%)  1.14 ± 0.35 ## 228 N/A 228 
7 None Yes Yes 0/4 (0.00%)** <0.10 34 34 N/A 
8 LPS Yes Yes 0/3 (0.00%)# <0.10 32 32 N/A 
 
B                 C       
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Figure 10. C57BL/6 mice were treated with a BALB/c donor-specific transfusion on day 
−7 and four injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 BALB/c bone marrow cells and BALB/c skin 
grafts. Mice in groups 7-8 were transplanted with BALB/c bone marrow and skin 
according to the standard protocol, but were not conditioned with DST and anti-CD154 
mAb. Mice in groups 3-8 were given three doses of 0.5mg anti-CD4 mAb i.p. on days 
−10, −9, and −8 relative to bone marrow and skin transplantation. Mice in groups 5-8 
were given three doses of 0.5mg anti-CD8 mAb i.p. on days −10, −9, and −8 relative to 
bone marrow and skin transplantation. Mice treated with a TLR4 agonist were given an 
i.p. injection of 100ug LPS on day -7 relative to bone marrow and skin transplantation. 
Panel A. Hematopoietic chimerism was defined as >0.10% donor-origin peripheral blood 
mononuclear cells (PBMCs) 7-8 weeks after bone marrow injection. % donor-origin 
PBMCs is the mean ± S.D. chimerism levels in chimeric mice. *p<0.001 vs. group 1; 
**p<0.01 vs. group 5; #p<0.01 vs. group 6; ##p<0.05 vs. group 5 by chi-square analysis. 
N/A – not applicable. Skin survival data have been separated into three groups to 
distinguish chimeric mice from non-chimeric mice. Data from groups 1-2 shown in 
Figure 5 are reproduced here for ease of comparison with other treatment groups. Panel 
B-C. Kaplan-Meier plots for allogeneic skin graft survival is shown (third column from 
the right in Panel A). Panel B. p<0.001 for DST, anti-CD154 mAb vs. DST, anti-CD154 
and anti-CD4 mAbs; p<0.001 for DST, anti-CD154, and LPS vs. DST, anti-CD154, anti-
CD4 mAbs and LPS. Panel C. p=NS for DST and anti-CD154 mAb vs. DST, anti-
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CD154, anti-CD8, and anti-CD4 mAbs; p<0.001 for DST, anti-CD154 mAb and LPS vs. 
DST, anti-CD154, anti-CD8, anti-CD4 mAbs and LPS; p=NS for DST, anti-CD154, anti-
CD8 and anti-CD4 mAbs vs. DST, anti-CD154, anti-CD8, anti-CD4 mAbs and LPS. 
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7.  LPS administration leads to the generation of effector/memory alloreactive CD8+ T 
cells in mice treated with costimulation blockade 
Given that the removal of host CD8+ T cells was required for the establishment of 
chimerism, we next investigated whether alloreactive effector/memory CD8+ T cells were 
generated in mice treated with LPS, costimulation blockade, and transplanted with 
allogeneic bone marrow. To investigate this, we performed ex vivo intracellular staining 
for IFN-γ on splenocytes isolated from C57BL/6 mice treated with our standard 
conditioning regimen and transplanted with BALB/c bone marrow and skin with or 
without LPS treatment. In this assay, recovered splenocytes are incubated with either 
syngeneic or donor-specific stimulator cells, and the production of IFN-γ by 
CD8+CD11ahigh T cells is a marker of an effector/memory phenotype [224]. We observed 
that splenocytes isolated from control mice exhibited essentially background levels of 
BALB/c-reactive IFN-γ-producing CD8+CD11ahigh T cells two weeks after bone marrow 
and skin transplantation. In contrast, mice given a LPS injection at the time of DST 
developed high levels of IFN-γ-producing CD8+CD11ahigh T cells following stimulation 
with BALB/c splenocytes (Figure 11). These data indicate that in contrast to transplanted 
mice treated with only DST and anti-CD154 mAb, mice given costimulation blockade 
and LPS generate donor-specific effector/memory CD8+ T cells. 
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FIGURE 11: LPS TREATMENT INDUCES THE GENERATION OF 
EFFECTOR/MEMORY ALLOREACTIVE CD8+ T CELLS  
 
A        B 
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Figure 11. C57BL/6 mice were treated with BALB/c DST and anti-CD154 mAb 
according to our standard protocol with or without co-injection of 100μg LPS on day −7 
relative to transplantation of BALB/c bone marrow and skin on day 0. All mice were bled 
two weeks after transplantation. Panels A-B: Peripheral blood cells were recovered two 
weeks after transplantation and stimulated in vitro for 5 hr with either irradiated 
syngeneic (H-2b) or allogeneic BALB/c (H-2d) splenocytes and their production of IFNγ 
was quantified by flow cytometry. Panel A: Representative flow dot plots showing 
CD11a and IFNγ expression in gated CD8+ lymphocytes. As a positive control, C57BL/6 
mice were primed to H-2d by injection of BALB/c splenocytes (DST) seven days prior to 
blood cell recovery. Panel B: The mean + one standard deviation of the percentage of 
CD8+ lymphocytes producing IFNγ is shown. Data are representative of two independent 
experiments with at least three mice per group. *p=0.012 by unpaired t-test.  
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8.  LPS upregulates costimulatory molecules on cells in the DST in mice treated with 
anti-CD154 mAb  
The observation that LPS promotes the generation of alloreactive CD8+ T cells after 
treatment with costimulation blockade prompted us to evaluate the potential mechanisms 
of T cell activation. Given that allogeneic antigens are presented for recognition by host 
alloreactive T cells via either direct or indirect presentation, we next investigated whether 
LPS treatment may modulate either of these pathways. We have previously shown that 
anti-CD154 mAb prevents upregulation of CD80 on APCs in the DST, and this was 
associated with prolonged skin allograft survival [225]. Therefore, we hypothesized that 
LPS treatment at the time of DST may act to increase the maturation status of the DST, 
making it more immunogenic.  
To investigate the activation status of cells in the DST following administration of 
LPS, spleen cells from C57BL/6 mice were analyzed by flow cytometry 15 hr after 
treatment with BALB/c DST, anti-CD154 mAb, with or without LPS administration at 
the time of DST (Figure 12). Gating on H-2Kb–H-2Kd+ (donor) cells, the DST of mice 
treated with anti-CD154 mAb and LPS had a modest, but statistically significant increase 
in the expression of CD80 (MFI=9.6±0.8, n=4) compared to mice treated with anti-
CD154 mAb but not LPS (MFI=8.3±0.4; n=4; p=0.025; Figure 12). Expression of CD86 
was enhanced two-fold on the DST of mice treated with anti-CD154 mAb and LPS (MFI 
= 36.0±1.1, n=4) compared to mice treated with anti-CD154 mAb but not LPS (MFI = 
17.6±3.4; n=4; p < 0.0001). These data suggest that LPS increases the expression of 
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costimulatory molecules on cells of the DST, even in the presence of anti-CD154 mAb.  
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FIGURE 12: LPS TREATMENT RESULTS IN THE UPREGULATION OF 
COSTIMULATORY MOLECULES ON THE DONOR-SPECIFIC 
TRANSFUSION IN MICE TREATED WITH ANTI-CD154 MAB 
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Figure 12. C57BL/6 mice were injected with 10x106 BALB/c DST and 0.5mg of anti-
CD154 mAb with or without an i.p. injection of LPS. Fifteen hours later, splenocytes 
were recovered and stained with antibodies to H-2Kb (host), H-2Kd (donor), and CD80 or 
CD86 and analyzed by flow cytometry. Panel A: Representative flow dot plots showing 
host H-2Kb and donor H-2Kd staining. A group of non-transplanted mice were used as 
negative controls for H-2Kd staining. Panels B-C: Left panels show a representative 
histogram of the MFI of CD80 (B) and CD86 (C) expression on the H-2Kb−H-2Kd+ 
(donor) cells that are seen in Figure 5A. These cells represent cells in the BALB/c DST. 
The right panels are histograms that summarize the MFI plus one standard deviation of 
CD80 (B) and CD86 (C) expression. Data contains four mice per group. #p=0.025; 
*p<0.0001. 
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9.  LPS upregulates expression of costimulatory molecules on host alloantigen-
presenting dendritic cells 
Although LPS treatment appears to increase expression of CD80/86 on the DST, and 
thus may play a role in abrogating tolerance, Thornley et al. have observed that LPS 
treatment can still prevent the deletion of alloreactive CD8+ T cells even when DST 
genetically deficient in CD80/86 expression is transfused [204]. This suggests that LPS 
must be mediating other effects that modulate tolerance induction. This led us to 
hypothesize that LPS administration may be acting to mature host antigen-presenting 
cells (APCs) that have picked up and processed alloantigen. To investigate this, we 
adapted a protocol from Iyoda et al. [226] to track cells within the donor specific 
transfusion after it was injected into the host. BALB/c splenocytes were labeled with 
5μM of the dye CFSE and injected into C57BL/6 mice that were treated with anti-CD154 
mAb with or without co-injection of LPS. Using flow cytometry, this method allows us to 
detect host DCs that have phagocytosed the CFSE-labeled DST, as these are FITC+ cells 
that are expressing host MHC class I (H-2Kb+) and the dendritic cell marker CD11c (the 
gating scheme used to analyze host alloantigen-presenting DCs can be seen in Figure 
13). Using the Y-Ae mAb, Iyoda et al. determined that nearly all of the CFSE-labeled 
DCs were indirectly presenting alloantigen [226].  
To analyze the maturation status of host alloantigen-presenting DCs following LPS 
treatment, splenocytes were harvested 16 hours after injection of the CFSE-labeled DST 
and LPS, and were analyzed by flow cytometry for the expression of CFSE, host class I 
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(H-2Kb), CD11c, CD8α and CD86. Similar to the findings of Iyoda et al., we observed 
that essentially all of the alloantigen-containing host DCs were CD8α+ [226] (Figure 13).  
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FIGURE 13: GATING STRATEGY TO ANALYZE HOST ALLOANTIGEN-
PRESENTING DENDRITIC CELLS 
 
A. Input Cells – CFSE-labeled DST 
 
 
 
 
B. Splenocytes recovered from an untransplanted animal 
 
 
 
 
C. Splenocytes from an animal transplanted with CFSE-labeled DST 
 
 
 
 
D. Back gate of CFSE+ DCs from Panel C 
 
 
 
                  
        Viability Gate                  Host Cell Gate             Dendritic Cell Gate                apDC Gate 
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Figure 13. C57BL/6 mice were injected with 10x106 CFSE-labeled BALB/c DST and 
0.5mg of anti-CD154 mAb with or without an i.p. injection of LPS. Fifteen hours later 
splenocytes were harvested, stained with Live/Dead blue, antibodies to H-2Kb (host), 
CD8α, CD11c, and CD86 and analyzed by flow cytometry. For each panel, the dot plot 
on the left shows the cells that were considered “viable” based on Live/Dead blue 
staining. The dot plot second from the left shows the cells that were considered of host 
origin based on staining with H-2Kb. The dot plot second from the right show the cells 
that were considered dendritic cells based on staining with CD11c. The dot plot on the 
right shows dendritic cells that have engulfed CFSE+ DST. Panel A. Representative flow 
cytometry dot plots of the input cell, i.e. CFSE-labeled BALB/c splenocytes. Panel B. 
Representative flow cytometry dot plots of splenocytes from an uninjected C57BL/6 
mouse. These splenocytes do not contain a CFSE+ population. Panel C. Representative 
flow cytometry dot plots of splenocytes from a C57BL/6 mouse injected with CFSE-
labeled BALB/c DST. Panel D. A “back gate” of the CFSE+CD11c+H-2Kb+ cells from 
panel C. This panel indicates that the host alloantigen-presenting DCs are found in the 
mid-to-upper right of the “Host Cell Gate” (second panel from the left). That population 
is only present in the spleen of animals transfused with DST.  
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Gating on host H-2Kb+CD11c+CD8α +CFSE+ cells, we determined that TLR4 ligation 
results in a marked upregulation of both class I (MFI = 92,104.0 ± 6419; n=4) and CD86 
(MFI = 6487.0 ± 829.5; n=4) compared to non-LPS treated controls (MFI of H-2Kb = 
54,565.0 ± 8207.0; n=4; p< 0.001; Figure 14A; MFI of CD86 = 2398.0 ± 458.3; n=4; p< 
0.001; Figure 14B).  
Given that poly I:C and Pam3Cys also prevent the establishment of transplantation 
tolerance to allogeneic bone marrow and skin, we hypothesized that treatment with those 
agents at the time of DST would also result in the maturation of host alloantigen 
presenting DCs. To investigate this, we performed the above experiment, substituting 
LPS with either poly I:C or Pam3Cys. We observed that similar to LPS, poly I:C also 
increased the expression of both host MHC class I H-2Kb (MFI = 88,678.0 ± 13,528; 
n=4; p<0.001 vs. DST and anti-CD154 mAb; Figure 14A) and CD86 (MFI = 4,314 ± 
754.0; n=4; p<0.01 vs. DST and anti-CD154 mAb; Figure 14B) on host alloantigen 
presenting DCs. Interestingly, although poly I:C and LPS were equivalent in their ability 
to upregulate class I expression, they differed in the degree to which they induced the 
expression of CD86. LPS increased the CD86 expression nearly ~1.5x more than poly 
I:C (p<0.01). Pam3Cys treatment also resulted in an increase in MHC class I expression 
on alloantigen presenting DCs (MFI = 93,195.0 ± 4,215; n=4; p<0.001 vs. DST and anti-
CD154 mAb; Figure 14A). CD86 expression was induced with Pam3Cys treatment (MFI 
= 3,546 ± 440.6; n=4; p<0.05 vs. DST and anti-CD154 mAb; Figure 14B); however, like 
poly I:C, it was markedly lower than that seen by LPS treatment (p<0.001).  
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FIGURE 14: TLR ACTIVATION ENHANCES HOST APDC MATURATION 
A         B 
 
 
 
 
 
 
 
 
Figure 14. C57BL/6 mice were injected with 10x106 CFSE-labeled BALB/c DST and 
0.5mg of anti-CD154 mAb with or without an i.p. injection of 100ug LPS, 50ug poly I:C 
(pI:C), or 100ug of Pam3Cys (PAM). Sixteen hours later splenocytes were harvested, 
stained with Live/Dead blue, and antibodies to H-2Kb (host), CD8α, CD11c, and CD80 or 
CD86 and analyzed by flow cytometry. Panel A: Histogram of the MFI of the MHC class 
I molecule H-2Kb. *p<0.001 vs. DST and anti-CD154 mAb by Bonferroni’s multiple 
comparison test. Panel B: Histogram of the MFI of CD86. *p<0.001 vs. DST and anti-
CD154 mAb; # p<0.01 vs. DST and anti-CD154 mAb; **p<0.05 vs. DST and anti-
CD154 mAb by Bonferroni’s multiple comparison test. 
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Summary: 
We have shown that activation of TLRs at the initiation of tolerance induction by 
costimulation blockade prevents the establishment of mixed hematopoietic chimerism 
and significantly shortens skin allograft survival. This effect does not correlate with the 
production of alloantibodies, nor is it dependent on host NK cells. TLR4 activation, 
however, did appear to break costimulation blockade-mediated tolerance in both the 
CD8+ and CD4+ alloreactive T cell compartments, as removal of both populations were 
required to establish chimerism when LPS was administered at the initiation of tolerance 
induction. We further document that activated alloreactive CD8+ T cells were generated 
in mice treated with costimulation blockade plus a TLR agonist. We also observed that 
following TLR activation, APCs of the DST and the host significantly upregulated 
costimulatory molecule expression. Therefore, we speculate that alloreactive T cell 
activation may be the result of TLR-enhancement of both the direct and indirect 
allorecognition pathways.  
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CHAPTER IV: LPS PREVENTS THE ESTABLISHMENT OF MIXED 
HEMATOPOIETIC CHIMERISM IN MICE TREATED WITH 
COSTIMULATION BLOCKADE THROUGH A MECHANISM THAT INVOLVES 
HOST TLR4, IFNAR1 AND MYD88 
Introduction: 
We have shown that activation of the immune system by microbial components can 
prevent the ability of costimulation blockade-based protocols to induce mixed 
hematopoietic chimerism. Host CD4+ and CD8+ T cells are required for this effect, and 
are likely activated by DCs that have been matured by activation through their TLRs. 
However, the molecular mechanisms that control this process are not known. In this 
chapter, we address several important questions. 1) Is ligation of host TLR required for 
the ability TLR agonists to prevent the establishment of mixed hematopoietic chimerism 
induction in mice treated with costimulation blockade? 2) What TLR signaling cascades 
are involved in preventing the establishment of mixed chimerism? 3) Does TLR 
activation at time points other than during the initiation of costimulation blockade also 
prevent the establishment of mixed chimerism? 
LPS administration at the time of tolerance induction matures DCs in the DST as 
well as DCs in the host. Therefore, it is possible that activation of TLR4 on either cell 
population is sufficient to prevent establishment of chimerism and to shorten skin 
allograft survival by providing alloreactive T cells with the necessary costimulatory 
molecules for activation even in the presence of anti-CD154 mAb. TLR4 signals through 
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two distinct pathways that can stimulate pro-inflammatory programs in immune cells, the 
MyD88-dependent and the MyD88-independent pathways. Finally, the effects of TLR 
signaling are transient, and therefore, activation at various time points during 
conditioning may result in different outcomes. We addressed these questions by 
introducing LPS a day before tolerance induction, and one day following transplantation. 
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Results: 
1.  TLR4 expression is required on host cells for LPS to prevent the establishment of 
chimerism in mice treated with costimulation blockade 
Our laboratory has shown that LPS-induced rejection of skin allografts in the setting 
of costimulation blockade was dependent on engaging TLR4 on host cells [133]. To 
address whether engagement of TLR4 on host cells was also required for LPS to prevent 
the induction of mixed chimerism, C57BL/10 and C56BL/10.TLR4−/− mice were treated 
with BALB/c DST, anti-CD154 mAb, and given BALB/c bone marrow and skin 
allografts with or without co-injection of LPS at the time of tolerance induction. 
Treatment of wild-type C57BL/10 mice with costimulation blockade led to 
chimerism (2/6) and prolonged skin graft survival (MST=70 days), which was prevented 
by administration of LPS (0/8 became chimeric; MST=10; p<0.05 Figure 15). In 
contrast, C57BL/10.TLR4−/− mice treated with DST and anti-CD154 mAb in the presence 
or absence of LPS became chimeric at similar frequencies (6/7 mice treated with LPS 
became chimeric vs. 7/10 mice not treated with LPS; p=NS) and exhibited prolonged skin 
graft survival (MST>176 for LPS treated mice vs. MST = 129 for control mice; p=NS; 
Figure 15). These data suggest that similar to the results seen by Thornley et al. with 
LPS and skin alone [133], host TLR4 expression is required for LPS treatment to prevent 
the establishment of mixed hematopoietic chimerism in mice treated with costimulation 
blockade.  
We next hypothesized that in the absence of host TLR4 expression, LPS treatment at 
111 
 
 
 
the start of costimulation blockade would not result in the upregulation of costimulatory 
molecules on host APCs that was observed in wild-type mice (Figure 12). To test this 
hypothesis, C57BL/10 and C57BL/10.TLR4−/− mice (H-2b) were injected with CFSE-
labeled BALB/c splenocytes (H-2d) and treated with anti-CD154 mAb with or without 
LPS injection. Sixteen hours after treatment, splenocytes were recovered and analyzed 
for the expression of host MHC class I (H-2Kb), CD80 and CD86. We observed that in 
contrast to wild-type mice, mice deficient in TLR4 did not upregulate the expression of 
H-2Kb, CD80 or CD86 (Figure 15C, D, and E, respectively). These data document that 
in the absence of TLR4 signaling, LPS administration at the time of DST does not result 
in the maturation of host alloantigen-presenting DCs.  
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FIGURE 15: LPS EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT SURVIVAL  
IN MICE TREATED WITH COSTIMULATION BLOCKADE ARE DEPENDENT ON HOST TLR4  
 
A 
Group Recipient Donor TLR Agonist 
Chimerism 
Frequency 
% Donor-origin 
PBMCs (8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 C57BL/10 BALB/c None 2/6 (33.3%) 1.59 ± 1.81 70 70 93 
2 C57BL/10 BALB/c LPS 0/8 (0.00%) <0.10 10 10 N/A 
3 TLR4-/- BALB/c None 7/10 (70.0%) 2.98 ± 1.84 129 18 152 
4 TLR4-/- BALB/c LPS 6/7 (85.7%) 2.50 ± 1.00 >176 10 >176 
 
B            C 
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Figure 15. Panels A-B. All mice were treated with a donor-specific transfusion on day 
−7 and four injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice treated with a TLR agonist were given an i.p. injection of 100ug LPS on day 
-7 relative to bone marrow cell and skin transplantation. Panel A. Hematopoietic 
chimerism was defined as >0.10% donor-origin peripheral blood mononuclear cells 
(PBMCs) 7-8 weeks after bone marrow injection. % donor-origin PBMCs is the mean ± 
S.D. chimerism levels in chimeric mice. *p<0.0001 vs. group 1; **p=NS vs. group 3 by 
chi-square analysis. N/A – not applicable. Skin graft survival data have been separated 
into three groups to distinguish chimeric mice from non-chimeric mice in regards to skin 
MST. Data from groups 1-2 shown in Figure 5 are reproduced here for ease of 
comparison with other treatment groups. Panel B. Kaplan-Meier plots for allogeneic skin 
graft survival for the entire cohort of mice conditioned and transplanted with bone 
marrow and skin is shown (third column from the right in Panel A). p=NS for DST and 
anti-CD154 mAb vs. DST, anti-CD154 mAb and LPS in TLR4−/− mice. Panels C-E. 
Mice were injected with 10x106 CFSE-labeled BALB/c DST, 0.5mg of anti-CD154 mAb 
and an i.p. injection of 100ug LPS. Sixteen hours later splenocytes were harvested, 
stained with Live/Dead blue, and antibodies to H-2Kb (host), CD8α, CD11c, and CD80 or 
CD86 and analyzed by flow cytometry. Each group contains four mice. Panel C: 
Histogram of the MFI of the class I molecule H-2Kb. Panel D: Histogram of the MFI of 
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CD80. *p<0.001 vs. all other groups. Panel E: Histogram of the MFI of CD86. *p<0.001 
vs. all other groups. 
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2.  IL-12p40 expression is not required for LPS to prevent the establishment of 
chimerism in mice treated with costimulation blockade 
The finding that LPS prevents the establishment of mixed chimerism by signaling 
through TLR4 expressed on host APCs led us next to investigate which cytokines 
downstream of the TLR4 signaling pathway may be required. LPS is a known inducer of 
interleukin (IL)-12, a cytokine essential for the optimal differentiation of naïve T cells 
into IFN-γ-producing TH-1 cells [227,228]. Furthermore, IL-12 is also thought to be 
important in the activation of naïve CD8+ T cells, perhaps by acting as “signal 3” in the T 
cell activation cascade [70] (Figure 1). IL-12 is a heterodimeric cytokine comprised of 
two subunits (p35 (IL-12α) and p40 (IL-12β)) linked by two disulfide bonds [228]. The 
IL-12p40 subunit is essential for the production of IFN-γ in response to LPS [229,230]. 
Therefore, to examine the role of IL-12, we treated mice deficient in IL-12p40 with our 
standard costimulation blockade and transplantation protocol with or without LPS. 
Treatment of C57BL/6.IL-12p40-/- mice with costimulation blockade produced low 
levels of mixed hematopoietic chimerism (2.42 ± 1.03% donor-origin PBMCs at 8 weeks 
post transplant) in 3 of 5 recipients (Figure 16, group 3). These mice also exhibited 
prolonged skin graft survival (MST = 164 days). In contrast, C57BL/6.IL-12p40−/− mice 
treated with DST, anti-CD154 mAb and LPS did not develop mixed chimerism (0/5, 
p<0.05 vs. group 3), and skin survival was short (MST = 11 days, p<0.001 vs. group 3; 
Figure 16). These data suggest that IL-12 signaling is not required for LPS to prevent the 
establishment of hematopoietic chimerism and shorten skin allograft survival in mice 
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treated with costimulation blockade.  
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FIGURE 16: LPS EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT SURVIVAL  
IN MICE TREATED WITH COSTIMULATION BLOCKADE ARE NOT DEPENDENT ON HOST IL-12p40 
 
A 
Group Recipient Donor TLR Agonist 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 C57BL/6 BALB/c None 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
2 C57BL/6 BALB/c LPS 0/23 (0.00%)* <0.10 11 11 N/A 
3 IL-12p40-/- BALB/c None 3/5 (60.0%) 2.42 ± 1.03 172 130 >216 
4 IL-12p40-/- BALB/c LPS 0/6 (0.00%)** <0.10 11 11 N/A 
 
B          
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Figure 16. All mice were treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice treated with TLR agonist were given an i.p. injection of 100ug LPS on day -
7 relative to bone marrow cell and skin transplantation. Panel A. Hematopoietic 
chimerism was defined as >0.10% donor-origin peripheral blood mononuclear cells 
(PBMCs) 7-8 weeks after bone marrow injection. % donor-origin PBMCs is the mean ± 
S.D. chimerism levels in chimeric mice. *p<0.0001 vs. group 1; **p<0.05 vs. group 3 by 
chi-square analysis. N/A – not applicable. Skin survival data have been separated into 
three groups to distinguish chimeric mice from non-chimeric mice in regards to skin 
MST. Data from groups 1-2 shown in Figure 5 are reproduced here for ease of 
comparison with other treatment groups. Panel B. Kaplan-Meier plots for skin allograft 
survival for the entire cohort of mice treated with costimulation blockade and 
transplanted with bone marrow and skin is shown (third column from the right in Panel 
A). p<0.01 for DST and anti-CD154 mAb vs. DST, anti-CD154 mAb and LPS in IL-
12p40-/- mice.  
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3.  Host TLR4→Myd88 axis is not required for LPS to prevent the establishment of 
chimerism in mice treated with costimulation blockade 
The finding that host IL-12p40 was not required for LPS to prevent the establishment 
of chimerism led us to next investigate which signaling molecules in the TLR4 cascade 
were necessary for the detrimental effects of LPS. LPS can activate innate immunity by 
signaling through two distinct pathways following ligation of TLR4, the myeloid 
differentiation factor-88 (MyD88)-dependent pathway, and the Toll/Interleukin-1 
receptor domain-containing adaptor protein inducing interferon-β (TRIF) pathway [123]. 
Therefore, we first determined whether the MyD88 pathway was required for LPS to 
prevent the establishment of hematopoietic chimerism in mice treated with costimulation 
blockade. To investigate this hypothesis, we transplanted C57BL/6.MyD88-/- mice with 
allogeneic bone marrow after treatment with DST and anti-CD154 mAb with or without 
co-injection of LPS. The majority of C57BL/6.MyD88-/- mice not treated with LPS 
developed mixed chimerism (4/5; 2.30 ± 2.47% donor-origin PBMCs at 8 weeks post 
transplant; Figure 17, group 3). Interestingly, however, mice treated with LPS did not 
(0/9; p=0.0015; Figure 17 group 4). These data suggest that host MyD88 is not required 
for the ability of LPS to prevent the establishment of mixed chimerism in mice treated 
with costimulation blockade. 
We then asked why the effects of LPS were still evident in C57BL/6.MyD88-/- mice. 
We reasoned that in the absence of MyD88-dependent cytokines, LPS treatment may still 
induce the maturation of host alloantigen-presenting DCs. To determine this, 
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C57BL/6.MyD88−/− mice were injected with CFSE-labeled BALB/c splenocytes and 
treated with anti-CD154 mAb with or without LPS injection. Sixteen hours after 
treatment, splenocytes were recovered and analyzed for the expression of host MHC class 
I (H-2Kb), and CD86. We observed that similar to wild-type mice, but in contrast to 
TLR4-/- mice, mice deficient in MyD88 did upregulate the expression of H-2Kb and CD86 
in response to LPS treatment. LPS-treated C57BL/6.MyD88-/- mice had a greater than 
two fold increase in the expression of H-2Kb (p<0.001; Figure 17B) and CD86 (p<0.001; 
Figure 17C) when compared to non-LPS treated C57BL/6.MyD88-/- mice. We also 
observed that the expression of CD86 in LPS-treated MyD88-/- mice was slightly 
decreased compared to wild-type mice treated with LPS (p<0.05). These data indicate 
that LPS can upregulate expresssion of CD86 in the absence of MyD88, although full 
maturation may require a contribution from MyD88-dependent factors.  
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FIGURE 17: LPS EFFECTS ON BONE MARROW CHIMERISM AND SKIN 
ALLOGRAFT SURVIVAL IN MICE TREATED WITH COSTIMULATION 
BLOCKADE ARE NOT DEPENDENT ON HOST MYD88 
 
A 
Group Recipient Donor TLR Agonist 
Chimerism 
Frequency 
% Donor-origin 
PBMCs (8 wk) 
1 C57BL/6 BALB/c None 6/9 (66.7%) 2.43 ± 1.37 
2 C57BL/6 BALB/c LPS 0/7 (0.00%)* <0.10 
3 MyD88-/- BALB/c None 4/5 (80%) 2.30 ± 2.47 
4 MyD88-/- BALB/c LPS 0/9 (00.0%)** <0.10 
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Figure 17. Panel A. All mice were treated with a donor-specific transfusion on day −7 
and four injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells. Mice treated with 
TLR agonist were given an i.p. injection of 100ug LPS on day -7 relative to bone marrow 
cell and skin transplantation. Hematopoietic chimerism was defined as >0.10% donor-
origin peripheral blood mononuclear cells (PBMCs) 7-8 weeks after bone marrow 
injection. % donor-origin PBMCs is the mean ± S.D. chimerism levels in chimeric mice. 
*p<0.01 vs. group 1; **p<0.01 vs. group 3, and p=NS vs. group 2 by chi-square analysis. 
Panels B-C. Mice were injected with 10x106 CFSE-labeled BALB/c DST, 0.5mg of anti-
CD154 mAb and an i.p. injection of 100ug LPS. Sixteen hours later splenocytes were 
harvested, stained with Live/Dead blue, and antibodies to H-2Kb (host), CD8α, CD11c, 
and CD86 and analyzed by flow cytometry. Each group contains four mice. Panel B: 
Histogram of the MFI of the class I molecule H-2Kb. *p<0.05 vs. all other groups; 
#p<0.001 vs. all other groups. Panel C: Histogram of the MFI of CD86. *p<0.05 vs. 
MyD88-/- mice treated with DST, anti-CD154 mAb and LPS, p<0.001 vs. both MyD88-/- 
and wild-type mice treated with DST and anti-CD154 mAb; # p<0.05 vs. wild-type mice 
treated with DST, anti-CD154 mAb and LPS, p<0.001 vs. both MyD88-/- and wild-type 
mice treated with DST and anti-CD154 mAb. 
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4.  Signaling through the Type 1 IFN receptor is important for LPS and Poly I:C, but 
not Pam3Cys, to prevent the establishment of chimerism in mice treated with 
costimulation blockade  
The observation that the adaptor molecule MyD88 was not required for LPS to 
prevent the establishment of mixed chimerism prompted us to hypothesize that the 
MyD88-independent (TRIF) pathway may be involved. TLR4 signaling through the 
TRIF pathway leads to the upregulation of the type I interferon, IFN-β, and it has been 
hypothesized that TLR4 induction of IFN-β is entirely dependent on the MyD88-
independent pathway [159]. Furthermore, our laboratory has also shown that signaling 
through the type 1 IFN receptor is important for LPS to prevent the induction of tolerance 
to skin allografts in mice treated with costimulation blockade [204]. Therefore, to test our 
hypothesis that signaling through the type 1 IFN receptor is also important for LPS to 
prevent the establishment of bone marrow chimerism, we treated mice deficient in the 
type 1 IFN receptor (IFNAR1) with DST, anti-CD154 mAb , BALB/c bone marrow and 
skin with or without co-injection of LPS. The majority of C57BL/6.IFNAR1-/- mice 
treated without LPS developed mixed chimerism (13/15 developed chimerism; 3.52 ± 
2.14% donor-origin PBMCs at 8 weeks post transplant) and chimeric mice exhibited 
permanent skin allograft survival (MST >218 days; Figure 18, group 4). Interestingly, in 
contrast to wild-type and MyD88-/- mice, a subset of IFNAR1-/- mice treated with LPS 
became chimeric (6/17; p <0.01 vs. wild-type animals treated with LPS (group 2)) and 
chimeric mice exhibited permanent skin allograft survival (MST >218 days; Figure 18, 
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group 5). However, the percentage of IFNAR1-/- mice treated with LPS that became 
chimeric was significantly lower than that achieved in IFNAR1-/- mice not treated with 
LPS (p=0.008). These data suggest that although signaling through the type I IFN 
receptor is important for LPS-mediated rejection, other mediators may be involved.  
Because the TLR3 agonist poly I:C is also a known inducer of type I IFN, we next 
used IFNAR1-/- mice to investigate the hypothesis that signaling through the type 1 IFN 
receptor was also required for poly I:C to prevent the establishment of mixed chimerism 
in mice treated with costimulation blockade. Similar to LPS, we observed that a subset of 
IFNAR1-/- mice treated with poly I:C at the start of the conditioning regimen became 
chimeric (5/12) and chimeric mice exhibited permanent skin graft survival (MST > 218; 
Figure 18, group 6). The frequency of chimerism was different from IFNAR1-/- mice 
treated without a TLR agonist (p<0.05), again suggesting the involvement of other 
mediators.   
Since the type I IFN receptor appeared to be playing an important role in the 
detrimental effects of both LPS and poly I:C, we next tested if signaling through the type 
1 IFN receptor was also important in effects induced by Pam3Cys. TLR2 activation is not 
believed to induce type I interferons [123], but still shortens skin allograft survival in 
mice treated with costimulation blockade [204]. Therefore, we hypothesized that 
Pam3Cys would still inhibit the establishment of mixed chimerism in IFNAR1-/- mice 
treated with costimulation blockade. In support of this hypothesis, we observed that mice 
deficient in signaling through the type I IFN receptor did not become chimeric when 
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treated with Pam3Cys (0/4; p<0.001 vs. group 5), and skin allograft survival was short 
(MST = 10 days; p<0.0001 vs. groups 5; Figure 18, group 8). These data suggest that 
signaling through the type 1 IFN receptor has an important role in preventing the 
establishment of mixed chimerism and shortening skin allograft survival in mice treated 
with costimulation blockade and given TLR3 and TLR4 agonists, but not a TLR2 
agonist.  
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FIGURE 18: LPS AND POLY I:C BUT NOT PAM3CYS EFFECTS ON BONE MARROW CHIMERISM  
AND SKIN ALLOGRAFT SURVIVAL IN MICE TREATED WITH COSTIMULATION BLOCKADE  
ARE DEPENDENT ON SIGNALING THROUGH THE TYPE 1 IFN RECEPTOR 
 
A 
Group Recipient Donor TLR Agonist 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 C57BL/6 BALB/c None 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
2 C57BL/6 BALB/c LPS 0/23 (0.00%)* <0.10 11 11 N/A 
3 C57BL/6 BALB/c poly I:C 0/20 (0.00%)* <0.10 9 9 N/A 
4 C57BL/6 BALB/c Pam3Cys 0/3 (0%)** <0.10 10 10 N/A 
5 IFNAR1-/- BALB/c None 13/15 (87.0%) 3.52 ± 2.14 # >218 28 >218 
6 IFNAR1-/- BALB/c LPS 6/17 (35.0%)## 2.12 ± 1.11 80 14 >218 
7 IFNAR1-/- BALB/c poly I:C 5/12 (41.7%)$ 2.22 ± 0.97 84 16 >218 
8 IFNAR1-/- BALB/c Pam3Cys 0/4 (0.00%)$$ <0.10 10 10 N/A 
 
B              C                                      D      
 
128 
 
 
 
Figure 18. All mice were treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice treated with TLR agonist were given either an i.p. injection of 50ug of poly 
I:C, 100ug LPS, or 100ug of Pam3Cys on day -7 relative to bone marrow cell and skin 
transplantation. Panel A. Hematopoietic chimerism was defined as >0.10% donor-origin 
PBMCs 7-8 weeks after bone marrow injection. % donor-origin PBMCs is the mean ± 
S.D. chimerism levels in chimeric mice. *p<0.0001 vs. group 1; **p<0.05 vs. group 1; 
##p<0.01 vs. group 2 and vs. group 5; $p<0.01 vs. group 3 and p<0.05 vs. group 5; 
$$p<0.001 vs. group 5 by chi-square analysis. #p<0.01 vs. group 1 by unpaired t-test. N/A 
– not applicable. Skin survival data have been separated into three groups to distinguish 
chimeric mice from non-chimeric mice in regards to skin graft survival. Data from groups 
1-4 shown in Figure 5 are reproduced here for ease of comparison with other treatment 
groups. Panel B-D. Kaplan-Meier plots for allogeneic skin graft survival for the entire 
cohort of mice conditioned and transplanted with bone marrow and skin is shown (i.e., 
third column from the right in Panel A). Panel B. p<0.0001 for IFNAR1-/- mice treated 
with DST, anti-CD154 mAb and LPS vs. wild-type (WT) mice treated with DST, anti-
CD154 mAb and LPS; p<0.05 for IFNAR1-/- mice treated with DST, anti-CD154 mAb 
and LPS vs. WT mice treated with DST, anti-CD154 mAb and vs. IFNAR1-/- mice 
treated with DST and anti-CD154 mAb. Panel C. p<0.0001 for IFNAR1-/- mice treated 
with DST, anti-CD154 mAb and poly I:C vs. WT mice treated with DST, anti-CD154 
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mAb and poly I:C. Panel D. p=NS for IFNAR1-/- mice treated with DST, anti-CD154 
mAb and Pam3Cys vs. WT mice treated with DST, anti-CD154 mAb and Pam3Cys. 
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5.  LPS-induced activation of alloreactive CD8+ T cells is dependent on signaling 
through the type 1 IFN receptor 
We have shown that LPS administration at the initiation of costimulation blockade 
results in: 1) an increase in the maturation state of host alloantigen-presenting dendritic 
cells (Figure 12), and 2) the generation of effector/memory alloreactive CD8+ T cells 
(Figure 11). Therefore, the observation that mixed chimerism could develop in LPS-
treated mice that were deficient in the type I IFN receptor led us to hypothesize that there 
would be an attenuation of host DC activation following TLR4 activation in these mice. 
To address this, wild-type C57BL/6 and C57BL/6.IFNAR1−/− mice were injected with 
CFSE-labeled BALB/c splenocytes and treated with anti-CD154 mAb with or without 
LPS injection. Fifteen hours after treatment, splenocytes were recovered and analyzed for 
the expression of H-2Kb and CD86. We observed that alloantigen-presenting DCs from 
mice deficient in type I IFN signaling exhibited significantly lower expression of both 
molecules after injection of LPS as compared to alloantigen-presenting DCs from wild-
type mice. (MFI of H-2Kb = 69,793 ± 7,852 vs. 92,104 ± 6,419, respectively; p<0.01; 
Figure 19A, Experiment 1) (MFI of CD86 = 4,650 ± 1,066 vs. 6,487 ± 829, respectively; 
p<0.01; Figure 19B, Experiment 1). The expression of both molecules, however, was 
higher in IFNAR1-/- mice treated with LPS when compared to their non-LPS-treated 
controls (p<0.05). Thus, in the absence of signaling through the type I IFN receptor, LPS 
treatment can induce alloantigen presenting DC maturation, although the degree of 
maturation appears to be attenuated.  
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We next hypothesized that decreased DC activation in the absence of signaling 
through the type I IFN receptor may prevent the generation of alloreactive CD8+ 
effector/memory T cells. To test this, we performed intracellular flow cytometry for IFNγ 
on CD8+ splenocytes isolated from C57BL/6 and C57BL/6.IFNAR1−/− mice one week 
after treatment with our standard conditioning regimen with or without co-administration 
of LPS at the initiation of costimulation blockade. Interestingly, we observed that mice 
deficient in signaling through the type I IFN receptor did not develop effector/memory 
CD8+ T cells when exposed to LPS, whereas wild-type C57BL/6 mice did (Figure 19C). 
These data suggest that signaling through the type I IFN receptor is required for priming 
of alloreactive CD8+ effector/memory T cells in mice treated with costimulation 
blockade. 
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FIGURE 19: LPS-INDUCED ACTIVATION OF ALLOREACTIVE CD8+ T 
CELLS IS DEPENDENT ON SIGNALING THROUGH THE TYPE 1 IFN 
RECEPTOR 
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Figure 19. Panels A-B: C57BL/6 and IFNAR1−/− mice were injected with 10x106 
CFSE-labeled BALB/c DST and 0.5mg of anti-CD154 mAb with or without an i.p. 
injection of LPS. Fifteen hours later splenocytes were harvested, stained with antibodies 
to H-2Kb, CD8α, CD11c, and CD86 and analyzed by flow cytometry. Left panel show a 
representative histogram of the MFI of CD86 expression on the H-
2Kb+CD11c+CD8α+CFSE+ cells. These cells represent host DCs that have phagocytosed 
CFSE-labeled DST. Panel A: Histogram of the MFI of the MHC class I molecule H-2Kb. 
*p<0.01 vs. all other groups; #p=NS vs. wild-type mice treated with DST and anti-CD154 
mAb, p<0.01 vs. wild-type mice treated with DST, anti-CD154 mAb and LPS, p<0.05 vs. 
IFNAR1-/- mice treated with DST and anti-CD154 mAb . Panel B: Histogram of the MFI 
of CD86. *p<0.05 vs. IFNAR1-/- mice treated with DST, anti-CD154 mAb and LPS, 
p<0.001 vs. both IFNAR1-/- and wild-type mice treated with DST and anti-CD154 mAb. 
#p<0.01 vs. both IFNAR1-/- and wild-type mice treated with DST and anti-CD154 mAb. 
Panel C: All mice were treated with a BALB/c DST, bone marrow and anti-CD154 mAb 
according to our standard protocol with or without an i.p. injection of 100μg LPS. 
Splenocytes were harvested one week after bone marrow transplantation, stimulated in 
vitro with either irradiated syngeneic (H-2b) or allogeneic (H-2d) splenocytes, and 
analyzed by flow cytometry for intracellular IFNγ production. The percentage of CD8+ 
lymphocytes producing IFNγ is shown (bar represents the mean). Only wild type mice 
treated with DST, anti-CD154 mAb and LPS had IFNγ-producing alloreactive CD8+ 
lymphocytes in the spleen. Mice deficient in type I IFN receptor signaling did not 
134 
 
 
 
generate IFNγ-producing alloreactive CD8+ lymphocytes when injected with LPS during 
costimulation blockade. #p<0.05 vs. wild type mice treated with DST, anti-CD154 mAb 
and LPS. P=NS vs. IFNAR1−/− treated with DST and anti-CD154 mAb.  
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6.  LPS treatment results in a transient induction of type I IFN 
The observation that signaling through the type I IFN receptor  was important for 
LPS-mediated bone marrow rejection prompted us to investigate the kinetics of IFN-α/β 
induction by LPS in the presence or absence of costimulation blockade. We first 
quantified serum levels of IFN-α/β in wild-type C57BL/6 mice following LPS 
administration using a standard IFN-α/β bioassay [217]. Serum was collected 8 and 24 
hours after treatment with PBS, or DST and anti-CD154 mAb with or without co-
injection of 100ug of LPS. The serum was then diluted serially in wells containing mouse 
L-929 cells and incubated overnight. The following day, each well was infected with 
vesicular stomatitis virus (VSV) and incubated for 2 days. The cytopathic effects were 
evaluated using microscopy, and the IFN-α/β titer was determined as the reciprocal of the 
dilution that provided 50% protection from cytopathic effects.  
IFN-α/β was not detected in untreated mice (n=3), and only low levels were detected 
in mice treated with DST and anti-CD154 mAb at 8 hours after treatment (5.0±3.9 U/ml, 
n=7), and dropped to nearly undetectable levels at 24 hours (0.8±2.1 U/ml; Figure 20). In 
contrast, mice treated with DST, anti-CD154 mAb and LPS had three-fold higher levels 
of IFNα/β (15.4±6.0 U/ml; n=5; p<0.01; Figure 20) 8 hours after treatment compared 
with mice treated with DST and anti-CD154 mAb. We also observed that levels of 
IFNα/β were greater at 24 hours in mice treated with DST, anti-CD154 mAb and LPS as 
compared with untreated controls (6.6±2.5 U/ml; p<0.01; Figure 20). However, the 
levels 24 hours after LPS treatment were not different from those attained 8 hours after 
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treatment with DST and anti-CD154 mAb. 
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FIGURE 20: LPS TREATMENT RESULTS IN A TRANSIENT INDUCTION OF 
TYPE I INTERFERON 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Serum was collected from C57BL/6 mice 8 and 24 hours after indicated 
treatment. The IFN-α/β titer was determined as the reciprocal of the dilution that 
protected L-929 cells from cytopathic effect by VSV infection. Sera from untreated mice 
did not exhibit any protection. Data are presented as mean + S.D. 
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7.  LPS-mediated effects on the establishment of mixed chimerism in mice treated with 
costimulation blockade is dependent on the time of administration and correlates with 
the transient spike in serum IFN-α/β 
Given the important role of type I IFN, and our observation that LPS treatment 
appeared to induce a transient spike in IFN-α/β, we hypothesized that LPS administration 
24 hours prior to DST and anti-CD154 mAb would not prevent the induction of 
chimerism. To test this, three cohorts of C57BL/6 mice were treated with DST and anti-
CD154 mAb and given BALB/c bone marrow. One cohort was not treated further, one 
cohort was given LPS on the day of DST (day -7), and one cohort was given LPS on day 
−8 (24 hours prior to DST and anti-CD154 mAb). Interestingly, we observed that mice 
treated with LPS on day −8 became chimeric at the same frequency (6/7) as mice not 
treated with LPS (6/7), while mice given LPS on day −7 did not become chimeric (0/7; 
p=0.0012; Figure 21). These data suggest that the detrimental effects of LPS are 
transient, and correlate with the production of IFN-α/β in response to TLR4 activation. 
The data do not exclude, however, the role of other inflammatory mediators that may 
have a similar expression pattern as type I interferon. 
Based on the observation that the effects of LPS were temporally dependent, we next 
determined whether TLR4 activation at other time points could prevent the establishment 
of chimerism in mice treated with costimulation blockade. Indeed, we found that mice 
treated with DST, anti-CD154 mAb and bone marrow did not become chimeric if LPS 
was given 1 day after bone marrow transplantation (0/7; Figure 21, group 4). This 
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suggests that costimulation blockade-based protocols for chimerism induction are 
sensitive to TLR-activation during the conditioning regimen, but not before.  
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FIGURE 21: KINETICS OF LPS ADMINISTRATION 
 
Group Recipient Donor TLR Agonist Chimerism Frequency 
% Donor-origin 
PBMCs (8 wk) 
1 C57BL/6 BALB/c None 6/7 (85.7%) 3.2 ± 1.84 
2 C57BL/6 BALB/c LPS (Day-8) 6/7 (85.7%) 4.93 ± 2.04 
3 C57BL/6 BALB/c LPS (Day -7) 0/7 (0%)* <0.10 
4 C57BL/6 BALB/c LPS (Day +1) 0/7 (0%)* <0.10 
 
 
Figure 21. All mice were treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells. Mice treated with 
TLR agonist were given either an i.p. injection of 100ug LPS on day -8 (group 2), day -7 
(group 3) or day +1 (group 4) relative to bone marrow cell transplantation. Hematopoietic 
chimerism was defined as >0.10% donor-origin peripheral blood mononuclear cells 
(PBMCs) 7-8 weeks after bone marrow injection. % donor-origin PBMCs is the mean ± 
S.D. chimerism levels in chimeric mice. *p<0.01 vs. group 1 and group 2 by chi-square 
analysis. N/A, not applicable.  
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8.  IFN-β is sufficient to prevent the establishment of mixed chimerism in mice treated 
with costimulation blockade 
Following the observation that: 1) signaling through the type I IFN receptor is 
important for LPS-mediated effects on establishment of bone marrow chimerism, 2) IFN-
α/β production correlates with the window for which LPS treatment prevented chimerism 
induction, and 3) administration of recombinant IFN-β at the time of tolerance induction 
impairs the deletion of alloreactive T cells [204], we next postulated that administration 
of recombinant IFN-β would be sufficient to prevent the establishment of mixed 
chimerism. To determine this, we treated C57BL/6 mice with BALB/c bone marrow and 
skin grafts, and our standard conditioning regimen with or without 5.0x104 or 7.5x104 
units of IFN-β on day -7. Only one of three mice treated with 5.0x104 units of IFN-β 
became chimeric, however, two of three mice did exhibit prolonged skin graft survival 
(MST >252; Figure 22, group 2). Mice treated with 7.5x104 units of IFN-β on day -7 
uniformly failed to become chimeric (0/4; p<0.05 vs. group 1), and skin survival was 
short (MST = 36; Figure 22, group 3). These data suggest that IFN-β by itself is a 
sufficient barrier to the establishment of chimerism and prolongation of skin allograft 
survival when given at the time of tolerance induction.  
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FIGURE 22: IFN-β IS SUFFICIENT TO PREVENT THE INDUCTION OF MIXED HEMATOPOIETIC 
CHIMERISM IN MICE TREATED WITH COSTIMULATION BLOCKADE 
 
A 
Group Recipient Donor IFN-β Chimerism Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of 
skin grafts 
in chimeric 
mice (days) 
1 C57BL/6 BALB/c None 6/10 (60.0%) 1.98 ± 2.34 >252 35 >252 
2 C57BL/6 BALB/c 5.0x104 Units 1/3 (33.3%) 2.65 >252 181 >252 
3 C57BL/6 BALB/c 7.5x104 Units 0/4 (0.00%)* <0.10 36 36 N/A 
 
B          
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Figure 22. All mice were treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice treated with recombinant IFN-β were given an i.p. injection of the indicated 
amount on day -7 relative to bone marrow cell and skin transplantation. Panel A. 
Hematopoietic chimerism was defined as >0.10% donor-origin peripheral blood 
mononuclear cells (PBMCs) 7-8 weeks after bone marrow injection. % donor-origin 
PBMCs is the mean ± S.D. chimerism levels in chimeric mice. *p<0.05 vs. group 1 by 
unpaired t-test. N/A – not applicable. Skin survival data have been separated into three 
groups to distinguish chimeric mice from non-chimeric mice in regards to skin MST. 
Panel B. Kaplan-Meier plots for allogeneic skin graft survival for the entire cohort of 
mice treated with costimulation blockade and transplanted with bone marrow and skin is 
shown (i.e., third column from the right in Panel A). p<0.05 for DST and anti-CD154 
mAb vs. DST, anti-CD154 mAb and 7.5x104Units IFN-β  
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9.  Host IRF3 is not required for LPS to prevent the establishment of mixed 
hematopoietic chimerism in mice treated with costimulation blockade 
The observation that type I interferon can pose a significant barrier to chimerism 
induction and allograft survival led us to investigate further the molecular mechanisms 
involved in LPS-mediated effects. We have previously shown that: 1) host signaling 
through the type I IFN receptor is important in LPS-mediated rejection, and 2) IFN-β 
itself can recapitulate the effects of TLR agonists. However, we have not demonstrated 
that type I IFN induction by LPS is required to prevent mixed chimerism. To investigate 
this, we examined the role of interferon regulatory factor (IRF)3. IRF3 has been shown to 
be essential for the induction of IFN-β in DCs following TLR4 activation [159,231]. 
Therefore, we treated C57BL/6.IRF3-/- mice with our standard conditioning regimen with 
or without LPS, and transplanted them with BALB/c bone marrow and skin. All of the 
IRF3-/- mice transplanted in the absence of LPS developed hematopoietic chimerism at 
levels slightly higher than wild-type mice (5.38 ± 3.45% donor-origin PBMCs at 8 weeks 
post transplant; p<0.001 vs. group 1), and exhibited prolonged skin graft survival (MST = 
125 days; Figure 23, group 3). In contrast, none of the C57BL/6.IRF3-/- mice treated with 
LPS became chimeric (p<0.001 vs. group 3; Figure 23, group 4). Skin graft survival in 
C57BL/6.IRF3-/- mice treated with LPS was significantly shortened compared to 
C57BL/6.IRF3-/- mice not treated with LPS (MST = 20 days; p<0.05 vs. group 3; Figure 
23, group 4). However, skin graft survival was prolonged as compared to wild-type mice 
treated with LPS (p<0.01). These data indicate that host IRF3 is not required for LPS to 
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mediate its effects in mice treated with costimulation blockade but IRF3 does seem to 
have a modest role in the kinetics of LPS-mediated skin graft rejection.  
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FIGURE 23: LPS EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT SURVIVAL                 
IN MICE TREATED WITH COSTIMULATION BLOCKADE ARE NOT DEPENDENT ON HOST IRF3 
 
A 
Group Recipient Donor TLR Agonist 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in non-
chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 C57BL/6 BALB/c None 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
2 C57BL/6 BALB/c LPS 0/23 (0.00%)* <0.10 11 11 N/A 
3 IRF3-/- BALB/c None 8/8 (100.0%) 5.38 ± 3.45 # 125 N/A 125 
4 IRF3-/- BALB/c LPS 0/7 (0.00%)** <0.10 20 20 N/A 
 
B          
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Figure 23. All mice were treated with a donor-specific transfusion on day −7 and four 
injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice treated with TLR agonist were given an i.p. injection of 100ug LPS on day -
7 relative to bone marrow cell and skin transplantation. Panel A. Hematopoietic 
chimerism was defined as >0.10% donor-origin peripheral blood mononuclear cells 
(PBMCs) 7-8 weeks after bone marrow injection. % donor-origin PBMCs is the mean ± 
S.D. chimerism levels in chimeric mice. *p<0.0001 vs. group 1; **p<0.001 vs. group 3; 
and p=NS vs. group 3 by chi-square analysis. #p<0.001 vs. group 1 by unpaired t-test. 
N/A – not applicable. Skin survival data have been separated into three groups to 
distinguish chimeric mice from non-chimeric mice in regards to skin graft survival. Data 
from groups 1-2 shown in Figure 5 are reproduced here for ease of comparison with other 
treatment groups. Panel B. Kaplan-Meier plots for allogeneic skin graft survival for the 
entire cohort of mice conditioned and transplanted with bone marrow and skin is shown 
(i.e., third column from the right in Panel A). p<0.01 for IRF3-/- mice treated with DST, 
anti-CD154 mAb and LPS vs. wild-type mice treated with DST, anti-CD154 mAb and 
LPS; p=0.0158 for IRF3-/- mice treated with DST and anti-CD154 mAb vs. IRF3-/- mice 
treated with DST, anti-CD154 mAb and LPS.  
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10.  Host MyD88 and IFN-α/β signaling are required for LPS to prevent the 
establishment of mixed hematopoietic chimerism in mice treated with costimulation 
blockade 
The observation that IFNAR1-/- mice treated with LPS became chimeric at a 
frequency that was significantly lower than IFNAR1-/- mice not treated with LPS (Figure 
18), led us to conclude that other molecules in the TLR4 pathway were important. We 
hypothesized that in the absence of IFN-α/β signaling, downstream mediators of the 
TLR4→MyD88 axis might be sufficient to prevent the establishment of chimerism with 
allogeneic bone marrow. However, we have previously shown that in the absence of host 
MyD88, bone marrow chimerism could not be established when LPS was given at the 
time of DST, presumably because in those mice the TLR4→IFN-β axis was intact. 
Therefore, to examine if in the absence of signaling through the type 1 IFN receptor that 
MyD88-dependent cytokines were important, we created mice that were deficient in both 
the adaptor molecule MyD88 and the type 1 IFN receptor. C57BL/6.MyD88-/- and 
C57BL/6.IFNAR1-/- mice were mated, and a F1 intercross was performed to isolate mice 
deficient in both molecules. MyD88-/-IFNAR1-/- mice were identified by PCR of ear 
DNA as described in the material and methods.  
C57BL/6.MyD88-/-IFNAR1-/- mice were treated with our standard costimulation 
blockade protocol with or without co-injection of LPS, and transplanted with BALB/c 
bone marrow and skin. The majority of the MyD88-/-IFNAR1-/- mice transplanted in the 
absence of LPS developed hematopoietic chimerism at levels slightly higher than wild-
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type mice (5/7 developed chimerism; 4.13 ± 0.98% donor-origin PBMCs at 8 weeks post 
transplant; p<0.05 vs. group 1; Figure 24A, group 3), and exhibited prolonged skin graft 
survival (MST >116 days; Figure 24A, group 3). Similar to TLR4-/- mice, a cohort of 
MyD88-/-IFNAR1-/- mice treated with LPS also developed mixed chimerism (5/8; 
p<0.001 vs. group 2, p = NS vs. group 3), and displayed prolonged skin allograft survival 
(MST >116 days; Figure 24A, group 4). Importantly, in the absence of both proteins, 
mice not conditioned with costimulation blockade did not become chimeric (0/3), and 
rapidly rejected skin allografts (MST = 11). These data suggest that both signaling 
through the type I IFN receptor and mediators downstream of MyD88 are important for 
LPS-mediated effects in mice treated with costimulation blockade.  
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11. MyD88 and IFN-α/β signaling are required for the maturation of alloantigen-
presenting DC following TLR4 ligation 
We next hypothesized that in the absence of host MyD88 and signaling through the 
IFN receptor, LPS activation of TLR4 would not stimulate host alloantigen-presenting 
DCs to mature. To test this hypothesis, MyD88-/-IFNAR1−/− mice were injected with 
CFSE-labeled BALB/c splenocytes and treated with anti-CD154 mAb with or without 
LPS injection. Sixteen hours after treatment, splenocytes were recovered and analyzed 
for the expression of H-2Kb and CD86. We observed that alloantigen-presenting DCs 
from mice deficient in both MyD88 and type I IFN signaling did not upregulate CD86 
after injection of LPS (MFI of CD86 = 3,801 ± 384; n=5; p = NS vs. non-LPS-treated 
controls; Figure 24D). Interestingly, we did observe the LPS treatment did result in a 
slight increase in MHC class I expression in the absence of MyD88 and IFNAR (MFI of 
H-2Kb = 80,171 ± 14,105; n=5) compared to non LPS-treated MyD88-/-IFNAR1−/− mice 
(p <0.05; Figure 24C). However, this level of expression was not different from tolerant, 
wild-type mice not treated with LPS. These data suggest that host DCs require both type I 
IFN signaling as well as the adaptor molecule MyD88 to upregulate costimulatory 
molecules following phagocytosis of alloantigen in the context of TLR4 activation. 
However modest increases in MHC class I may occur in the absence of either signaling 
pathway.  
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FIGURE 24: LPS EFFECTS ON BONE MARROW CHIMERISM AND SKIN ALLOGRAFT SURVIVAL  
IN MICE TREATED WITH COSTIMULATION BLOCKADE ARE DEPENDENT ON HOST MYD88  
AND TYPE 1 IFN RECEPTOR EXPRESSION 
 
A 
Group Recipient Donor TLR Agonist 
Chimerism 
Frequency 
% Donor-
origin PBMCs 
(8 wk) 
MST of skin 
grafts in 
transplanted 
mice (days) 
MST of skin 
grafts in 
non-chimeric 
mice (days) 
MST of skin 
grafts in 
chimeric 
mice (days) 
1 C57BL/6 BALB/c None 29/45 (64.0%) 1.59 ± 1.81 144 88 >260 
2 C57BL/6 BALB/c LPS 0/23 (0.00%)* <0.10 11 11 N/A 
3 MyD88-/-IFNAR1-/- BALB/c None 5/7 (71.4%) 4.13 ± 0.98 # >116 50 >116 
4 MyD88-/-IFNAR1-/- BALB/c LPS 5/8 (62.5%)** 5.37 ± 1.08 # >116 57 >116 
 
B         C           D 
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Figure 24. Panels A-B. All mice were treated with a donor-specific transfusion on day 
−7 and four injections of 0.5 mg of anti-CD154 mAb on days −7, −4, 0, and +4 relative to 
transplantation on day 0 with 50x106 allogeneic bone marrow cells and allogeneic skin 
grafts. Mice treated with TLR agonist were given an i.p. injection of 100ug LPS on day -
7 relative to bone marrow and skin transplantation. Panel A: Hematopoietic chimerism 
was defined as >0.10% donor-origin PBMCs 7-8 weeks after bone marrow injection. % 
donor-origin PBMCs is the mean ± S.D. chimerism levels in chimeric mice. *p<0.0001 
vs. group 1; **p<0.001 vs. group 2 by chi-square analysis. #p<0.05 vs. group 1 by 
unpaired t-test. N/A – not applicable. Skin graft survival data has been separated into 
three groups to distinguish chimeric mice from non-chimeric mice. Data from groups 1-2 
shown in Figure 5 are reproduced here for ease of comparison with other treatment 
groups. Panel B: Kaplan-Meier plots for allogeneic skin graft survival for the entire 
cohort of mice conditioned and transplanted with bone marrow and skin is shown (i.e., 
third column from the right in Panel A). p<0.01 for MyD88-/-IFNAR1-/- mice treated with 
DST, anti-CD154 mAb and LPS vs. wild-type mice treated with DST, anti-CD154 mAb 
and LPS. Panels C-D: Maturation of host DCs in response to LPS treatment is dependent 
on signaling through the type 1 IFN receptor and host MyD88. Mice were injected with 
10x106 CFSE-labeled BALB/c DST, 0.5mg of anti-CD154 mAb and an i.p. injection of 
100ug LPS. Sixteen hours later splenocytes were harvested, stained with Live/Dead blue, 
and antibodies to H-2Kb (host), CD8α, CD11c, and CD86 and analyzed by flow 
cytometry. Each group contains at least four mice. Panel C: Histogram of the MFI of the 
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class I molecule H-2Kb. *p<0.01 vs. DST and anti-CD154 mAb treated MyD88-/-
IFNAR1-/- mice. **p<0.05 vs. DST and anti-CD154 mAb treated MyD88-/-IFNAR1-/-
mice. Panel D: Histogram of the MFI of CD86. *p<0.001 vs. all other groups. 
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Summary: 
We have demonstrated that LPS treatment on the day of tolerance induction prevents 
the establishment of mixed chimerism and transplantation tolerance by signaling through 
the host TLR4 receptor. Signaling through the MyD88-independent pathway was 
sufficient to prevent the establishment of mixed hematopoietic chimerism. 
Administration of recombinant IFN-β was sufficient to recapitulate the effects of LPS on 
establishment of bone marrow chimerism and skin allograft survival. We then 
demonstrated that signaling through the host type I IFN receptor was important for LPS-
mediated effects, although additional MyD88-dependent mediators were also involved. 
We further demonstrated that LPS treatment prior to costimulation blockade induction 
did not prevent the establishment of mixed chimerism or shorten skin allograft survival, 
but that administration of LPS the day after bone marrow transplantation did.  
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CHAPTER V: DISCUSSION 
TLR Activation Prevents the Establishment of Mixed Hematopoietic Chimerism in 
Mice Treated with Costimulation Blockade 
Hematopoietic mixed chimerism has proven to induce a robust form of 
transplantation tolerance. Conditioning regimens based on costimulation blockade to 
induce mixed chimerism provide a promising strategy while also being minimally toxic. 
However, costimulation blockade-based regimens to induce tolerance to solid organs 
have reduced effectiveness in the setting of perturbations that activate the TLR system, 
such as infection. We originally hypothesized that similar stimuli would reduce the 
efficacy of costimulation blockade-based protocols to establish mixed chimerism. In 
support of this hypothesis, we demonstrated that administration of agonists to TLR2 
(Pam3Cys), TLR3 (polyI:C), and TLR4 (LPS) on the day of tolerance induction 
universally prevented the establishment of mixed hematopoietic chimerism (Figure 5). 
As a readout for mixed chimerism-induced transplantation tolerance to solid organs, our 
protocol includes simultaneous grafting of donor-specific skin allografts. We observed 
that TLR activation on the first day of the conditioning regimen also shortened skin 
allograft survival (Figure 5).  
TLR Activation Preventing the Establishment of Mixed Chimerism is Not Dependent 
on Production of Alloantibodies or on NK Cells 
We first addressed the possibility that activation of TLRs at the start of tolerance 
induction may prevent bone marrow engraftment by activating B cells to produce 
alloantibodies. Donor-specific antibodies are a potent barrier to allograft survival 
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[232,233] and could be generated in response to direct stimulation of TLRs on B cells or 
via T cell help. Our observation that TLR-mediated rejection was not accompanied by a 
rise in alloantibodies (Figure 6) was somewhat surprising, given that TLR activation has 
been shown to both promote T-dependent B-cell responses [186] and abrogate 
costimulation blockade-induced T cell tolerance [108,133]. However, CD154-CD40 
interactions have been demonstrated to be essential for T-dependent antibody responses 
[234-236], such as those generated against alloantigens [232]. Therefore, it is likely that 
despite receiving a stimulatory signal through TLRs, blocking CD154-CD40 interactions 
using anti-CD154 mAb precludes the generation of alloantibodies by B cells. This 
hypothesis is supported by recent work done by Chen and colleagues [108]. In a model 
where tolerance is induced with anti-CD154 mAb, they found that CpG-induced rejection 
of cardiac allografts was also independent of alloantibodies. Another possibility is that 
direct TLR activation of B cells may have resulted in the production of non-specific 
antibodies by a polyclonal population, and because our assay is specific for antibodies 
directed against alloantigens, an increase in overall immunoglobulin was not detected. In 
this population, antibodies with low-affinity to allogeneic antigens may have been 
present. However, without CD154-CD40 interaction, affinity maturation did not take 
place, and high-affinity alloantibody was not detected.  
We then addressed the role that host natural killer cells had in TLR-mediated effects 
on establishment of hematopoietic chimerism. NK cells have a complicated function in 
transplantation. They are known to present a potent barrier to the establishment of 
hematopoietic chimerism; however, their role in solid organ acceptance appears to be 
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more complex. Although NK cells are cytotoxic to cells that do not express self MHC 
molecules [237], they are not sufficient to reject solid organs directly, as evidenced by the 
survival of allografts in recipients that lack T and B lymphocytes. Nonetheless, NK cells 
have been shown to promote allograft rejection by inducing inflammation early in the 
rejection process, which acts to facilitate adaptive immune responses [92,238]. 
Interestingly, despite their role as sentinels guarding against foreign insults, their function 
in promoting tolerance to allografts is only now being appreciated [239,240]. For 
example, NK cells were shown to facilitate tolerance induction by minimizing direct 
allorecognition through eliminating donor-derived APCs [240]. NK cells express various 
TLRs, and can be stimulated directly by TLR agonists [223,241], or indirectly via the 
secretions of cytokines produced by other TLR-stimulated cells such as macrophages 
[242]. Therefore, we hypothesized that TLR signaling would promote NK activation, and 
in effect raise the barrier to hematopoietic engraftment. In contrast, however, we 
observed that NK cells were not required for LPS or poly I:C to prevent the establishment 
of mixed chimerism (Figure 7 and 8). Despite not being required, TLR-activated NK 
cells could still be sufficient to prevent establishment of mixed chimerism. This 
possibility, however, was excluded because mixed chimerism could be established 
following administration of TLR4 agonists when CD4+ and CD8+ cells, but not NK cells 
were removed (Figure 10). 
TLR Activation Breaks Tolerance in the CD4+ and CD8+ T Cell Compartments 
We began to address the role that T cells have in preventing the establishment of 
mixed chimerism by examining the CD8+ T cell compartment. Previously, our lab had 
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demonstrated that costimulation blockade induces the deletion of alloreactive CD8+ T 
cells prior to transplantation [86]. This tolerance-promoting mechanism is compromised, 
however, by the administration of TLR agonists [133]. Here, we show that activation of 
TLR4 during costimulation blockade not only prevents the deletion of alloreactive CD8+ 
T cells, but also results in the generation of effector CTLs with donor-specificity, as 
evidenced by ex vivo production of IFNγ upon restimulation with alloantigen (Figure 
11). Although tolerance in the CTL compartment can be broken by TLR activation, we 
observed that removal of CD8+ cells was not sufficient to establish mixed chimerism in 
the setting of TLR activation, suggesting that an additional barrier was present (Figures 8 
and 9). We hypothesized that TLR activation abrogated costimulation blockade-induced 
tolerance in the CD4+ compartment as well, and this would explain why removing CTLs 
was not enough to permit bone marrow engraftment. This was supported by the 
observation that TLR4 triggering did not prevent the establishment of mixed chimerism if 
CD4+ and CD8+ cells were both depleted (Figure 10). The fact that mixed hematopoietic 
chimerism could only be established in the absence of both T cell subsets indicates that 
either subset is sufficient to prevent mixed chimerism. This mechanism is interesting 
because it differs from what is observed with solid organ allografts such as skin [133]. 
This point will be discussed in more detail in a later section. 
It is also important to note that in the absence of DST and antiCD154 mAb 
treatment, depletion of CD4+ and CD8+ cells was not sufficient to establish mixed 
chimerism in our system. We speculate that the requirement of costimulation blockade in 
this setting is due to the NK cell barrier to hematopoietic engraftment. In unpublished 
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data, we have found that DST and anti-CD154 mAb treatment significantly lowers NK 
cytotoxicity during the peri-transplant period, perhaps due to transient depletion of 
CD154+ NK cells [74]. However, in addition, costimulation blockade is also important to 
supplement T cell depletion strategies because it is effective at inhibiting the graft’s 
immune response against the host [58,243]. In the absence of costimulation blockade, 
mixed allogeneic chimerism can result in graft versus host disease [243-245]. 
TLR Agonists As Adjuvants 
We have shown that TLR-activation can abrogate costimulation blockade-induced 
tolerance in both CD4+ and CD8+ T cell pools. Nevertheless, the precise cell 
population(s) that is targeted by TLR agonists has not been identified. One possibility is 
that T cells, which do express certain TLRs, could be directly stimulated by TLR 
engagement. TLR activation could prevent tolerance induction either by directly 
activating effector cells, or by indirectly by inhibiting regulatory T cell activity. 
However, these possibilities seem unlikely to explain why T cell tolerance is broken upon 
LPS treatment for two reasons. First, effector CD4+ T cells do not express TLR4 [192], 
and not surprisingly, LPS treatment does not induce downstream molecules of the TLR4 
pathway such as IkB and p38 in effector T cells [246]. Second, specific activation of 
TLR4 on regulatory T cells is reported to either enhance their suppressive capabilities 
[192], or have no effect on their phenotype [193,194]. For these reasons, TLR agonists 
likely activate alloreactive T cells indirectly by modulating other populations. We 
speculate that APCs are the most likely target of TLR activity.  
The prevailing hypothesis for costimulation blockade-induced graft tolerance in our 
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system is that conditioning with a transfusion of donor cells in the anti-CD154 mAb-
suppressed environment results in a preemptive state of hyporesponsiveness in the donor-
reactive T cell pool prior to the transplantation of the immunogenic allograft. The state of 
hyporesponsiveness towards the graft is thought to be largely due to early abortive 
expansion that results in the deletion of the majority of the alloreactive T cell pool, and 
renders the remaining cells nonresponsive [85,86,189,247]. This process is thought to be 
initiated by the presentation of allopeptides via either the direct or indirect allorecognition 
pathways [77]. One hypothesis postulates that direct recognition of APCs in the DST by 
host alloreactive T cells leads to hyporesponsiveness because anti-CD154 mAb prevents 
adequate activation of the DST. Consequently, donor-reactive T cells do not receive the 
necessary costimulation required for full activation. Work from our lab has supported this 
hypothesis, as we have shown that down regulation of the costimulatory molecule CD80 
on the DST was required for costimulation blockade-induced tolerance to islet allografts 
[225]. Using a transgenic model, in which B cells of the DST expressed CD80 under the 
control of the IgM promoter, it was shown that recipients of allogeneic islets could not be 
tolerized when cells of the DST expressed high levels of CD80. Others have shown a 
critical requirement for indirect presentation of alloantigen for tolerance induction 
[77,248]. This hypothesis contends that cells of the DST are quickly rendered apoptotic 
and phagocytosed by immature host DCs following transfer. Co-administration of anti-
CD154 mAb prevents the maturation of the host alloantigen-presenting DCs and, 
consequently, alloreactive T cells are tolerized by a mechanism that closely mimics those 
used to maintain peripheral self-tolerance [249]. TLR activation at the time of DST 
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transfer could be interfering with either, or both, of these mechanisms. We addressed 
both of these possibilities experimentally, and these will be discussed in the next section.  
Role of Direct Alloantigen Presentation 
We observed that APCs in the DST upregulated the costimulatory molecules CD80 
and CD86 in response to LPS administration (Figure 12). Therefore, it is possible that 
TLR activation increases the immunogenicity of the DST, which leads to alloreactive T 
cell priming and rescue from costimulation blockade-mediated apoptosis. TLR-mediated 
maturation of APCs within the DST could result from direct receptor engagement, or 
through the secretion of cytokines by TLR-stimulated cells of the host. We observed that 
mixed chimerism and long-term skin graft survival could be established in the presence 
of costimulation blockade and LPS when only the host was deficient in TLR4 (Figure 
15). This would suggest that activation of APCs within the DST by direct ligand-receptor 
interaction is not sufficient to prevent tolerance induction. This does not exclude the 
possibility that in wild-type animals, the production of cytokines by endotoxin-stimulated 
host cells could activate APCs in the graft, which may be a sufficient barrier. However, 
previous work by our lab indicates that maturation of APCs in the DST may not be 
required for the effects of LPS on naïve allospecific T cells. Thornley et al. showed that 
expression of the costimulatory molecules CD80 and CD86 on the cells of DST was not 
required for LPS to prevent the deletion of alloreactive CD8+ T cells in mice treated with 
costimulation blockade [204]. This suggests that: 1) there are either alternative 
costimulatory molecules expressed by APCs in the DST that prime donor-specific CTLs, 
or 2) antigen presentation by host APCs matured by direct TLR stimulation is playing an 
162 
 
 
important role.  
TLR Activation Enhances Indirect Presentation 
To address the effects of TLR activation on indirect allopresentation, we used a 
CFSE-labeling system that allowed us to track the DST and examine the phenotype of 
host DCs that had engulfed the transferred cells. We showed that activation of TLR2, 3, 
or 4 on the day of tolerance induction led to a rapid and marked upregulation of MHC 
class I and costimulatory molecules on host DCs that had phagocytosed CFSE-labeled 
DST (Figure 14). Therefore, we speculate that TLR activation on the day of tolerance 
induction significantly alters the context in which allopeptides are presented to the 
alloreactive T cell compartment. Instead of mimicking the mechanism of cross-tolerance 
to self-antigens and inducing transplantation tolerance, TLR-licensed APCs deliver an 
immunogenic signal to alloreactive T cells that prevents tolerization (Figure 25). This is 
supported by our data with mice deficient in various signaling molecules in the TLR4 
pathway. We observed that the effects of LPS were lost in mice deficient in both MyD88 
and the type I IFN receptor or TLR4. Chimerism was established in these mice in the 
presence of LPS, and interestingly, host alloantigen-presenting DCs in these mice did not 
upregulate costimulatory molecules. In contrast, activation of TLR4 did prevent tolerance 
induction in mice deficient in only MyD88 or the type I IFN receptor, and host 
alloantigen presenting DCs were matured to a significant extent. It is important to note 
that although mice deficient in type I IFN signaling did upregulate MHC class I and 
CD86 in response to LPS, these mice were partially protected, while the absence of 
MyD88 provided no protection. Host alloantigen presenting DCs in IFNAR1 knockout 
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mice may have been less mature, as their expression of the MHC class I molecule was 
decreased compared to LPS treated wild-type controls, whereas this was not seen with 
MyD88-/- mice. This could suggest that a critical threshold of costimulation is needed to 
activate alloreactive T cells, and that this threshold is reached more effectively in the 
absence of MyD88 than in the absence of signaling through the type 1 IFN receptor. It is 
also possible that the reason for this difference depends on other mechanisms, 
independent of allopresentation by host DCs. We will discuss these possibilities in the 
next section.  
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FIGURE 25: TLR-LICENSED APCS ACTIVATE ALLOREACTIVE T CELLS 
 
 
Figure 25: Upon TLR activation, APCs produce inflammatory cytokines such as IFN-
α/β, TNF-α and IL-6. These cytokines activate alloantigen-processing APCs in a 
paracrine or autocrine fashion to upregulate MHC class I and II, as well as costimulatory 
molecules, such as CD80 and CD86. The heightened expression of costimulatory 
molecules elicits the proliferation and differentiation of alloreactive T cells, in effect 
circumventing the effects of costimulation blockade. 
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Role of Regulatory T Cells 
In addition to enhancing the maturation of alloantigen-presenting DCs, TLR 
activation may prevent tolerance induction by inducing cytokines on accessory cells that 
feedback onto T cells. In addition to providing stimulatory cytokines to effector T cells 
(Teff), TLR-induced mediators may modulate Teff – Treg interactions. Although we did 
not address this experimentally, regulatory T cells are thought to have a vital role in 
tolerance induction [90,189], and thus we turn our discussion briefly to this possibility. 
TLR activation could impair regulation via several mechanisms. First, TLR-induced 
cytokines could act in trans to render alloreactive effector T cells refractory to Treg-
mediated suppression (Figure 26). This idea is supported by work from Pasare et al. 
demonstrating that ligation of TLRs on DCs enabled effector T cells to overcome 
suppression by CD4+CD25+ regulatory cells [198]. They reported that secretion of 
soluble mediators (principally IL-6) by TLR-activated DCs blocked the suppressive 
effect of Tregs, permitting activation of antigen-specific T cells in the presence of 
regulatory T cells. 
Second, engagement of TLRs could also prevent the differentiation of regulatory T 
cells through the upregulation of cytokines that affect naïve T cell differentiation. Studies 
have shown that CD4+ T cells develop a FoxP3+ regulatory T cell phenotype when they 
are activated in the presence of TGF-β [250]. However, when CD4+ T cells are activated 
in the presence of TGF-β and IL-6, this regulatory phenotype is suppressed and the cells 
develop a pro-inflammatory TH17 cell phenotype [251]. Therefore, TLR activation may 
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precipitate allograft rejection by preventing the generation of Tregs following 
costimulation blockade and instead favor development of pro-inflammatory effector T 
cells (Figure 26). 
Third, TLR signals could impair the recruitment of regulatory T cells to the allograft. 
This is supported by recent data demonstrating that activation of TLR2 or TLR9 
prevented the anti-CD154 mAb-mediated induction of Treg-associated chemokines in 
cardiac allografts, and decreased accumulation of intra-graft Tregs [108] (Figure 27A).  
Finally, direct activation of TLR2 on Tregs has been shown to induce expansion of 
regulatory T cells, while simultaneously inhibiting their suppressive capability [194] 
(Figure 26A). This mechanism may explain why Pam3Cys, but not LPS or poly I:C, was 
able to completely prevent tolerance induction in mice deficient in signaling through the 
type 1 IFN receptor (Figure 18). Since LPS and poly I:C cannot directly inhibit Treg 
function, they may require type I IFN for their adjuvanticity. Pam3Cys, in contrast, may 
not require signaling through the type 1 IFN receptor to prevent tolerance, because it can 
directly inhibit regulatory T cells from suppressing alloreactive effectors.  
Hence, TLR activation may trigger allograft rejection by compromising key 
regulatory mechanisms such as preventing the recruitment of Tregs to the site of the 
allograft, precluding the generation of regulatory T cells by costimulation blockade, 
enabling alloreactive T cells to escape Treg-mediated suppression, as well as by directly 
inhibiting the suppressive capability of regulatory cells. Consequently, we propose that 
activation of the TLR system by environmental perturbations prevents chimerism 
induction by breaking T cell tolerance via a multimodal mechanism that involves both the 
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licensing of alloantigen-presenting DCs and the impairment of regulatory mechanisms.  
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FIGURE 26: TLR ACTIVATION ABROGATES REGULATORY MECHANISMS 
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Figure 26: Regulatory T cells play a crucial role in transplantation tolerance to allogeneic 
organs. Regulatory mechanisms that prevent immune attack on allogeneic tissues may be 
compromised in the setting of TLR activation by several mechanisms. Release of 
inflammatory cytokines by TLR-activated cells can prevent the differentiation of 
uncommitted naïve CD4+ T cells into Tregs. Naïve CD4+ T cells can differentiate into 
regulatory T cells in the presence of TGF-β. However, in the presence of TGF-β and 
proinflammatory cytokines such as IL-6, and perhaps IL-21, naïve T cells can be skewed 
to turn into effector T cells such as the IL-17-producing TH17 cells. In a separate 
mechanism, release of cytokines such as IL-6 by activated APCs can render alloreactive 
effector cells refractory to suppression by regulatory T cells. 
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FIGURE 27: TLR ACTIVATION INHIBITS TREG RECRUITMENT AND TREG-
MEDIATED SUPPRESSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Regulatory T cells may be affected by TLR activation by two additional 
mechanisms. Panel A: TLR activation may decrease the recruitment Tregs to the 
allograft by decreasing the expression of Treg-recruiting chemokines such as CCL17 and 
CCL21. Panel B: Direct activation of certain TLRs, such as TLR2, can induce 
proliferation of regulatory T cells, while simultaneously inhibiting their suppressive 
phenotype.  
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Role of TLR Signaling Pathways 
In order to identify additional therapeutic targets to improve the efficacy of 
costimulation blockade-based chimerism induction protocols in the setting of TLR 
perturbation, we examined the molecules involved in the TLR signaling cascade. In doing 
so, we observed a critical role for both the adaptor molecule MyD88 and for the type I 
IFN receptor. These observations support a bimodal mechanism whereby ligation of 
TLRs impairs tolerance induction by both maturating dendritic cells and inhibiting 
regulatory cells. They also highlight the idea that different mechanisms may underlie 
costimulation blockade-induced transplantation tolerance to solid organ allografts and 
those that establish mixed chimerism. We will discuss both concepts in this section. 
Role of the MyD88-dependent and MyD88-independent Pathways 
The adjuvant effects of LPS are due chiefly to the production of inflammatory 
cytokines and the maturation of antigen-presenting cells. Cytokine response to TLR4 
engagement is almost completely dependent on MyD88, while DC maturation is thought 
to be principally regulated by the MyD88-independent pathway [252,253]. Similarly, we 
found that in the absence of host MyD88, LPS treatment increased the expression of the 
costimulatory molecule CD86 more than 2-fold on host cells that had phagocytosed 
alloantigens (Figure 17). We also documented that recipients deficient in MyD88 could 
not become chimeric following costimulation blockade conditioning if they were exposed 
to LPS (Figure 17). This would suggest that in the absence of TLR-mediated cytokines, 
enhanced presentation of allopeptides via the indirect pathway might be sufficient to 
prevent the establishment of mixed chimerism.  
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The upregulation of costimulatory molecules following LPS treatment has been 
shown to be dependent on the adaptor molecule TRIF and the downstream effector type I 
IFN [253]. Therefore, we hypothesized that the TLR4→TRIF→ IFN-α/β axis would be 
important for the effect of LPS. In support of this hypothesis, we observed that mice 
treated with costimulation blockade but lacking the ability to signal through the type I 
IFN receptor did develop mixed chimerism even in the presence of LPS or polyI:C 
(Figure 18). We also observed a decrease in the number of activated alloreactive CTLs in 
costimulation blockade and LPS–treated IFNAR1-/- mice compared to wild-type controls, 
suggesting that type I IFN is important in preventing tolerance in the alloreactive CD8+ T 
cell compartment (Figure 19). These observations correlated with an reduced expression 
of costimulatory molecules host alloantigen presenting DCs in response to TLR4 agonists 
(Figure 18). Thus, these data are consistent with the idea that mice null for the type 1 
IFN receptor are more resistant to the tolerance-abrogating effects of LPS stimulation due 
to the incomplete maturation of their DCs, which phagocystose and present alloantigen to 
activate allospecific T cells.  
In further support of the role of type I IFNs, we demonstrated that administration of 
recombinant IFN-β at the start of the conditioning regimen was sufficient to prevent the 
establishment of mixed chimerism (Figure 22). The effect of IFN-β appeared to be dose-
dependent, as 5 x 104 units/mouse prevented the establishment of chimerism in two thirds 
of the mice, while 7.5 x 104 units/mouse prevented the establishment of mixed chimerism 
in all of the mice treated (Figure 22). Given that type I IFN can directly stimulate APCs 
to increase expression of costimulatory molecules [253-255], our observations with 
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recombinant IFN-β are consistent with a mechanism the involves type 1 IFN-dependent 
upregulation of costimulatory molecules on host APCs. However, it does not exclude the 
possibility that other mechanisms are involved. Type 1 IFN can affect immune responses 
in a variety of ways. For example, in addition to directly stimulating upregulation of 
costimulatory molecules on APCs, type 1 IFN can also enhance cross-presentation of 
antigen by DCs to CD8+ T cells, which could facilitate priming of alloreactive CTLs 
[256]. Type I IFN can also directly act on T cells and provide a signal for clonal 
expansion and proliferation during T cell activation [257]. This role in naïve T cell 
activation could help explain why mice deficient in type I IFN signaling were partially 
protected from the effects of LPS, but MyD88-/- mice were not.  
Given the important role of type 1 IFN, we were somewhat surprised to find that 
mice deficient in IRF3 were not protected from the effects of LPS. We had originally 
hypothesized that because IRF3 is essential for the induction of IFN-β following TLR4 
activation with LPS [231], mice lacking IRF3 would be resistant to the effects of LPS, 
similar to IFNAR1-/- mice. Interestingly, IRF3-/- mice treated with costimulation blockade 
and LPS uniformly failed to become chimeric (Figure 23). Therefore, it appears that type 
1 IFN induction by host cells is not required for LPS to prevent the establishment of 
mixed chimerism. However, the cells of the DST did have functional IRF3; thus, it is 
possible that type 1 IFN production by donor cells in response to LPS was able to act in 
trans on host cells, which unlike IFNAR1-/- mice, were able to respond to type I IFN.  
Interestingly, although we observed that mice deficient in the type 1 IFN receptor 
became chimeric when exposed to LPS at the start of the conditioning regimen, the 
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frequency of chimerism was statistically different from IFNAR1-/- mice not given LPS 
(Figure 18). This suggested that an additional mediator was acting synergistically with 
type 1 IFN to prevent mixed chimerism. We demonstrated, using mice deficient in both 
MyD88 and IFNAR1, that the additional factor was MyD88 dependent. We observed that 
MyD88-/-IFNAR1-/- mice treated with costimulation blockade and LPS exhibited similar 
frequencies of mixed chimerism as their non LPS-treated controls (Figure 24). We also 
observed that in the absence of both proteins, host alloantigen-presenting cells did not 
upregulate the costimulatory molecule CD86 in response to LPS (Figure 24). These data 
indicate that a mediator(s) downstream of MyD88 acts synergistically with type 1 IFN to 
prevent tolerance induction. Our lab has observed that IL-12 (Figure 16 and [133]) and 
TNF-α [133] are not required for the effects of LPS on tolerance induction, making these 
cytokines unlikely candidates. IL-6, however, remains an attractive possibility that we 
have not yet examined. As described earlier, IL-6 has been shown to impair the induction 
of regulatory T cells, decrease their recruitment to the site of the graft, and render effector 
T cells refractory to the effects of Treg-mediated suppression. An important caveat to our 
observation in MyD88 and IFNAR1 double knockout mice is that MyD88 is also crucial 
for the signaling downstream of the IL-1 and IL-18 receptors [214,258]. Therefore, the 
additional mediator(s) could be extrinsic to the TLR4→MyD88 axis. 
Different Mechanisms May Control Tolerance to Hematopoietic and Solid-Organ 
Allografts  
There is mounting evidence that different tissues vary in their susceptibility to 
tolerance induction by costimulation blockade. For example, survival of cardiac and islet 
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allografts can be significantly prolonged with anti-CD154 mAb monotherapy, whereas 
skin allografts cannot [78,79,84]. Data also suggest that the mechanisms that control the 
abrogation of tolerance induction in the context of TLR activation may differ between 
tissues as well [108,133]. Our studies with mixed chimerism induction appear to extend 
this observation. For example, our laboratory documented previously that when 
transplanted alone, skin allograft survival could be prolonged with costimulation 
blockade when LPS was co-administered on the first day of the conditioning regimen if 
the host lacked either MyD88 or IFNAR1 [204]. This indicates that a synergy between 
the MyD88-dependent and the MyD88-independent pathways are required to prevent 
tolerance to skin allografts. In contrast, we observed that a synergy was not required, as 
either pathway could contribute to prevent the establishment of mixed chimerism. This 
suggests that the mechanisms to induce tolerance to hematopoietic grafts are more 
sensitive to environmental perturbations than are those required to prolong solid organ 
grafts such as skin allografts.  
Our examination of the cellular mechanisms revealed similar differences between 
hematopoietic and solid organ grafts. Previously, our laboratory has shown that the 
abrogation of costimulation blockade-induced tolerance to skin allografts following LPS 
treatment was solely dependent on host CD8+ cells [133], while another group found that 
CpG-mediated rejection of cardiac allografts was solely dependent on host CD4+ T cells 
[108]. Here we show the neither population is the sole mediator of the effects of LPS, as 
either subset is sufficient to prevent the establishment of mixed chimerism. Given that 
more immunosuppression is required for the induction of mixed chimerism by 
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costimulation blockade in the setting of TLR signaling, these data suggest further that the 
barrier to hematopoietic cell engraftment is higher than the barrier to solid-organ 
acceptance.  
Many explanations have been proposed to account for the differences in tissue 
susceptibility to allograft rejection. These include differences in the immunogenicity of 
the tissue, the presence of tissue-specific antigens in the graft, and differences in the 
susceptibility of various tissues to T cell-mediated rejection [191,259]. Reasons to 
account for the differences in the susceptibility to rejection of various tissues in the 
context of TLR activation are not known. One reason that hematopoietic allografts can be 
acutely rejected in the absence of CTLs following TLR ligation, but skin allografts 
cannot, could reflect a differential susceptibility to helper T cell effector mechanisms. For 
example, activated CD4+ T cells may contribute to the acute rejection of hematopoietic 
grafts by secreting IL-2 to enhance NK cytotoxicity. NK cells are potent killers of 
allogeneic hematopoietic cells, but are not effectively cytolytic towards solid allografts 
[92].  
Another explanation could be that hematopoietic grafts, unlike solid organ grafts, 
must not only evade the host’s immune system, but also home to a particular niche in the 
recipient. In order for long-term mixed chimerism to develop, pluripotent hematopoietic 
stem cells must engraft in specific niches in the bone marrow. Recent work has shown 
that migration of hematopoietic stem cells is affected by fluctuations in soluble mediators 
such as CXCL12, which can be modulated by stressors such as LPS [260]. Interestingly, 
activated macrophages have been shown to produce noradrenaline [261], a substance that 
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can potentially inhibit hematopoietic stem cell homing to the bone marrow by decreasing 
CXCL12 expression in bone marrow stromal cells [260]. Therefore, activation of 
macrophages via direct LPS stimulation or via CD4+ T cell licensing may increase the 
barrier to hematopoietic cell engraftment by precluding donor hematopoietic stem cells 
from establishing a niche in the recipient’s bone marrow. Therefore, although the precise 
mechanisms that distinguish the host’s response to hematopoietic and solid organ 
allografts in the setting of TLR activation are not known, it does appear that the barrier to 
mixed chimerism is higher than that of solid-organ allografts.  
TLR-Activation After Transplantation 
We have until now focused our discussion solely on the mechanisms governing the 
establishment of mixed chimerism and the effects following administration of TLR 
agonists at the start of costimulation blockade. However, stimuli that activate the TLR 
system, such as infection, may occur at any time during the peri-transplant period. It has 
been shown that skin allograft survival in mice treated with costimulation blockade can 
be impaired by viral infection the day after transplantation [107]. Similarly, we observed 
that LPS treatment 1 day after bone marrow transplantation completely prevented the 
establishment of mixed chimerism (Figure 21). Although we did not experimentally 
address the mechanisms involved, several are possible.  
Similar to TLR-activation at the start of costimulation blockade, LPS treatment on 
day +1 could also affect regulatory mechanisms or disrupt homing of hematopoietic stem 
cells to the stem cell niche. LPS treatment the day after transplantation may also raise the 
barrier to hematopoietic cell engraftment by activating host natural killer cells. Long-term 
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stable chimerism in mixed allogeneic chimeras suggests that donor and host NK cells are 
mutually tolerant. In fact several studies have shown that NK cell tolerance does develop 
in mixed allogeneic chimeras [220,262]. Proposed mechanisms include modulation of 
NK activating and inhibitory receptors, clonal deletion of donor and host-reactive NK 
cells, and anergy [263]. The kinetics involved in these mechanisms have not been fully 
elucidated; however, it appears that NK cell tolerance to donor cells may not develop 
within 24 hours of transplantation. Treatment with LPS the day after bone marrow 
transfer prevents the establishment of mixed chimerism, perhaps by directly activating 
NK cells to kill the donor hematopoietic stem cells. TLR activation could also raise the 
NK cell barrier indirectly by inhibiting Tregs. Recent evidence suggests that CD4+CD25+ 
Tregs can modulate NK cell function in vivo. Barao et al. demonstrated that the adoptive 
transfer of Tregs could prevent NK cell-mediated rejection of allogeneic bone marrow via 
a TGF-β-dependent mechanism [264]. It therefore possible, that TLR activation 
immediately following bone marrow transplantation could prevent engraftment directly 
by activating NK cells, or indirectly by inhibiting Treg-mediated regulation of both T 
cells and NK cells.  
It is also interesting to note that a discord exists between tolerance induction to 
allogeneic hematopoietic cells and skin in regards to TLR activation the day after 
transplantation. Previously, our lab showed that poly I:C treatment one day after skin 
allograft transplantation does not prevent costimulation blockade-induced allograft 
survival [107]. Similarly, in ongoing experiments in our laboratory, we have observed 
that costimulation blockade-conditioned mice simultaneously transplanted with 
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allogeneic bone marrow and skin that have been treated with LPS on day +1 do not 
become chimeric, but do not acutely reject their skin grafts. This observation further 
supports the idea that hematopoietic and solid organ allografts in mice treated with 
costimulation blockade differ in their susceptibility to TLR-mediated effects.  
Targets for Therapeutic Intervention 
The ultimate objective of our research is to create a conditioning regimen that is both 
maximally effective at establishing mixed allogeneic chimerism and transplantation 
tolerance, and minimally toxic to the recipient. We have shown that our costimulation 
blockade-based protocol is sensitive to a variety of environmental perturbants that could 
be encountered in the clinic. Consequently, we turn our discussion towards potential 
strategies to improve its efficacy.  
We have used a reductionist approach to study the effect individual microbial 
components have on costimulation blockade. However, it is likely that during clinical 
transplantation, many stimuli will be present and, consequently, multiple pathways will 
be activated. For example, transplantation of colonized tissues such as skin will introduce 
multiple pathogen associated molecular patterns, but it could also induce danger 
associated molecular patterns (DAMPs), such as heat-shock proteins, secondary to tissue 
injury. Any bacteria present on the allograft will activate multiple receptors, which as we 
have seen, can reduce the efficacy of costimulation blockade via distinct mechanisms. It 
is also probable that the timing of the insult, in addition to its nature, will prove critical. 
As we have proposed, perturbations that occur following transplantation may operate 
through distinct mechanisms. Given the pleiotropic nature of the challenge, it is likely 
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that multiple targets will need to be addressed.  
One possibility would be to augment the conditioning regimen with depleting 
antibodies directed against specific immune populations. We have demonstrated that in 
the absence CD4+ and CD8+ cells, mixed chimerism could be established in the presence 
of LPS treatment. Therefore, the costimulation blockade protocol could be supplemented 
with a short course of depleting antibodies directed against these subsets. Although the 
transient removal of T cells is undoubtedly preferable to a lifetime of chronic 
immunosuppression, even a temporary loss of T cells may put the patient at risk of 
opportunistic infection. Therefore, targeting components of the TLR system may be a 
more favorable approach.  
The increased awareness of the role of TLRs in a variety of pathological conditions 
has generated a deep interest in the development of compounds that contravene the TLR 
system. By combining compounds that inhibit both cell surface receptors and 
downstream molecules, it may be possible to buttress the tolerance-promoting effects of 
costimulation blockade, without significantly increasing the risk to the patient. We will 
now turn our discussion to a few potential candidates.  
Receptor Inhibitors 
Given the indispensible role of host TLR4 in the LPS-mediated rejection of 
allogeneic hematopoietic cells, specific antagonists of the LPS receptor may work as a 
successful adjunct to costimulation blockade. The synthetic lipid A analog eritoran (E-
5564), a potent antagonist of TLR4, has emerged an interesting candidate (Table 3). It is 
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currently being investigated for its potential therapeutic use in gram-negative bacterial 
sepsis, and has also shown efficacy at mitigating the inflammatory response to cardiac 
ischemia-reperfusion injury [265-267]. Eritoran infusion into healthy patients was 
demonstrated to inhibit the TNF-α response to LPS ex vivo [268], verifying both its 
safety and efficacy in humans. Antibodies directed against TLR4 [269] and the 
TLR4/MD-2 complex [270] have also been demonstrated to be effective at blunting the 
immune response to LPS.  
TLR4 can also be indirectly targeted through administration of the secosteroid 
hormone vitamin D3, or the NADPH oxidase inhibitor diphenylene iodonium (DPI). 
Treatment of monocytes with 1α,25-dihydrocholecalciferol (Vitamin D3) was shown to 
significantly impair LPS-induced TNF-α production and NF-κB translocation [271]. 
Endotoxin hyporesponsiveness was attributed to a vitamin D receptor-dependent 
downregulation of TLR4 [271]. In contrast, DPI was shown to induce 
hyporesponsiveness to LPS by impairing the recruitment of TLR4 to lipid rafts, an early 
event in the immune cascade [272]. The inhibition of NADPH-oxidase by DPI prevented 
the generation of reactive oxygen species (ROS), a critical step in the trafficking of TLR4 
to membrane rafts [272].  
Blockade of the LPS-binding protein CD14 has also shown efficacy at reducing the 
pathophysiological effects of LPS in animal models [273,274]. Treatment with the anti-
CD14 mAb IC14 was shown to be well-tolerated and attenuated the LPS-response in a 
small subset of patients [275]. However, a recent phase I clinical trial for patients with 
severe sepsis did not reveal any statistical differences in clinical outcome between 
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patients treated with IC14 mAb or placebo [276]. Hence, there are multiple strategies 
under investigation that attenuate TLR4 activation, including competitive inhibitors such 
as lipid A analogs and monoclonal antibodies, as well as indirect inhibitors that can either 
prevent TLR4 expression or trafficking to the membrane.  
Although we did not directly implicate the role of TLR7 and TLR9 in our model, 
activation of TLR9 has been shown to prevent costimulation blockade-mediated tolerance 
to cardiac and skin allografts [108,133]. In all likelihood, agonism at these receptors 
would also prevent tolerance to allogeneic hematopoietic cells. Immunoregulatory 
sequences (IRS) with specificity for TLR7 and 9 have been demonstrated to inhibit IFN-α 
production by plasmacytoid DCs, and to ameliorate symptoms of disease in an animal 
model of lupus [277,278]. Given the critical role of type I IFN in our system, these 
oligonucleotide-based inhibitors may also be beneficial adjuncts.  
Signaling Inhibitors 
Targeting each individual receptor of the TLR system concomitantly as a therapeutic 
strategy could prove untenable; consequently, utilizing therapies that inhibit molecules 
common to multiple receptors might be an alternative approach. The indispensable role 
of MyD88 in the signaling of many receptors makes it an attractive target for inhibition. 
Several compounds have been shown to effectively inhibit MyD88-dependent signaling 
(Table 3). The synthetic peptide-mimic ST2825 disrupts the homotypic interactions of 
the TIR domains of MyD88, preventing the adaptor from dimerizing [279]. 
Consequently, the compound interferes with recruitment of IRAK-1 and IRAK-4 to 
MyD88, and oral administration of the peptide has been demonstrated to inhibit MyD88-
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depenedent production of IL-6 in mice [279]. The TIR family member ST2 has also 
shown to inhibit TLR4 signaling by sequestering MyD88 and the adaptor Mal [280].  
Inhibitors of molecules downstream of MyD88 may also be useful. The polyphenol 
component of green tea, (-)-epigallocatechin-3-gallate (EGCG), is a well known anti-
inflammatory and chemoprotective agent, and has also been shown to attenuate LPS-
induced TNF-α production and abrogate endotoxin-mediated lethality in mice [281]. The 
protective effects were partly due to inhibition of IKK, a key activator of NF-κB 
downstream of MyD88 [282]. Importantly, EGCG was also shown to inhibit TBK1, a 
kinase downstream of TRIF and IPS-1 [283]. TBK1 is critical for the activation of IRF3 
and IFR7, and the subsequent induction of type 1 IFN. Given the important role for type I 
IFN in preventing of the establishment of mixed chimerism in mice treated with 
costimulation blockade, targeting molecules upstream of type 1 IFNs may also prove 
useful. In addition to EGCG, the polyphenol component of grapes 3,4’,5-trihydroxy-
trans-stilbene (resveratrol), has potent anti-inflammatory properties [284] that have been 
attributed to its inhibition of TBK1 and RIP1 [283]. Hence, these polyphenolic 
compounds, or more powerful derivatives of them, may prove useful alone, or in concert 
with other compounds that can inhibit TLR signaling.  
Although the aforementioned agents may be useful at improving the efficacy of 
protocols based on costimulation blockade, they may also significantly weaken the 
patient’s ability to defend against infection. Therefore, the risk/benefit ratio of their use 
must be carefully weighed.  
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TABLE 3: OVERVIEW OF TLR-TARGETED THERAPEUTICS 
 
Compound Target Comments 
Eritoran TLR4 Synthetic Lipid A analog [285] 
5E3 TLR4/MD-2 mAb directed against TLR4/MD-2 complex [270] 
15C1 TLR4 mAb directed against TLR4 [269] 
Vitamin D3 TLR2 & 4 Downregulates expression of TLR2 and TLR4 [271] 
Diphenylene 
iodonium NADPH Oxidase 
Impairs ligand-induced recruitment of TLR4 to lipid rafts 
by inhibiting reactive oxygen species formation [272] 
IC14 CD14 mAb directed against CD14 [275] 
IRS945 TLR7 & 9 Immunoregulatory sequence antagonizes TLR7 and TLR9 [278] 
ST2825 MyD88 Prevents dimerization of TIR domains [279] 
A46R & A52R MyD88 Open-reading frames of vaccinia virus inhibited MyD88-dependent signaling [286] 
ST2 MyD88 and Mal TIR-family member inhibits TLR4 signaling by sequestering MyD88 and Mal [280] 
EGCG TBK1& IKK Polyphenol component of green tea inhibits TBK1 [283] and IKK [282] 
Resveratrol TBK1 & RIP1 Polyphenol component of grapes inhibits TBK1 and RIP1 [283] 
 
 
Table 3: A table of selected compounds with known effects on the TLR system that may 
be useful as adjuncts to costimulation blockade-based regimens for tolerance induction. 
EGCG, (-)-epigallocatechin-3-gallate. IKK, IκB kinase. MAL, MyD88-adaptor-like. 
MyD88, myeloid differentiation primary response gene-88. RIP1, receptor-interacting 
protein 1.TBK-1, TANK-binding kinase 1.  
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Conclusions and Future Directions 
Hematopoietic mixed chimerism can be used to induce a robust form of 
transplantation tolerance to a variety of allografts. Our laboratory has demonstrated that 
mixed hematopoietic chimerism can be established using a minimally toxic conditioning 
regimen based on costimulation blockade. In this dissertation, we have shown that the 
efficacy of the induction protocol can be significantly affected by perturbations that 
activate toll-like receptors. It appears that perturbations at the start of the regimen, as well 
as immediately following transplantation, can abrogate the establishment of 
hematopoietic chimerism. We have identified a crucial role for host alloreactive CD4+ 
and CD8+ cells, the adaptor molecule MyD88 and type I IFNs, but not for IL-12 or IRF3 
following activation of TLR4 by LPS. Our research has highlighted several potential 
cellular and molecular targets to improve the effectiveness of costimulation blockade-
based protocols for the induction of mixed chimerism. However, the precise cellular 
target(s) of TLR agonists have not been identified. Demonstrating a more precise role for 
host APCs, as well as the function of regulatory T cells following TLR activation in our 
system will be important. In addition, further research needs to be performed with 
additional microbial components, as we have evidence that distinct PAMPs operate 
through distinct mechanisms. Therefore, to extrapolate our results to setting of the clinic, 
additional studies combining agonists to simulate an actual infection or direct study of 
microbes or viruses will need to be performed. We hope that these additional insights, 
paired with those from this dissertation, will help enable costimulation blockade-induced 
mixed chimerism to become a practical strategy to achieve long-term survival of 
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allogeneic organs without chronic immunosuppression.  
187 
 
 
REFERENCES  
1. Sorta-Bilajac I, Muzur A (2007) The nose between ethics and aesthetics: Sushruta's 
legacy. Otolaryngol Head Neck Surg 137:707 
2. Majno G (1975) The Healing Hand. Man and Wound in the Ancient World. 
Cambridge, MA: Cambridge, MA 
3. Silverstein A (1989) A History of Immunology. San Diego: San Diego 
4. Carrel A (1902) The operative technique for vascular anastomoses and 
transplantation of viscera. Lyon Medicine 98:859 
5. Gorer PA (1937) The genetic and antigenic basis of tumour transplantation. J Pathol 
Bacteriol 44:691 
6. Gorer PA, Lyman S, Snell GD (1948) Studies on the genetic and antigenic basis of 
tumor transplantation: linkage between a histocompatibility gene and "fused" in mice. 
Proc R Soc Lond Biol 135:449 
7. Snell GD (1992) Studies in Histocompatibility. Nobel Lectures, Physiology or 
Medicine 1971-1980:1 
8. Gibson T, Medawar PB (1943) The fate of skin homografts in man. J Anat 77:299 
9. Medawar PB (1944) The behaviour and fate of skin autografts and skin homografts 
in rabbits: A report to the War Wounds Committee of the Medical Research Council. J 
Anat 78:176 
10. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA (1999) Phylogenetic 
perspectives in innate immunity. Science 284:1313 
11. Galili U (1993) Interaction of the natural anti-Gal antibody with alpha-galactosyl 
epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 14:480 
12. Gould DS, Auchincloss H, Jr. (1999) Direct and indirect recognition: the role of 
MHC antigens in graft rejection. Immunol Today 20:77 
13. Larsen CP, Morris PJ, Austyn JM (1990) Migration of dendritic leukocytes from 
cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 
171:307 
14. Larsen CP, Austyn JM, Morris PJ (1990) The role of graft-derived dendritic 
leukocytes in the rejection of vascularized organ allografts. Recent findings on the 
migration and function of dendritic leukocytes after transplantation. Ann Surg 212:308 
15. Felix NJ, Allen PM (2007) Specificity of T-cell alloreactivity. Nat Rev Immunol 
7:942 
16. Womer KL, Sayegh MH, Auchincloss H, Jr. (2001) Involvement of the direct and 
indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B 
Biol Sci 356:639 
17. Unos (2008) United Network of Organ Sharing Transplant Registry (Accessed April 
1, 2008, at http://www.unos.org). In: 
18. Dausset J (1958) [Iso-leuko-antibodies.]. Acta Haematol 20:156 
19. Billingham RE, Krohn PL, Medawar PB (1951) Effect of cortisone on survival of 
skin homografts in rabbits. Br Med J 1:1157 
20. Starzl TE, Zinkernagel RM (2001) Transplantation tolerance from a historical 
perspective. Nat Rev Immunol 1:233 
188 
 
 
21. Starzl TE (2000) History of clinical transplantation. World J Surg 24:759 
22. Schwartz R, Dameshek W (1960) The effects of 6-mercaptopurine on homograft 
reactions. J Clin Invest 39:952 
23. Schwartz R, Dameshek W (1959) Drug-induced immunological tolerance. Nature 
183:1682 
24. Meeker WR, Jr., Condie RM, Good RA, Varco RL (1960) Alteration of the 
homograft response by antimetabolites. Ann N Y Acad Sci 87:203 
25. Calne RY (1960) The rejection of renal homografts. Inhibition in dogs by 6-
mercaptopurine. Lancet 1:417 
26. Borel JF, Feurer C, Gubler HU, Stahelin H (1976) Biological effects of cyclosporin 
A: a new antilymphocytic agent. Agents Actions 6:468 
27. Krensky AM, Vincenti F, M BW (2006) Immunosuppressants, tolerogens, and 
immunostimulants. In: LL Brunton (ed) Goodman and Gilman's the pharmacological 
basis of therapeutics. New York: McGraw-Hill Companies, Inc, 1405 
28. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR (1992) 
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358:70 
29. Kung P, Goldstein G, Reinherz EL, Schlossman SF (1979) Monoclonal antibodies 
defining distinctive human T cell surface antigens. Science 206:347 
30. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, 
Waldmann H (1988) Remission induction in non-Hodgkin lymphoma with reshaped 
human monoclonal antibody CAMPATH-1H. Lancet 2:1394 
31. Nakakura EK, Shorthouse RA, Zheng B, McCabe SM, Jardieu PM, Morris RE 
(1996) Long-term survival of solid organ allografts by brief anti-lymphocyte function-
associated antigen-1 monoclonal antibody monotherapy. Transplantation 62:547 
32. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, 
Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J (1998) Interleukin-2-receptor 
blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab 
Triple Therapy Study Group. N Engl J Med 338:161 
33. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP (1997) 
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in 
renal allograft recipients. CHIB 201 International Study Group. Lancet 350:1193 
34. Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J 
Med 351:2715 
35. Habwe VQ (2006) Posttransplantation quality of life: more than graft function. Am J 
Kidney Dis 47:S98 
36. Cantarovich D, Vistoli F, Soulillou JP (2008) Immunosuppression minimization in 
kidney transplantation. Front Biosci 13:1413 
37. Ferry C, Socie G (2003) Busulfan-cyclophosphamide versus total body irradiation-
cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell 
transplantation for acute myeloid leukemia: what have we learned? Exp Hematol 31:1182 
38. Soulillou JP, Giral M (2001) Controlling the incidence of infection and malignancy 
by modifying immunosuppression. Transplantation 72:S89 
39. Laederach-Hofmann K, Bunzel B (2000) Noncompliance in organ transplant 
recipients: a literature review. Gen Hosp Psychiatry 22:412 
189 
 
 
40. Paul LC (1995) Immunobiology of chronic renal transplant rejection. Blood Purif 
13:206 
41. Kreis HA, Ponticelli C (2001) Causes of late renal allograft loss: chronic allograft 
dysfunction, death, and other factors. Transplantation 71:SS5 
42. Kamoun M (2006) Mechanisms of chronic allograft dysfunction. Ther Drug Monit 
28:14 
43. Rossini AA, Greiner DL, Mordes JP (1999) Induction of immunologic tolerance for 
transplantation. Physiol Rev 79:99 
44. Billingham RE, Brent L, Medawar PB (1953) Actively acquired tolerance of foreign 
cells. Nature 172:603 
45. Owen RD (1945) Immunogenetic Consequences of Vascular Anastomoses between 
Bovine Twins. Science 102:400 
46. Burnet F, Fenner F (1949) The production of antibodies. Melbourne: Melbourne 
47. Main JM, Prehn RT (1955) Successful skin homografts after the administration of 
high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 15:1023 
48. Nikolic-Zugic J, Bevan MJ (1990) Role of self-peptides in positively selecting the T-
cell repertoire. Nature 344:65 
49. Starr TK, Jameson SC, Hogquist KA (2003) Positive and negative selection of T 
cells. Annu Rev Immunol 21:139 
50. Derbinski J, Schulte A, Kyewski B, Klein L (2001) Promiscuous gene expression in 
medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2:1032 
51. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, 
Bronson R, Dierich A, Benoist C, Mathis D (2002) Projection of an immunological self 
shadow within the thymus by the aire protein. Science 298:1395 
52. Kisielow P, Bluthmann H, Staerz UD, Steinmetz M, von Boehmer H (1988) 
Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ 
thymocytes. Nature 333:742 
53. Sha WC, Nelson CA, Newberry RD, Kranz DM, Russell JH, Loh DY (1988) 
Positive and negative selection of an antigen receptor on T cells in transgenic mice. 
Nature 336:73 
54. Kappler JW, Roehm N, Marrack P (1987) T cell tolerance by clonal elimination in 
the thymus. Cell 49:273 
55. Nossal GJ (1994) Negative selection of lymphocytes. Cell 76:229 
56. Sykes M (2001) Mixed chimerism and transplant tolerance. Immunity 14:417 
57. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, 
Sykes M (2000) Allogeneic bone marrow transplantation with co-stimulatory blockade 
induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 
6:464 
58. Seung E, Mordes JP, Rossini AA, Greiner DL (2003) Hematopoietic chimerism and 
central tolerance created by peripheral-tolerance induction without myeloablative 
conditioning. J Clin Invest 112:795 
59. Durham MM, Bingaman AW, Adams AB, Ha J, Waitze SY, Pearson TC, Larsen CP 
(2000) Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to 
hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. 
190 
 
 
J Immunol 165:1 
60. Wekerle T, Sykes M (2001) Mixed chimerism and transplantation tolerance. Annu 
Rev Med 52:353 
61. Sharabi Y, Sachs DH (1989) Mixed chimerism and permanent specific 
transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 169:493 
62. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, 
Hoppe RT, Lowsky R, Engleman EG, Strober S (2008) Tolerance and chimerism after 
renal and hematopoietic-cell transplantation. N Engl J Med 358:362 
63. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, 
Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, 
Wong W, Williams WW, Jr., Colvin RB, Sykes M, Sachs DH (2008) HLA-mismatched 
renal transplantation without maintenance immunosuppression. N Engl J Med 358:353 
64. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD (2006) A new look at 
blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance 
immunosuppression. Am J Transplant 6:876 
65. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, 
Popescu F, Xiao Z (2006) Signals required for programming effector and memory 
development by CD8+ T cells. Immunol Rev 211:81 
66. Snanoudj R, de Preneuf H, Creput C, Arzouk N, Deroure B, Beaudreuil S, Durrbach 
A, Charpentier B (2006) Costimulation blockade and its possible future use in clinical 
transplantation. Transpl Int 19:693 
67. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev 
Immunol 23:515 
68. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305 
69. Curtsinger JM, Gerner MY, Lins DC, Mescher MF (2007) Signal 3 availability limits 
the CD8 T cell response to a solid tumor. J Immunol 178:6752 
70. Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus 
full activation of naive CD8 T cells: dissociating proliferation and development of 
effector function. J Exp Med 197:1141 
71. Ranheim EA, Kipps TJ (1993) Activated T cells induce expression of B7/BB1 on 
normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177:925 
72. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R (1995) Studies on the 
interdependence of gp39 and B7 expression and function during antigen-specific immune 
responses. Eur J Immunol 25:596 
73. Wu Y, Xu J, Shinde S, Grewal I, Henderson T, Flavell RA, Liu Y (1995) Rapid 
induction of a novel costimulatory activity on B cells by CD40 ligand. Curr Biol 5:1303 
74. Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu 
Rev Immunol 16:111 
75. Larsen CP, Pearson TC (1997) The CD40 pathway in allograft rejection, acceptance, 
and tolerance. Curr Opin Immunol 9:641 
76. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ (1996) Immune regulation 
by CD40 and its ligand GP39. Annu Rev Immunol 14:591 
77. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ (2004) CD40/CD154 interactions at 
the interface of tolerance and immunity. Annu Rev Immunol 22:307 
191 
 
 
78. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, Noelle RJ, 
Mordes JP, Rossini AA (1995) Survival of mouse pancreatic islet allografts in recipients 
treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad 
Sci U S A 92:9560 
79. Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, 
Hendrix R, Pearson TC (1996) CD40-gp39 interactions play a critical role during 
allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 
pathway. Transplantation 61:4 
80. Elster EA, Xu H, Tadaki DK, Montgomery S, Burkly LC, Berning JD, Baumgartner 
RE, Cruzata F, Marx R, Harlan DM, Kirk AD (2001) Treatment with the humanized 
CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin 
allografts in nonhuman primates. Transplantation 72:1473 
81. Kenyon NS, Fernandez LA, Lehmann R, Masetti M, Ranuncoli A, Chatzipetrou M, 
Iaria G, Han D, Wagner JL, Ruiz P, Berho M, Inverardi L, Alejandro R, Mintz DH, Kirk 
AD, Harlan DM, Burkly LC, Ricordi C (1999) Long-term survival and function of 
intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 
48:1473 
82. Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL, Kirk 
AD, Harlan DM, Burkly LC, Ricordi C (1999) Long-term survival and function of 
intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc 
Natl Acad Sci U S A 96:8132 
83. Preston EH, Xu H, Dhanireddy KK, Pearl JP, Leopardi FV, Starost MF, Hale DA, 
Kirk AD (2005) IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion 
facilitate operational tolerance in non-human primates. Am J Transplant 5:1032 
84. Markees TG, Phillips NE, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA 
(1997) Prolonged survival of mouse skin allografts in recipients treated with donor 
splenocytes and antibody to CD40 ligand. Transplantation 64:329 
85. Iwakoshi NN, Markees TG, Turgeon N, Thornley T, Cuthbert A, Leif J, Phillips NE, 
Mordes JP, Greiner DL, Rossini AA (2001) Skin allograft maintenance in a new 
synchimeric model system of tolerance. J Immunol 167:6623 
86. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL (2000) 
Treatment of allograft recipients with donor-specific transfusion and anti-CD154 
antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a 
CTLA4-dependent manner. J Immunol 164:512 
87. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley 
PS, Bluestone JA (1992) Long-term survival of xenogeneic pancreatic islet grafts induced 
by CTLA4lg. Science 257:789 
88. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA (1993) 
Long-term acceptance of major histocompatibility complex mismatched cardiac 
allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 178:1801 
89. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, 
Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC (1996) Long-term 
acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. 
Nature 381:434 
192 
 
 
90. Yamazaki M, Pearson T, Brehm MA, Miller DM, Mangada JA, Markees TG, Shultz 
LD, Mordes JP, Rossini AA, Greiner DL (2007) Different mechanisms control peripheral 
and central tolerance in hematopoietic chimeric mice. Am J Transplant 7:1710 
91. Durie FH, Aruffo A, Ledbetter J, Crassi KM, Green WR, Fast LD, Noelle RJ (1994) 
Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic 
forms of graft-vs-host disease. J Clin Invest 94:1333 
92. LaRosa DF, Rahman AH, Turka LA (2007) The innate immune system in allograft 
rejection and tolerance. J Immunol 178:7503 
93. Obhrai J, Goldstein DR (2006) The role of toll-like receptors in solid organ 
transplantation. Transplantation 81:497 
94. Goldstein DR (2004) Toll-like receptors and other links between innate and acquired 
alloimmunity. Curr Opin Immunol 16:538 
95. Goldstein DR (2006) Toll like receptors and acute allograft rejection. Transpl 
Immunol 17:11 
96. Goldstein DR, Palmer SM (2005) Role of Toll-like receptor-driven innate immunity 
in thoracic organ transplantation. J Heart Lung Transplant 24:1721 
97. Andrade CF, Waddell TK, Keshavjee S, Liu M (2005) Innate immunity and organ 
transplantation: the potential role of toll-like receptors. Am J Transplant 5:969 
98. Tesar BM, Goldstein DR (2007) Toll-like receptors and their role in transplantation. 
Front Biosci 1:4221 
99. Pascher A, Proesch S, Pratschke J, Reutzel-Selke A, Sawitzki B, Lehmann M, Tullius 
SG, Neuhaus P, Volk HD, Reinke P (2006) Rat cytomegalovirus infection interferes with 
anti-CD4 mAb-(RIB 5/2) mediated tolerance and induces chronic allograft damage. Am J 
Transplant 6:2035 
100. Stapler D, Lee ED, Selvaraj SA, Evans AG, Kean LS, Speck SH, Larsen CP, 
Gangappa S (2008) Expansion of Effector Memory TCR V{beta}4+CD8+ T Cells Is 
Associated with Latent Infection-Mediated Resistance to Transplantation Tolerance. J 
Immunol 180:3190 
101. Williams MA, Tan JT, Adams AB, Durham MM, Shirasugi N, Whitmire JK, 
Harrington LE, Ahmed R, Pearson TC, Larsen CP (2001) Characterization of virus-
mediated inhibition of mixed chimerism and allospecific tolerance. J Immunol 167:4987 
102. Williams MA, Onami TM, Adams AB, Durham MM, Pearson TC, Ahmed R, Larsen 
CP (2002) Cutting edge: persistent viral infection prevents tolerance induction and 
escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 
169:5387 
103. Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM, Wherry 
EJ, Onami T, Lanier JG, Kokko KE, Pearson TC, Ahmed R, Larsen CP (2003) 
Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin 
Invest 111:1887 
104. Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM (2003) 
Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells 
generated in response to viral infections. J Immunol 170:4077 
105. Forman D, Welsh RM, Markees TG, Woda BA, Mordes JP, Rossini AA, Greiner DL 
(2002) Viral abrogation of stem cell transplantation tolerance causes graft rejection and 
193 
 
 
host death by different mechanisms. J Immunol 168:6047 
106. Turgeon NA, Iwakoshi NN, Phillips NE, Meyers WC, Welsh RM, Greiner DL, 
Mordes JP, Rossini AA (2000) Viral infection abrogates CD8(+) T-cell deletion induced 
by costimulation blockade. J Surg Res 93:63 
107. Welsh RM, Markees TG, Woda BA, Daniels KA, Brehm MA, Mordes JP, Greiner 
DL, Rossini AA (2000) Virus-induced abrogation of transplantation tolerance induced by 
donor-specific transfusion and anti-CD154 antibody. J Virol 74:2210 
108. Chen L, Wang T, Zhou P, Ma L, Yin D, Shen J, Molinero L, Nozaki T, Phillips T, 
Uematsu S, Akira S, Wang CR, Fairchild RL, Alegre ML, Chong A (2006) TLR 
engagement prevents transplantation tolerance. Am J Transplant 6:2282 
109. Janeway CA, Jr., Medzhitov R (2002) Innate immune recognition. Annu Rev 
Immunol 20:197 
110. Anderson KV, Bokla L, Nusslein-Volhard C (1985) Establishment of dorsal-ventral 
polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 
42:791 
111. Anderson KV, Jurgens G, Nusslein-Volhard C (1985) Establishment of dorsal-ventral 
polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. 
Cell 42:779 
112. Belvin MP, Anderson KV (1996) A conserved signaling pathway: the Drosophila 
toll-dorsal pathway. Annu Rev Cell Dev Biol 12:393 
113. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA (1996) The 
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal 
response in Drosophila adults. Cell 86:973 
114. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. (1997) A human homologue of 
the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394 
115. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K 
(2006) Genetic analysis of host resistance: Toll-like receptor signaling and immunity at 
large. Annu Rev Immunol 24:353 
116. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, 
Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-
like receptor 7 and 8. Science 303:1526 
117. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral 
responses by means of TLR7-mediated recognition of single-stranded RNA. Science 
303:1529 
118. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino 
K, Wagner H, Takeda K, Akira S (2000) A Toll-like receptor recognizes bacterial DNA. 
Nature 408:740 
119. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune 
responses. Nat Immunol 5:987 
120. Reis e Sousa C (2004) Toll-like receptors and dendritic cells: for whom the bug tolls. 
Semin Immunol 16:27 
121. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-
stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732 
122. Pichlmair A, Reis e Sousa C (2007) Innate recognition of viruses. Immunity 27:370 
194 
 
 
123. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. 
Cell 124:783 
124. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335 
125. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S 
(1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to 
lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162:3749 
126. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, 
Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) 
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. 
Science 282:2085 
127. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, 
Freeman MW, Golenbock DT, Anderson LJ, Finberg RW (2000) Pattern recognition 
receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 
1:398 
128. Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is 
a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164:558 
129. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss 
JF, 3rd (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol 
Chem 276:10229 
130. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, 
Freudenberg M, Galanos C, Simon JC (2002) Oligosaccharides of Hyaluronan activate 
dendritic cells via toll-like receptor 4. J Exp Med 195:99 
131. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S 
(2002) Cutting edge: role of Toll-like receptor 1 in mediating immune response to 
microbial lipoproteins. J Immunol 169:10 
132. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A 
(1999) The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates 
between pathogens. Nature 401:811 
133. Thornley TB, Brehm MA, Markees TG, Shultz LD, Mordes JP, Welsh RM, Rossini 
AA, Greiner DL (2006) TLR agonists abrogate costimulation blockade-induced 
prolongation of skin allografts. J Immunol 176:1561 
134. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, 
Akira S (2001) Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int 
Immunol 13:933 
135. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, 
Schroeder L, Aderem A (2000) The repertoire for pattern recognition of pathogens by the 
innate immune system is defined by cooperation between toll-like receptors. Proc Natl 
Acad Sci U S A 97:13766 
136. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M (2000) 
Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal 
transduction by Taxol. J Biol Chem 275:2251 
137. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, Morrison SG, 
Morrison RP, Arditi M (2002) Chlamydial heat shock protein 60 activates macrophages 
and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent 
195 
 
 
pathway. J Immunol 168:1435 
138. Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, 
Schwartz DA (2003) The role of innate immunity in acute allograft rejection after lung 
transplantation. Am J Respir Crit Care Med 168:628 
139. Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, 
Schwartz DA (2005) Innate immunity influences long-term outcomes after human lung 
transplant. Am J Respir Crit Care Med 171:780 
140. Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P, Kazory A, 
Chalopin JM, Tiberghien P (2005) Relevance of Toll-like receptor-4 polymorphisms in 
renal transplantation. Kidney Int 67:2454 
141. Palmer SM, Burch LH, Mir S, Smith SR, Kuo PC, Herczyk WF, Reinsmoen NL, 
Schwartz DA (2006) Donor polymorphisms in Toll-like receptor-4 influence the 
development of rejection after renal transplantation. Clin Transplant 20:30 
142. Fekete A, Viklicky O, Hubacek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, 
Heemann U, Reusz G, Szabo AJ (2006) Association between heat shock protein 70s and 
toll-like receptor polymorphisms with long-term renal allograft survival. Transpl Int 
19:190 
143. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, 
Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is 
mediated by Toll-like receptor 5. Nature 410:1099 
144. Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS, 
Hieny S, Sutterwala FS, Flavell RA, Ghosh S, Sher A (2005) TLR11 activation of 
dendritic cells by a protozoan profilin-like protein. Science 308:1626 
145. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, Ghosh S 
(2004) A toll-like receptor that prevents infection by uropathogenic bacteria. Science 
303:1522 
146. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira 
K, Akira S, Fujita T (2004) The RNA helicase RIG-I has an essential function in double-
stranded RNA-induced innate antiviral responses. Nat Immunol 5:730 
147. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, 
Loo YM, Gale M, Jr., Akira S, Yonehara S, Kato A, Fujita T (2005) Shared and unique 
functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate 
immunity. J Immunol 175:2851 
148. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, 
Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, 
Matsuura Y, Fujita T, Akira S (2006) Differential roles of MDA5 and RIG-I helicases in 
the recognition of RNA viruses. Nature 441:101 
149. Martinon F, Agostini L, Meylan E, Tschopp J (2004) Identification of bacterial 
muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 
14:1929 
150. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric 
acid crystals activate the NALP3 inflammasome. Nature 440:237 
151. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee 
WP, Weinrauch Y, Monack DM, Dixit VM (2006) Cryopyrin activates the inflammasome 
196 
 
 
in response to toxins and ATP. Nature 440:228 
152. O'Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors 
in Toll-like receptor signalling. Nat Rev Immunol 7:353 
153. Lord KA, Hoffman-Liebermann B, Liebermann DA (1990) Nucleotide sequence and 
expression of a cDNA encoding MyD88, a novel myeloid differentiation primary 
response gene induced by IL6. Oncogene 5:1095 
154. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S (1999) Unresponsiveness of 
MyD88-deficient mice to endotoxin. Immunity 11:115 
155. Takeuchi O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira S (2000) Cellular 
responses to bacterial cell wall components are mediated through MyD88-dependent 
signaling cascades. Int Immunol 12:113 
156. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, 
Pitha PM, Golenbock DT (2003) LPS-TLR4 signaling to IRF-3/7 and NF-kappaB 
involves the toll adapters TRAM and TRIF. J Exp Med 198:1043 
157. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K, Akira S (2003) 
Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with 
TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct 
transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor 
signaling. J Immunol 171:4304 
158. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M, Tschopp J 
(2004) RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B 
activation. Nat Immunol 5:503 
159. Honda K, Taniguchi T (2006) IRFs: master regulators of signalling by Toll-like 
receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6:644 
160. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, 
Raz E, Wagner H, Hacker G, Mann M, Karin M (2006) Specificity in Toll-like receptor 
signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439:204 
161. Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, Perry A, Cheng 
G (2006) Critical role of TRAF3 in the Toll-like receptor-dependent and -independent 
antiviral response. Nature 439:208 
162. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, 
Inoue J, Uematsu S, Takeuchi O, Akira S (2004) Interferon-alpha induction through Toll-
like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat 
Immunol 5:1061 
163. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, 
Coban C, Ishii KJ, Kawai T, Takeuchi O, Akira S (2005) Interleukin-1 receptor-
associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-
mediated interferon-{alpha} induction. J Exp Med 201:915 
164. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, Ohara O, 
Akira S, Kaisho T (2006) IkappaB kinase-alpha is critical for interferon-alpha production 
induced by Toll-like receptors 7 and 9. Nature 440:949 
165. Takeuchi O, Akira S (2007) Recognition of viruses by innate immunity. Immunol 
Rev 220:214 
166. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, 
197 
 
 
Takaoka A, Yoshida N, Taniguchi T (2005) IRF-7 is the master regulator of type-I 
interferon-dependent immune responses. Nature 434:772 
167. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T (2003) TICAM-1, an 
adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta 
induction. Nat Immunol 4:161 
168. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, 
Sugiyama M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-
independent toll-like receptor signaling pathway. Science 301:640 
169. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, 
Akira S (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon 
induction. Nat Immunol 6:981 
170. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, 
Tschopp J (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is 
targeted by hepatitis C virus. Nature 437:1167 
171. Seth RB, Sun L, Ea CK, Chen ZJ (2005) Identification and characterization of 
MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. 
Cell 122:669 
172. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB (2005) VISA is an adapter protein 
required for virus-triggered IFN-beta signaling. Mol Cell 19:727 
173. Sun Q, Sun L, Liu HH, Chen X, Seth RB, Forman J, Chen ZJ (2006) The specific 
and essential role of MAVS in antiviral innate immune responses. Immunity 24:633 
174. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle 
AJ, Liao SM, Maniatis T (2003) IKKepsilon and TBK1 are essential components of the 
IRF3 signaling pathway. Nat Immunol 4:491 
175. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J (2003) Triggering 
the interferon antiviral response through an IKK-related pathway. Science 300:1148 
176. Kumar H, Kawai T, Kato H, Sato S, Takahashi K, Coban C, Yamamoto M, Uematsu 
S, Ishii KJ, Takeuchi O, Akira S (2006) Essential role of IPS-1 in innate immune 
responses against RNA viruses. J Exp Med 203:1795 
177. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, Takeshita F, Ludwig H, Sutter G, 
Suzuki K, Hemmi H, Sato S, Yamamoto M, Uematsu S, Kawai T, Takeuchi O, Akira S 
(2006) A Toll-like receptor-independent antiviral response induced by double-stranded B-
form DNA. Nat Immunol 7:40 
178. Stetson DB, Medzhitov R (2006) Recognition of cytosolic DNA activates an IRF3-
dependent innate immune response. Immunity 24:93 
179. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S (2005) Toll-like receptor-
independent gene induction program activated by mammalian DNA escaped from 
apoptotic DNA degradation. J Exp Med 202:1333 
180. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, 
Kodama T, Honda K, Ohba Y, Taniguchi T (2007) DAI (DLM-1/ZBP1) is a cytosolic 
DNA sensor and an activator of innate immune response. Nature 448:501 
181. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, Flavell RA, 
Girardin SE, Godzik A, Harton JA, Hoffman HM, Hugot JP, Inohara N, Mackenzie A, 
Maltais LJ, Nunez G, Ogura Y, Otten LA, Philpott D, Reed JC, Reith W, Schreiber S, 
198 
 
 
Steimle V, Ward PA (2008) The NLR gene family: a standard nomenclature. Immunity 
28:285 
182. Kanneganti TD, Lamkanfi M, Nunez G (2007) Intracellular NOD-like receptors in 
host defense and disease. Immunity 27:549 
183. Petrilli V, Dostert C, Muruve DA, Tschopp J (2007) The inflammasome: a danger 
sensing complex triggering innate immunity. Curr Opin Immunol 19:615 
184. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J 
(2008) The inflammasome recognizes cytosolic microbial and host DNA and triggers an 
innate immune response. Nature 452:103 
185. Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody 
JS, Blazar BR (2007) Preformed antibody, not primed T cells, is the initial and major 
barrier to bone marrow engraftment in allosensitized recipients. Blood 109:1307 
186. Pasare C, Medzhitov R (2005) Control of B-cell responses by Toll-like receptors. 
Nature 438:364 
187. Lampropoulou V, Hoehlig K, Roch T, Neves P, Gomez EC, Sweenie CH, Hao Y, 
Freitas AA, Steinhoff U, Anderton SM, Fillatreau S (2008) TLR-Activated B Cells 
Suppress T Cell-Mediated Autoimmunity. J Immunol 180:4763 
188. Pasare C, Medzhitov R (2004) Toll-dependent control mechanisms of CD4 T cell 
activation. Immunity 21:733 
189. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, 
Rossini AA (1998) Long-term survival of skin allografts induced by donor splenocytes 
and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-
gamma, and CTLA4. J Clin Invest 101:2446 
190. Graca L, Honey K, Adams E, Cobbold SP, Waldmann H (2000) Cutting edge: anti-
CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol 
165:4783 
191. Banuelos SJ, Markees TG, Phillips NE, Appel MC, Cuthbert A, Leif J, Mordes JP, 
Shultz LD, Rossini AA, Greiner DL (2004) Regulation of skin and islet allograft survival 
in mice treated with costimulation blockade is mediated by different CD4+ cell subsets 
and different mechanisms. Transplantation 78:660 
192. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J (2003) 
Regulatory T cells selectively express toll-like receptors and are activated by 
lipopolysaccharide. J Exp Med 197:403 
193. Crellin NK, Garcia RV, Hadisfar O, Allan SE, Steiner TS, Levings MK (2005) 
Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive 
capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol 
175:8051 
194. Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, 
Joosten LA, Akira S, Netea MG, Adema GJ (2006) Toll-like receptor 2 controls 
expansion and function of regulatory T cells. J Clin Invest 116:485 
195. Netea MG, Sutmuller R, Hermann C, Van der Graaf CA, Van der Meer JW, van 
Krieken JH, Hartung T, Adema G, Kullberg BJ (2004) Toll-like receptor 2 suppresses 
immunity against Candida albicans through induction of IL-10 and regulatory T cells. J 
Immunol 172:3712 
199 
 
 
196. Liu H, Komai-Koma M, Xu D, Liew FY (2006) Toll-like receptor 2 signaling 
modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A 
103:7048 
197. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang 
RF (2005) Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. 
Science 309:1380 
198. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T 
cell-mediated suppression by dendritic cells. Science 299:1033 
199. Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals 
are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 
5:508 
200. LaRosa DF, Gelman AE, Rahman AH, Zhang J, Turka LA, Walsh PT (2007) CpG 
DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent 
costimulation of effector CD4+ T cells. Immunol Lett 108:183 
201. Goldstein DR, Tesar BM, Akira S, Lakkis FG (2003) Critical role of the Toll-like 
receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 111:1571 
202. Tesar BM, Zhang J, Li Q, Goldstein DR (2004) TH1 immune responses to fully 
MHC mismatched allografts are diminished in the absence of MyD88, a toll-like receptor 
signal adaptor protein. Am J Transplant 4:1429 
203. McKay D, Shigeoka A, Rubinstein M, Surh C, Sprent J (2006) Simultaneous 
deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch 
allograft rejection. Eur J Immunol 36:1994 
204. Thornley TB, Phillips NE, Beaudette-Zlatanova BC, Markees TG, Bahl K, Brehm 
MA, Shultz LD, Kurt-Jones EA, Mordes JP, Welsh RM, Rossini AA, Greiner DL (2007) 
Type 1 IFN Mediates Cross-Talk between Innate and Adaptive Immunity That Abrogates 
Transplantation Tolerance. J Immunol 179:6620 
205. Walker WE, Nasr IW, Camirand G, Tesar BM, Booth CJ, Goldstein DR (2006) 
Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 
177:5307 
206. Lorenz E, Schwartz DA, Martin PJ, Gooley T, Lin MT, Chien JW, Hansen JA, Clark 
JG (2001) Association of TLR4 mutations and the risk for acute GVHD after HLA-
matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 
7:384 
207. Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R, 
Ottinger H, Rath PM, Ross RS, Roggendorf M, Grosse-Wilde H, Beelen DW (2006) 
Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes 
influence the risk for severe acute graft-versus-host disease in patients who underwent an 
allogeneic transplantation. Transplantation 81:247 
208. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, 
Schwartz DA (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness 
in humans. Nat Genet 25:187 
209. Hill GR, Ferrara JL (2000) The primacy of the gastrointestinal tract as a target organ 
of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic 
bone marrow transplantation. Blood 95:2754 
200 
 
 
210. Palmer SM, Klimecki W, Yu L, Reinsmoen NL, Snyder LD, Ganous TM, Burch L, 
Schwartz DA (2007) Genetic regulation of rejection and survival following human lung 
transplantation by the innate immune receptor CD14. Am J Transplant 7:693 
211. Jaramillo A, Fernandez FG, Kuo EY, Trulock EP, Patterson GA, Mohanakumar T 
(2005) Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome 
after lung transplantation. Pediatr Transplant 9:84 
212. Turgeon NA, Iwakoshi NN, Meyers WC, Welsh RM, Greiner DL, Mordes JP, 
Rossini AA (2000) Virus infection abrogates cd8(+) t cell deletion induced by donor-
specific transfusion and anti-cd154 monoclonal antibody. Curr Surg 57:505 
213. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, Comer 
JA, Guarner J, Paddock CD, DeMeo DL, Shieh WJ, Erickson BR, Bandy U, DeMaria A, 
Jr., Davis JP, Delmonico FL, Pavlin B, Likos A, Vincent MJ, Sealy TK, Goldsmith CS, 
Jernigan DB, Rollin PE, Packard MM, Patel M, Rowland C, Helfand RF, Nichol ST, 
Fishman JA, Ksiazek T, Zaki SR (2006) Transmission of lymphocytic choriomeningitis 
virus by organ transplantation. N Engl J Med 354:2235 
214. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, 
Akira S (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-
mediated function. Immunity 9:143 
215. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M 
(1994) Functional role of type I and type II interferons in antiviral defense. Science 
264:1918 
216. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A (1992) A 
39-kDa protein on activated helper T cells binds CD40 and transduces the signal for 
cognate activation of B cells. Proc Natl Acad Sci U S A 89:6550 
217. Rubinstein S, Familletti PC, Pestka S (1981) Convenient assay for interferons. J 
Virol 37:755 
218. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ (2000) Cutting edge: repurification 
of lipopolysaccharide eliminates signaling through both human and murine toll-like 
receptor 2. J Immunol 165:618 
219. Rifle G, Mousson C, Martin L, Guignier F, Hajji K (2005) Donor-specific antibodies 
in allograft rejection: clinical and experimental data. Transplantation 79:S14 
220. Kean LS, Hamby K, Koehn B, Lee E, Coley S, Stempora L, Adams AB, Heiss E, 
Pearson TC, Larsen CP (2006) NK cells mediate costimulation blockade-resistant 
rejection of allogeneic stem cells during nonmyeloablative transplantation. Am J 
Transplant 6:292 
221. Westerhuis G, Maas WG, Willemze R, Toes RE, Fibbe WE (2005) Long-term mixed 
chimerism after immunologic conditioning and MHC-mismatched stem-cell 
transplantation is dependent on NK-cell tolerance. Blood 106:2215 
222. Yu YY, Kumar V, Bennett M (1992) Murine natural killer cells and marrow graft 
rejection. Annu Rev Immunol 10:189 
223. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, 
Hartmann G (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular 
subsets of human peripheral blood mononuclear cells and sensitivity to CpG 
oligodeoxynucleotides. J Immunol 168:4531 
201 
 
 
224. Brehm MA, Mangada J, Markees TG, Pearson T, Daniels KA, Thornley TB, Welsh 
RM, Rossini AA, Greiner DL (2007) Rapid quantification of naive alloreactive T cells by 
TNF-alpha production and correlation with allograft rejection in mice. Blood 109:819 
225. Phillips NE, Markees TG, Mordes JP, Greiner DL, Rossini AA (2003) Blockade of 
CD40-mediated signaling is sufficient for inducing islet but not skin transplantation 
tolerance. J Immunol 170:3015 
226. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, 
Steinman RM, Inaba K (2002) The CD8+ dendritic cell subset selectively endocytoses 
dying cells in culture and in vivo. J Exp Med 195:1289 
227. Heinzel FP, Rerko RM, Ling P, Hakimi J, Schoenhaut DS (1994) Interleukin 12 is 
produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. 
Infect Immun 62:4244 
228. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and 
adaptive immunity. Nat Rev Immunol 3:133 
229. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, Stewart 
C, Sarmiento U, Faherty DA, Gately MK (1996) IL-12-deficient mice are defective in 
IFN gamma production and type 1 cytokine responses. Immunity 4:471 
230. Magram J, Sfarra J, Connaughton S, Faherty D, Warrier R, Carvajal D, Wu CY, 
Stewart C, Sarmiento U, Gately MK (1996) IL-12-deficient mice are defective but not 
devoid of type 1 cytokine responses. Ann N Y Acad Sci 795:60 
231. Sakaguchi S, Negishi H, Asagiri M, Nakajima C, Mizutani T, Takaoka A, Honda K, 
Taniguchi T (2003) Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta 
gene expression and endotoxin shock. Biochem Biophys Res Commun 306:860 
232. Shoker AS, Lun ZR, Choudry R, Saxena A (2001) Analysis of the CD40/CD40L role 
in the sustenance of alloreactive antibody production. Transpl Immunol 8:219 
233. Forster E, Krenger W, Joergensen J, Hof R, Geha RS, Hollander GA (1999) 
Contribution of CD40-CD154-mediated costimulation to an alloresponse in vivo. 
Transplantation 67:1284 
234. Van den Eertwegh AJ, Noelle RJ, Roy M, Shepherd DM, Aruffo A, Ledbetter JA, 
Boersma WJ, Claassen E (1993) In vivo CD40-gp39 interactions are essential for 
thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, 
and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 
178:1555 
235. Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ (1994) gp39-
CD40 interactions are essential for germinal center formation and the development of B 
cell memory. J Exp Med 180:157 
236. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath 
J, Grosmaire LS, Stenkamp R, Neubauer M, et al. (1993) The CD40 ligand, gp39, is 
defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 
72:291 
237. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225 
238. McNerney ME, Lee KM, Zhou P, Molinero L, Mashayekhi M, Guzior D, Sattar H, 
Kuppireddi S, Wang CR, Kumar V, Alegre ML (2006) Role of natural killer cell subsets 
in cardiac allograft rejection. Am J Transplant 6:505 
202 
 
 
239. Beilke JN, Kuhl NR, Van Kaer L, Gill RG (2005) NK cells promote islet allograft 
tolerance via a perforin-dependent mechanism. Nat Med 11:1059 
240. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC (2006) NK cells promote transplant 
tolerance by killing donor antigen-presenting cells. J Exp Med 203:1851 
241. Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, Wang F, 
Godowski PJ (2004) APC-independent activation of NK cells by the Toll-like receptor 3 
agonist double-stranded RNA. J Immunol 172:138 
242. Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, Orloff MS (2008) TLR-
dependent cross talk between human Kupffer cells and NK cells. J Exp Med 205:233 
243. Blazar BR, Taylor PA, Linsley PS, Vallera DA (1994) In vivo blockade of 
CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-
host disease across the major histocompatibility complex barrier in mice. Blood 83:3815 
244. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK, Kersey JH, 
Weisdorf DJ (1992) Acute graft-versus-host disease following unrelated donor marrow 
transplantation: failure of conventional therapy. Bone Marrow Transplant 10:77 
245. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, 
Filipovich A (1991) Risk factors for acute graft-versus-host disease in histocompatible 
donor bone marrow transplantation. Transplantation 51:1197 
246. Gelman AE, Zhang J, Choi Y, Turka LA (2004) Toll-like receptor ligands directly 
promote activated CD4+ T cell survival. J Immunol 172:6065 
247. Phillips NE, Greiner DL, Mordes JP, Rossini AA (2006) Costimulatory blockade 
induces hyporesponsiveness in T cells that recognize alloantigen via indirect antigen 
presentation. Transplantation 82:1085 
248. Quezada SA, Fuller B, Jarvinen LZ, Gonzalez M, Blazar BR, Rudensky AY, Strom 
TB, Noelle RJ (2003) Mechanisms of donor-specific transfusion tolerance: preemptive 
induction of clonal T-cell exhaustion via indirect presentation. Blood 102:1920 
249. Quezada SA, Bennett K, Blazar BR, Rudensky AY, Sakaguchi S, Noelle RJ (2005) 
Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: 
the interplay of clonal anergy and immune regulation. J Immunol 175:771 
250. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) 
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by 
TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875 
251. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK 
(2006) Reciprocal developmental pathways for the generation of pathogenic effector 
TH17 and regulatory T cells. Nature 441:235 
252. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S (2001) Endotoxin-induced 
maturation of MyD88-deficient dendritic cells. J Immunol 166:5688 
253. Hoebe K, Janssen EM, Kim SO, Alexopoulou L, Flavell RA, Han J, Beutler B 
(2003) Upregulation of costimulatory molecules induced by lipopolysaccharide and 
double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat 
Immunol 4:1223 
254. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J (1998) Type I 
IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161:1947 
255. Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons 
203 
 
 
(alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307 
256. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough 
DF (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. 
Nat Immunol 4:1009 
257. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs 
provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J 
Immunol 174:4465 
258. Muzio M, Ni J, Feng P, Dixit VM (1997) IRAK (Pelle) family member IRAK-2 and 
MyD88 as proximal mediators of IL-1 signaling. Science 278:1612 
259. Jones ND, Turvey SE, Van Maurik A, Hara M, Kingsley CI, Smith CH, Mellor AL, 
Morris PJ, Wood KJ (2001) Differential susceptibility of heart, skin, and islet allografts to 
T cell-mediated rejection. J Immunol 166:2824 
260. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS (2008) Haematopoietic stem cell 
release is regulated by circadian oscillations. Nature 452:442 
261. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, 
List RP, Day DE, Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward 
PA (2007) Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 
449:721 
262. Zhao Y, Ohdan H, Manilay JO, Sykes M (2003) NK cell tolerance in mixed 
allogeneic chimeras. J Immunol 170:5398 
263. Raulet DH (1999) Development and tolerance of natural killer cells. Curr Opin 
Immunol 11:129 
264. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, Blazar BR, Levy 
RB, Murphy WJ (2006) Suppression of natural killer cell-mediated bone marrow cell 
rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A 103:5460 
265. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, 
Hampton CR, Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, Verrier ED (2006) 
Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-
reperfusion injury. Circulation 114:I270 
266. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of 
innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552 
267. Kaneko K, Ueda R, Kikuchi K, Sano Y, Yoshimura T (1999) Quantitative 
determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by 
high-performance liquid chromatography with fluorescence detection. J Chromatogr B 
Biomed Sci Appl 736:67 
268. Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, Moran J, Lynn M (2004) 
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of 
eritoran (E5564) during continuous intravenous infusion into healthy volunteers. 
Antimicrob Agents Chemother 48:3233 
269. Dunn-Siegrist I, Leger O, Daubeuf B, Poitevin Y, Depis F, Herren S, Kosco-Vilbois 
M, Dean Y, Pugin J, Elson G (2007) Pivotal involvement of Fcgamma receptor IIA in the 
neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal 
antibody 15C1. J Biol Chem 282:34817 
270. Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, Kosco-Vilbois M, 
204 
 
 
Wagner H, Kirschning CJ, Ulevitch R, Elson G (2007) TLR4/MD-2 monoclonal antibody 
therapy affords protection in experimental models of septic shock. J Immunol 179:6107 
271. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, Zugel U, 
Steinmeyer A, Pollak A, Roth E, Boltz-Nitulescu G, Spittler A (2006) Vitamin D3 down-
regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-
associated molecular patterns. Eur J Immunol 36:361 
272. Nakahira K, Kim HP, Geng XH, Nakao A, Wang X, Murase N, Drain PF, Sasidhar 
M, Nabel EG, Takahashi T, Lukacs NW, Ryter SW, Morita K, Choi AM (2006) Carbon 
monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced 
trafficking of TLRs to lipid rafts. J Exp Med 203:2377 
273. Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ (1998) Anti-CD14 mAb treatment 
provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci U S 
A 95:13875 
274. Tasaka S, Ishizaka A, Yamada W, Shimizu M, Koh H, Hasegawa N, Adachi Y, 
Yamaguchi K (2003) Effect of CD14 blockade on endotoxin-induced acute lung injury in 
mice. Am J Respir Cell Mol Biol 29:252 
275. Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T, Souza S, Axtelle 
T, Hoek FJ, van Deventer SJ, van der Poll T (2001) IC14, an anti-CD14 antibody, inhibits 
endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 
166:3599 
276. Reinhart K, Gluck T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J, Opal S, 
Moldawer LL, Axtelle T, Turner T, Souza S, Pribble J (2004) CD14 receptor occupancy 
in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 
monoclonal antibody (IC14). Crit Care Med 32:1100 
277. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL (2007) Treatment of lupus-
prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody 
production and amelioration of disease symptoms. Eur J Immunol 37:3582 
278. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad 
O, Coffman RL (2005) Nucleic acids of mammalian origin can act as endogenous ligands 
for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 
202:1131 
279. Loiarro M, Capolunghi F, Fanto N, Gallo G, Campo S, Arseni B, Carsetti R, 
Carminati P, De Santis R, Ruggiero V, Sette C (2007) Pivotal Advance: Inhibition of 
MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic 
compound. J Leukoc Biol 82:801 
280. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, Liew FY (2004) ST2 
is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains 
endotoxin tolerance. Nat Immunol 5:373 
281. Yang F, de Villiers WJ, McClain CJ, Varilek GW (1998) Green tea polyphenols block 
endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J 
Nutr 128:2334 
282. Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW (2001) The green 
tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by 
inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol 
205 
 
 
Pharmacol 60:528 
283. Youn HS, Lee JY, Saitoh SI, Miyake K, Kang KW, Choi YJ, Hwang DH (2006) 
Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by 
(-)-epigallocatechin-3-gallate, a polyphenol component of green tea. Biochem Pharmacol 
72:850 
284. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, 
Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer 
chemopreventive activity of resveratrol, a natural product derived from grapes. Science 
275:218 
285. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, 
Chow J, Gusovsky F, Christ WJ, Rossignol DP (2003) Inhibition of endotoxin response 
by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp 
Ther 304:1093 
286. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA (2000) A46R 
and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor 
signaling. Proc Natl Acad Sci U S A 97:10162 
 
 
